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My time here in the Biomedical Engineering Department at Georgia Tech and 
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aspects of “lab life” and Atlanta.  I could not have reached this point without the support 
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determining my specific aims.  As the clinician on the committee from Emory, Dr. Yoon 
always offered the therapeutic perspective and his expertise in stem cells and 
angiogenesis were invaluable.  Each of these members of the committee has encouraged 
me through my research, and I thank you all for your time and commitment. 
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to my development as a scientist has been my advisor, Todd.  I came to Tech wanting to 
get away from stem cell research, but I was curious to hear about Todd’s newly formed 
lab, since it was the only ESC lab at Tech.  His innovative ideas and approaches to 
studying stem cells was unlike what I previously encountered, so here I was again, 
feeding cells over the weekend.  Todd always made it a point to make sure his door was 
open to his students, so it was not uncommon for me to stop by with some new data or 
discuss a number of research hurdles.  Throughout the years Todd’s lab has grown 
extensively and his schedule has achieved “rock star status” (according to Andrés 
García), but Todd always finds time to meet with his students.  He has continued to 
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has made him a great professor and advisor.  Todd, your support and guidance as a 
mentor through these years have influenced me as a person and a scientist, and to you I 
am sincerely thankful. 
There are a number of individuals in the BME department and the IBB who have 
contributed to this work.  The bioinformatics expertise of Dr. Melissa Kemp and the 
statistical knowledge of Dr. Brani Vidokovic improved the gene array analysis for that 
particular manuscript.  In the IBB core facilities, Sha’Aqua Asberry in the histology core 
and Steve Woodard in the microscopy core, have been tremendously helpful in training 
me on analytical instruments that were imperative to my research.  I would also like to 
thank the BME academic advisors past and present - Beth Bullock Spencer, Shannon 
Oliver Sullivan, and Sally Gerrish; as well as the financial staff – Sandra Wilson, 
Penelope Pollard for their patience and helping me with all the paperwork over the years. 
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 Not only were the members of the McDevitt lab great colleagues who challenged 
me scientifically, they are an entertaining group to have around during those long days n 
the lab.  When I first joined the lab, there were four grad students – Rich Carpenedo, Ima 
Ebong, Rekha Nair, and Carolyn Sargent.  To all of them, I thank you for setting up the 
lab a year earlier, which allowed me to get started in the lab once I joined.  Ima was a 
great person who always had a smile on her face and a song in her head that she always 
was willing to share.  At that point, Rich was the only guy in the lab who kept to himself, 
but came around once he found out we both shared an interest in golf and the Red Sox.  
Rich has not only been a great lab mate who asks those tough questions, but also has 
taught me quite a bit - particularly on the golf course and about strategies for competitive 
eating, so for those insights I must thank you.  Rekha was the lucky student to pioneer the 
acellular EB matrix project, and I was able to build upon her work’s strong foundation.  
In addition to being a great sounding board, Rekha, and her husband Kartik, have been 
good friends with whom I have enjoyed indulging in the fine foods Atlanta has to offer, 
as well as the other cities we visited together through the conferences we were fortunate 
enough to attend.  Maybe we’ll find out way back to Madrid one day to rectify “the 
incident” at the flamenco show.  Rich, Rekha, and Carolyn have all inspired me to not 
only challenge myself scientifically, but also recreationally.  Carolyn’s endurance to train 
for a number of triathlons (and hopefully an Ironman soon!) was particularly inspiring, 
and she has somehow infected me with that bug.  Not only was she was a great mentor 
while she trained Ken and I for our first triathlon, but also a good person who always lent 
an ear to anything I needed to vent about.   
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Leal, Barbara Nsiah, and Ken Sutha.  Andrés has a great sense of humor that can lighten 
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for his leadership, especially in our “Pumping Iron Crew”, where he ensures that we 
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lend a hand and has a smile on his face all the time – maybe it’s because he is also 
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friend of the “Pumping Iron Crew”, is an independent woman who does not succumb to 
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she wants to enjoy it, and is a great shopping buddy since she knows how to find the 
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fan and Mac-user, joined our lab.  Initially, Melissa started off pretty quiet, but she has 
acclimated to our lab quiet well and is always willing to help out.  She has been very 
productive in her first few years, and I’m sure she will continue to do so.  The latest 
McDevitt lab students – Kirsten Kepple, Anh Nguyen, Jenna Wilson, and Doug White 
are great additions to the lab, and I’m sure they will accomplish a great deal in the lab.  
The fellow graduate students in the lab have made my experience in the McDevitt lab a 
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So a “wicked big” thanks to you all. 
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one of the kindest souls I know, and I’m lucky to have him by my side for the rest of my 
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I couldn’t have done this without you. 
 Finally, I would like to give my greatest thanks to my family for their unwavering 
support throughout my life.  My younger sister, Tanya, has always challenged me to be a 
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Angiogenesis is the biological process involving the expansion of existing 
vascular networks through the sprouting of endothelial cells from existing vasculature to 
grow new blood vessels.  Current therapeutic strategies to stimulate endogenous 
angiogenic processes within injured tissue areas are typically based on introducing 
exogenous pro-angiogenic molecules or cell populations.  Stem cell transplantation for 
angiogenic therapy aims to deliver populations of cells that secrete angiogenic factors 
and/or engraft in the new branching vasculature within the damaged tissue.  Utilizing 
stem or progenitor cells has been shown to induce a rather robust angiogenic response 
despite minimal repopulation of the host vasculature, suggesting that stem cells may 
provide paracrine factors that transiently induce endogenous angiogenesis of tissues 
undergoing regeneration.  Early differentiating embryonic stem cell (ESC) aggregates, 
referred to as embryoid bodies (EBs), can undergo vasculogenic differentiation, and also 
produce extracellular matrix and growth factors that induce proliferation, differentiation, 
and tissue morphogenesis.  Taken together, the ESC extracellular environment may be an 
effective means by which to manipulate cell behavior.  Thus, the objective of this project 
was to harness morphogens derived from ESCs undergoing differentiation and analyze 
their bioactive potential.  The overall hypothesis was that the dynamic embryonic 
environment of EBs captured in an acellular matrix retains secreted bioactive factors and 
stimulates cells implemented in tissue remodeling.   
Temporal patterns of phenotypic gene expression, including vasculogenesis, have 
been relatively well characterized during the course of differentiation; coincident patterns 
 xx 
of endogenous extracellular matrix (ECM) and growth factor expression that accompany 
pluripotent stem cell differentiation remain poorly defined.  To examine the expression of 
extracellular factors within EBs, gene expression patterns obtained from low-density 
PCR arrays in conjunction with a variety of analytical tools were utilized to gain an 
understanding of the importance of extracellular factors in ESC differentiation.  Gene 
expression analysis of ECM and growth factors by ESCs differentiating as EBs for up to 
14 days was assessed using PCR arrays (168 unique genes total), and the results were 
examined by a series of different clustering and systems pathway analyses.  As expected, 
significant decreases in molecules regulating pluripotent stem cell fate preceded 
subsequent increases in morphogen expression associated with differentiation.  Pathway 
analysis indicated strong correlations between the expression patterns of ECM and 
growth factor genes and morphogenic cell phenomena, such as cell growth, migration, 
and intercellular signaling required for primitive tissue and organ developmental events.  
In addition, systems analysis of extracellular molecule expression alone identified key 
molecules and pathways potentially involved in the progression of pluripotent stem cell 
differentiation.  Overall, these studies represented a novel framework to dissect the 
complex, dynamic nature of the extracellular biochemical milieu of stem cell 
microenvironments that regulate pluripotent cell fate decisions and morphogenesis.  
Stem cells are being investigated as catalysts of tissue regeneration to either 
directly replace or promote cellularity due to traumatic injuries and degenerative diseases.  
In many instances, despite low numbers of stably integrated cells, the transient presence 
of cells delivered or recruited to the site of tissue remodeling globally benefited 
functional recovery.  Such reports have motivated subsequent studies to determine how 
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paracrine factors secreted from transplanted cells may be capable of positively impacting 
endogenous repair processes.  Thus, the effects of soluble factors secreted by ESCs 
during early stages of differentiation on exogenous cells (fibroblasts and endothelial 
cells) commonly involved in tissue remodeling events were investigated.  The expression 
patterns and quantities of several growth factors involved in differentiation, including 
bone morphogenic protein-4 (BMP-4), insulin-like growth factors (IGFs) and vascular 
endothelial growth factor-A (VEGF-A), were analyzed as a function of ESC 
differentiation as EBs, and found to generally increase over time.  Conditioned media 
collected from EBs at different stages of differentiation stimulated proliferation and 
migration of both fibroblasts and endothelial cells, based on BrdU incorporation and 
transwell assays, respectively.  Overall, these results demonstrated that differentiating 
ESCs generally expressed increasing amounts of various growth factors that altogether 
were capable of stimulating mitogenic and motogenic activity in exogenous cells.  
This soluble fraction of secreted factors contained within EB-conditioned media 
was compared to the matrix-associated factors produced by EBs, which led to the 
development of novel ESC-derived matrices via mechanical acellularization methods. 
Several acellularization protocols were applied to EBs, to develop a potential route to 
deliver ESC-derived molecules, independent of cells, to damaged tissues. 
Acellularization methods were developed to physically disrupt EBs via lyophilization or 
freeze-thaw cycling, and in combination with DNase treatment, while the efficacy of 
acellularization was based upon cell viability, DNA removal, and protein retention. 
Mechanical disruption and DNase treatment of EBs efficiently inhibited viability and 
removed DNA while retaining protein content to produce an acellular EB matrix. 
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Additionally, various batches of acellularized EBs consistently exhibited negligible 
amounts of endotoxin (< 0.5 EU/mL).  Extraction of proteins from acellularized EBs 
demonstrated the presence of IGF-2 and VEGF-A growth factors retained in the acellular 
matrix.  Biocompatibility of EB-derived acellular matrices was examined through the 
attachment and repopulation of the constructs by 3T3 fibroblasts in vitro.  These studies 
demonstrated that mechanical means effectively acellularized EBs and were utilized in 
subsequent studies to elucidate the composition and bioactive potential of embryonic 
acellular matrices  
The acellular embryonic stem cell-derived matrix was examined for its retention 
of bioactive factors that potentially could stimulate aspects of angiogenesis, including cell 
proliferation, chemotaxis, and structure formation as well as tissue morphogenesis.  
Protein extractions from EBM revealed that growth factors were harbored within the 
matrix in varying amounts depending on the day of EB differentiation.  Following heat 
inactivation, BMP-4 and FGF-2 were no longer identified, contrary to IGF-2 and VEGF-
A, which both showed increased amounts compared to non-heat inactivated EBM.  The 
reaction of fibroblasts to EBM extractions was typically enhanced compared to basal 
level controls, in contrast to the inhibition of endothelial cells in response to EBM 
extractions.  Endothelial cells were stimulated upon heat inactivation of EBM, especially 
during tube formation assays.  The impact of EBMs on CAM angiogenesis was not as 
obvious of a response compared to EC migration and proliferation, yet altogether these 
bioactivity studies demonstrated the retention of bioactive factors within EBM. 
In conclusion, this work has derived a novel embryonic stem cell matrix that is 
comprised of bioactive morphogens that further impact aspects of tissue remodeling, 
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particularly angiogenesis.  Moreover, these studies have elucidated the modulation of 
extracellular factors that reflect the progression of EB differentiation, while providing a 
means to deliver these ESC-secreted factors in a cell-free manner.  Future work will 
continue to elucidate the unique milieu of factors secreted by ESCs that will further 







 Tissue damage as a result of an ischemic event, such as myocardial infarction, 
stroke, or a chronic wound requires restoring blood flow to the area in order to rescue the 
injured site and prevent further injury.  The biological process of angiogenesis involves 
the growth of new vessels through endothelial cell sprouting from existing vasculature to 
grow new blood vessels [1, 2].  Current therapeutic strategies to stimulate endogenous 
angiogenic processes within injured tissue areas are typically based on introducing 
exogenous pro-angiogenic molecules or cell populations.  Isolated angiogenic growth 
factors have been examined as a potential therapeutic to stimulate an angiogenic 
response, with localized delivery resulting in slightly more effective blood vessel 
expansion in avascular areas than systemic delivery [3, 4].  However, purified growth 
factors are limited by the amount injected and their in vivo half-lives, thus a more robust 
reservoir of angiogenic growth factors that can be released over time would be more 
beneficial than a bolus injection. 
Cell transplantation for angiogenic therapy is an approach to deliver exogenous 
cell that secrete angiogenic factors and/or integrate with the new branching vasculature in 
the damaged tissue.  Utilizing stem or progenitor cells has been shown to induce a rather 
robust angiogenic response in ischemic tissues and improve overall healing by restoring 
normal tissue function [5-7].  However, isolating sufficient numbers of these stem cells 
from a primary source for transplantation has proven to be a challenge, thus necessitating 
their in vitro expansion and differentiation prior to transplantation.  Although several cell 
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transplantation studies have been effective in rescuing injured tissues and inducing 
endogenous angiogenic responses in vivo, the number of engrafting cells is low, which 
has shifted the focus to paracrine effects of transplanted cells.  A recent breakthrough 
study confirmed the importance of paracrine factors, revealing that ESCs transplanted 
into Id knockout blastocysts rescued the lethal knockout phenotype via extracellular 
factors secreted by the transplanted ESCs [8].  This seminal paper provided an interesting 
perspective on how to exploit ESCs for therapeutic applications. 
Early differentiating embryonic stem cell (ESC) aggregates, referred to as 
embryoid bodies (EBs), generate a 3D in vitro environment, which mimics aspects of 
development, including cell proliferation, migration, differentiation, and tissue 
morphogenesis, including vasculogenesis.  Evaluation of differentiated cell types present 
during EB culture has shown the presence all germ lineages, ectoderm, endoderm, and 
mesoderm.  Furthermore, specific tissue morphogenesis within the EB, such as formation 
of primitive vascular structures, requires cellular response to particular matrix molecules 
and chemotactic gradients, which illustrates modulation of the extracellular environment 
due ESC differentiation. 
Taken together, the ESC extracellular environment is an effective means by which 
to manipulate cell behavior, may it be modulating cell migration, proliferation, 
differentiation, or exerting a therapeutic response.  Thus, the objective of this project was 
to harness morphogens derived from ESCs undergoing differentiation and analyze their 
bioactive potential.  The overall hypothesis was that an acellular matrix capturing the 
differentiating EB embryonic environment retains secreted bioactive factors and 
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stimulates cells implemented in tissue remodeling.  This hypothesis was tested by the 
following specific aims: 
 
Specific Aim 1.  Evaluate the expression of growth factors by ESCs undergoing 
cardiovascular differentiation within EBs. The working hypothesis was that 
progressive cardiovascular differentiation of ESCs within EBs would yield increased 
expression of endothelial cell markers as well as angiogenic growth factors.  
Investigation of EB differentiation towards the cardiovascular lineage was assessed by 
RT-PCR gene expression of endothelial markers, including Flk-1, Flt-1, VE-Cadherin, 
and PECAM-1, in addition to protein expression via immunostaining. The changes in 
expression of certain angiogenic growth factors were compared to the shifts in 
endothelial marker expression to evaluate the progression cardiovascular differentiation 
within EBs.  Global gene expression of 168 extracellular factors, including extracellular 
matrix and growth factors, within EBs at days 4, 7, 10, and 14 of culture was assessed 
using low-density qPCR arrays and further analyzed via clustering methods (hierarchical 
and k-means), statistical testing, and pathway analysis.  The secretion of growth factors 
by differentiating EBs was further examined by analyzing EB-conditioned media 
collected at different time points of EB culture.  The content of specific growth factors, 
including VEGF-A, IGF-2, and BMP-4, was quantified using ELISAs while in vitro 
migration and proliferation studies were utilized to assess the bioactivity of factors 
contained within the EB-conditioned media.   
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Specific Aim 2.  Develop acellularization techniques to isolate embryonic ESC-
derived factors produced within EBs.  The working hypothesis was that acellularized 
EB matrices would retain embryonic factors produced during EB differentiation.  
Mechanical acellularization techniques were developed to devitalize and remove cellular 
content from ECM and ECM-associated factors to yield acellular EB matrices.  Two 
different methods of acellularization techniques were investigated, lyophilization and 
freeze-thaw, alone or in combination with DNase treatment.  Quantitative metrics were 
assessed for cell viability via alamarBlue assay, total protein content using bicinchonic 
assay (BCA), and DNA content with PicoGreen®.  More qualitative assessments on the 
resulting EB matrix were performed, including scanning electron microscopy (SEM), 
histology for overall matrix composition, and cell seeding for biocompatibility.  These 
acellular EB matrices were tested for endotoxin content and further analyzed for specific 
growth factor retention using ELISAs. 
 
Specific Aim 3.  Determine the bioactivity of isolated embryonic acellular EB 
matrices in vitro.  The working hypothesis was that ESC-derived embryonic factors 
isolated from EBs would stimulate exogenous cell types. The responses of NIH-3T3 
fibroblasts and human umbilical vein endothelial cells (HUVECs) to ESC-derived matrix 
factors were analyzed via proliferation and migration assays.  Proliferation assays were 
performed analyzed for bromodeoxyuridine (BrdU) incorporation of both cell types in 
response to EB matrix factors, while migration studies quantified chemoattractive cell 
migration as a result of EB matrix-derived factors for both cell types using a transwell 
insert.  Additionally, the HUVEC network formation assay on growth factor-reduced 
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Matrigel™ was utilized to evaluate endothelial cell response to ESC-derived matrix 
factors. 
 
Specific Aim 4.  Evaluate the angiogenic potency of acellular EB matrices ex ovo 
using a quail chorioallantoic membrane (CAM) assay.  The working hypothesis was 
that embryonic EBs undergoing vascular differentiation would yield a complex mixture 
of morphogens capable of promoting an angiogenic response.  EB matrices (EBM) 
retaining growth factors were applied to quail chorioallantoic membranes (CAMs) to 
assess the angiogenic potency of the ESC-derived factors.  Angiogenic responses were 
analyzed by quantifying the number of radiating vessels from the treatment location 
during the 48-hour treatment period.  Additional analyses were performed on CAMs 
fixed after 48 hours to compare EBM treatments by quantifying the total percent vessel 
area per CAM in conjunction with a semi-quantitative measure of angiogenesis evaluated 
by scoring the change in blood vessel morphology surrounding the matrix graft. 
 
 This research is significant because it directly examines the bioactive potential of 
extracellular factors produced by ESCs as a mode to stimulate the different cell types 
involved in tissue remodeling, specifically angiogenesis.  Evaluating the production and 
potency of angiogenic factors by differentiating EBs yielded insight into growth factors 
produced within an embryonic-like environment created by ESCs within EBs.  These 
insights could advance developments in utilizing ESCs for regenerative medicine 
therapeutics.  This work is also innovative because it demonstrates the ability to derive 
embryonic matrices to harness and deliver stem cell morphogens that in turn influence 
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exogenous cell and tissue responses.  Ultimately, this work circumvents major issues 
involving ESC transplantation and exploits the benefits of ESCs by developing a novel 





Adult stem cells 
The advent of stem cells several decades ago pioneered robust research that has 
established new frontiers in areas including biology, gene therapy, and regenerative 
medicine.  The identification of colony-forming, self-renewing stem cells from the bone 
marrow [9, 10] motivated the identification of resident stem cells in a variety of somatic 
tissues including, but not limited to, the brain [11, 12], adipose and muscle tissue [13, 
14], and the olfactory system [15].  A number of protocols have been published 
describing processes by which adult stem cells can be isolated, characterized, and 
expanded in vitro [16-18].  Due to the potential of adult stem cells to differentiate to a 
number of somatic cell lineages, these cells possess attractive therapeutic potential; yet 
the potency of these cells is limited based on the source.  
 
Embryonic stem cells 
The initial derivation of pluripotent embryonic stem cells (ESCs) was reported 
using mouse embryos a few decades after the advent of stem cells, followed by the 
development of culturing human embryonic stem cells in vitro 18 years later [19-21].  
ESCs are the cells derived from the inner cell mass of the blastocyst that expand and 
differentiate to yield all somatic cell types.  The pluripotency of embryonic stem cells has 
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been exploited to establish methods to direct ESC differentiation towards numerous 
somatic cell types in vitro.  In particular, ESCs have been widely differentiated towards 
cells from the three germ lineages (ectoderm, endoderm, and mesoderm).  Specific 
phenotypes achieved include: neurons (central and peripheral) [22, 23] and epithelial [24, 
25] cells from the ectoderm, hepatic [26, 27] and pancreatic [28, 29] cells from the 
endoderm, and blood [30, 31] and muscle [32, 33] from the mesoderm.  One of the 
extensively researched areas for in vitro ESC differentiation is mesoderm differentiation 
towards the cardiovascular lineage, especially the derivation of cardiomyocytes [34-38] 
and vascular endothelial cells [39, 40].  Typically, differentiation strategies involve 
culturing undifferentiated ESCs in an adherent culture with media containing soluble 
factors to direct differentiation, such as VEGF-A, BMP-4, [30, 31].  However, ESCs can 
also be differentiated via embryoid body (EB) formation, in which ESCs spontaneously 
differentiate into cells comprising the three germ lineages in a 3D environment 
recapitulating aspects of embryogenesis in vitro [41, 42].  EBs are widely used as an in 
vitro model system for embryogenesis, especially within the realm of vasculogenesis and 
angiogenesis [39, 43-46].  The formation of a visceral yolk sac containing blood-islands 
can be identified in spontaneously differentiating ESCs via EB formation in suspension 
culture [47].  .During in vitro EB culture, differentiating ESCs are capable of 
differentiating towards the endothelial lineage and forming vascular-like structures, [48-
50].  The formation of these primitive vascular networks within the EB can typically be 
identified after 11 days of EB suspension culture, after which point they are capable to 
producing endothelial outgrowths given the proper conditions – a 3D matrix, like 
collagen, supplemented with angiogenic growth factors [45, 51, 52].  However, prior to 
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endothelial sprouting occurring, the environment within the EBs would have needed to be 
primed by the cells in order to induce vasculogenesis.  Vascular-specific expression of 
phenotypic markers, including flk-1, CD-31, tie-1, tie-2, and Ve-cad, within intact EBs 
been well documented, thus recapitulating the progression of embryo vascular 
differentiation in vitro [48, 50, 53]. 
 
Induced-pluripotent stem cells 
Unlike adult stem cells, ESCs are not capable of being patient-specific, which 
hinders the use of ESCs for clinical applications.  Thus generating a cell that could be 
derived from a patient and possess the pluripotent nature of ESCs is an ideal cell source 
for potential therapeutic applications.  Recently, the engineering of induced-pluripotent 
stem cells (iPSCs) has invigorated the stem cell field with numerous studies of somatic 
cell mimicking the pluripotent attribute of ESCs.  The eminent discovery of iPSCs 
emerged from the Yamanaka group in 2006 using retroviral transduction of key 
pluripotent factors, Oct-4, c-Myc, Sox-2, and Klf-4, to reprogram mouse embryonic and 
adult fibroblasts [54], and was quickly followed by studies performed using human 
fibroblasts [55, 56].  Since then, a multitude of somatic cell types have been 
reprogrammed: keratinocytes [57], terminally differentiated lymphocytes [58] [59], 
neural cells [60-62], and liver cells [63, 64] using many methods to deliver pluripotent 
transcription factors: retroviral, lentiviral, transposons, adenoviral, plasmid DNA, protein, 
and RNA (reviewed in[65]).  The recent developments concerning IPSCs have inspired 




Angiogenesis is the sprouting of new blood vessels from existing vasculature and 
is present in both pathologic as well as regenerative responses.  In an ischemic 
environment, endothelial cells (ECs) from surrounding vasculature are stimulated by 
angiogenic growth factors, released from macrophages or tumor cells, and expand the 
existing blood vessel network by proliferating and then migrating out of the vessel 
structure.  The EC sprout continues to extend and form a tubular structure, eventually 
forming connections with other vessels in order to permit blood flow [1, 2].  The 
pathological angiogenic response has been widely researched in the realm of tumors 
where the development of vascular networks occurs in order to promote tumor growth.  
However, angiogenic responses during reparative processes are also being investigated in 
order to stimulate tissue regeneration.  The angiogenic response within a damaged tissue, 
also termed revascularization, restores blood flow to compromised areas providing 
oxygen and nutrients to the surrounding cells in order to re-establish normal tissue 
function and stimulate repair.  By restoring normal blood flow and oxygen levels in these 
compromised tissues, successful tissue regeneration can be achieved with concurrent 
angiogenesis, or revascularization.   
 
Models to study angiogenesis 
The process of generating new vasculature from existing vasculature primarily 
involves the migration and proliferation of endothelial cells.  Several assays have been 
developed to examine the motogenic and mitogenic response of endothelial cells in vitro 
and have been reviewed to a large extent [66-69].  The proliferation of ECs can be 
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assayed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay to correlate the amount of formazan by-product with cell number [70].  An 
alternative mitogenic assay examines the incorporation of bromodeoxyuridine (BrdU), a 
thymidine analog, into the DNA during replication [71].  Furthermore, the migration of 
ECs as a chemotactic response can be quantified using a modified Boyden chamber 
assay, where ECs are plated into the top chamber, and the number of cells migrating 
towards the chemoattractive factors in the bottom chamber are quantified [72].  Each of 
these in vitro assays assesses more general cell behaviors; however, ECs are specialized 
cells and necessitate more specified tests for angiogenesis.  Network formation assays 
examine the ability of ECs to form primitive tubular structures in vitro on a 3D matrix, 
typically Matrigel, in response to an anti- or pro-angiogenic molecule(s) [73, 74].  While 
organ cultures, such as the aortic ring assay [75], can evaluate the angiogenic response of 
endogenous ECs and other vascular cell types.  Overall, these in vitro assays do not 
provide a complex angiogenic response, but are timely, efficient, and less costly 
compared to animal studies and provide a means to screen numerous treatment samples. 
 The angiogenic process is mediated by various cell types, physiological systems, 
and extracellular factors that cannot be thoroughly recapitulated in vitro, thus in vivo 
animal models are imperative in analyzing therapeutic angiogenesis.  Several in vivo 
animal models have been established to examine the angiogenic response to a potential 
treatment.  Non-injury models, such as the Matrigel plug assay and corneal angiogenesis 
assay, are modes to examine angiogenic stimulation by a test sample by evaluating the 
extent of vascular ingrowth present in the implanted material [76, 77].  Furthermore, the 
angiogenic and revascularization response can be analyzed in an injury model to 
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demonstrate the efficacy of a potential therapeutic treatment to rescue to a damaged area 
of tissue.  One of the most widely used animal models for studying therapeutic 
angiogenesis is the hindlimb ischemia (HLI) model, typically performed in rabbits, rats, 
and mice.  Inducing ischemia involves ligating and/or excising arteries in the hindlimb; 
however, ischemic severity is dependent on the surgical technique use, which can 
understate or overstate the observed results [78].  As with all in vivo models, animals are 
costly, generally span several weeks, and require technical expertise, but these models do 
provide the native complexity of an angiogenic response.  Despite its limitations, the 
mouse hindlimb ischemia model is an effective and well-established in vivo model for 
evaluating angiogenic therapies within an ischemic environment. 
Another in vivo or ex ovo method to examine an angiogenic response is through 
the use of a chorioallantoic membrane (CAM) assay.  The CAM is comprised of two 
parts: (1) the allantois, the extra-embryonic tissue that is mesoderm-derived and contains 
primitive blood vessels and (2) the chorion, the membrane derived from the ectoderm 
surrounding the embryo [79].  Originally, CAMs were used by embryologists to study 
development in the chick embryo and were then utilized to examine the growth and 
vascularization of exogenous arterial grafts through a window created in the eggshell. 
However, modifications were made to permit efficient observations of the CAM using 
microscopy, including transferring the entire contents of the egg to a tissue culture dish 
and the use to quail embryos, which are smaller than chicks and permit culture in a 6-well 
plate format [80-82].  Upon transferring the embryo to a tissue culture dish, the embryos 
are typically allowed to grow between 8-10 days, at which point grafts and other 
angiogenic agents can be placed on the CAM to evaluate a vasoproliferative response 
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during a 48 – 72-hour time period [83, 84].  Numerous studies examining the angiogenic 
response of CAMs to purified growth factors, including FGF-2 [80, 85] or materials, 
including the gelatin sponge [86] and acellular tissues [87-89], have been performed.  
Angiogenic observations are quite noticeable, yet quantifying the angiogenic response is 
not as established as methods used for animal studies.  The angiogenic response of the 
CAMs is qualitatively assessed through the use of stereomicroscopy images by observing 
the convergence, branching, and density of blood vessels surrounding the treatment and 
semiquantitaively analyzed by counting the number of converging vessels [86, 90].  The 
drawbacks to CAM studies are that they are performed in an avian embryonic 
environment that does not possess a mature immune system, which promotes 
inflammation-induced angiogenesis [91, 92].  Despite the drawbacks, positive aspects of 
the CAM assays are lower cost and shorter time studies compared to animal studies as 
well as the ability to screen a larger number of samples and groups.   
 
Angiogenic therapies and growth factors  
Surgical intervention to restore the vascularity of damaged tissues, particularly 
limbs and myocardium, involves opening up the occluded vessel via balloon angioplasty 
or the use of stents, bypass surgery, or excimer laser technology [93].  Recently, 
investigations of growth factor delivery to promote endogenous blood vessel growth have 
been successful with one FDA-approved growth factor-based therapeutic, [94], based on 
a recombinant form of PDGF, and several undergoing clinical trials, specifically 
assessing delivery of vascular endothelial growth factor (VEGF) and fibroblast growth 
factor 2 (FGF-2).  Initial clinical trials have shown safety of use, but report mixed results 
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with respect to effectiveness [78, 95-100].  These advanced studies demonstrate the 
importance of extracellular factors in promoting revascularization, particularly 
angiogenic growth factors; however effectively delivering purified proteins in vivo has 
proven to be a challenge.  Systemic delivery of growth factors for site-specific 
angiogenesis is not favorable due to multiple doses, off-target effects, short in vivo half 
life, and minimal effective concentration of growth factor at the in the target site [101].  
Thus, localizing a source of angiogenic growth factors that can prolong release could 
provide a more effective means to deliver pro-angiogenic factors.  
 
Angiogenesis and the ECM 
Endogenous angiogenesis is regulated by the factors presented in the surrounding 
ECM [102, 103].  Not only do the matrix molecules themselves provide signals, but they 
can also regulate the release of soluble growth factors bound to the matrix to further 
enhance the response of surrounding endothelial cells.  For example, several extracellular 
growth factors bind to heparin for stabilization and their activation or release is mediated 
by ECM changes, typically via enzymes, in order to stimulate certain biological processes 
including angiogenesis [104-107].  The importance of ECM and growth factor 
interactions has provided substantial motivation for bioengineering approaches to mimic 
the natural ECM environment [104, 108, 109].  Novel materials have been designed to 
function as ECM analogs with instructive bioactive sites (such as cell adhesion ligands, 
degradation domains, or growth factor binding sites) that can subsequently stimulate 
biological responses such as angiogenesis [110-113].  While engineered matrices can 
provide specific matrix molecules and growth factors, decellularizing native ECMs has 
15 
also been shown to be effective in retaining bioactive factors to stimulate angiogenic 
responses [88, 89, 114, 115].  These acellular matrices contain a more complex milieu of 
growth factors and matrix molecules (compared to engineered materials) that can 
generally work synergistically to elicit an angiogenic response. 
 
Acellular Matrices 
The ECM provides a natural scaffold for structural support of tissues and harbors 
a complex assembly of biochemical cues comprised of proteins, glycosylaminoglycans 
(GAGs), proteoglycans, and growth factors [109, 116].  Acellularization techniques 
provide a means to extract cells from tissues, thereby isolating the extracellular matrix 
(ECM) components native to the specific tissue [117, 118].  The primary criterion for 
successful acellularization is efficient inhibition of tissue viability coupled with 
preservation of native ECM composition and structure.  Numerous tissues from various 
sources have been successfully acellularized in order to create scaffolds for tissue 
regeneration and include: small intestinal submucosa (SIS) [119], esophagus [120], 
bladder [121], cardiac valve [122, 123], dermis [124, 125], nerve [126], placenta [127], 
and pericardium [128].  More recently, entire organs have been acellularized, starting 
with the first report by Ott et al. of a whole rat heart [129].  Following the whole rat heart, 
rat liver [130] and rodent lungs [131-133] were then acellularized to provide intact 3D 
matrix structures with the vascular network preserved.  These acellular organs supported 
cellular repopulation, demonstrating biocompatibility, and provide a potential means to 
tissue engineering entire organs.   
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As mentioned above, not only have tissues been acellularized, but several of these 
acellular matrices have also been utilized in vivo.  Acellular pericardium has been used to 
repair rodent myocardial defects and showed infiltration of endogenous endothelial and 
smooth muscle cells [134].  Peripheral nerve segmentation injury in rats was treated with 
an acellular nerve graft that induced nerve regeneration and neovascularization [135].  
Although the aforementioned examples used acellular tissues derived from the organs 
requiring repair, acellular tissues from one tissue source can also be successful in 
repairing different damaged organs.  For example, SIS has been used for a number of 
tissue repair applications from arterial and venous grafts [136, 137], wound dressing 
[138], ventral hernia repair [139], to Achilles tendon repair [140].  The breadth of tissues 
that have been acellularized and successfully examined for tissue repair in vitro and in 
vivo, as well as the number of commercialized acellular matrix products currently 
available, attest to the utility of acellular tissue-derived materials as effective 
biomaterials.  Nonetheless, derivation of matrices from a dynamic tissue source that not 
only can provide structural ECM components for cell engraftment, but are comprised of 
morphogens that can stimulate cellular remodeling of the matrix have yet to be examined. 
 
Methods for acellularizing tissues 
Various methods have been established to acellularize tissues using techniques 
that include solution-based treatments and mechanical disruption.  Solution-based 
methods typically combine chemical treatments, such as detergents [126, 141-144], 
alkaline or acid solutions [145, 146], and hyper- or hypo-tonic solutions [144], as well as 
enzymatic reagents, including trypsin, endonucleases, and ectonucleases [147, 148].  
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Mechanical methods of acellularization provide a means to disrupt cells’ plasma 
membranes, typically by repeated freeze-thaw cycles, sonication, or lyophilization [149-
153].  Mechanical treatments alone are not capable of completely removing cellular 
content, thus a combination of physical and chemical/enzymatic methods is typically 
needed to successfully acellularize tissues.  Additionally, perfusion systems have been 
used to acellularize whole organs while maintaining the original 3D structure.  Solutions 
used to perfuse the organs via the vascular network included detergents, such as SDS, 
TritonX-100, or 3-[(3-cholamidopropyl)dimethylammonio]-1- propanesulfonate 
(CHAPs), and sometimes in combination with DNase enzymatic treatment [129-133].  
The possible combinations of acellularization techniques needed are numerous due to 
structural variations in tissues, ranging from tissues with dense ECM content like tendons 
and dermis to ones with thin basement membranes like nerves and blood vessels.  
Furthermore, the duration of treatment/perfusion with detergents and or enzymes depends 
on the size and mass of tissue.  Thus, there is no universal “optimal” method for 
acellularizing tissues, which suggests that the bioactive factors retained within the 
acellular matrix may vary based on the selected protocol. 
 
Bioactive factors retained within acellular matrices 
Protein characterization of acellularized tissues generally involves qualitative 
assessments of ECM proteins via histological staining, as well as more quantitative 
measure for collagens using the hydroxyproline assay, and GAGs using 
dimethylmethylene blue staining.  Bladder and pericardial matrices acellularized using 
hypotonic buffers and DNase retained collagens and GAGs at levels similar to the native 
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tissue [128, 154, 155].  Acellular aortic valves exhibited reduced GAG, chondroitin 
sulfate, fibronectin, and laminin content after either Triton-X or Trypsin treatment, yet 
retained elastin and collagen matrix components [142].  Surprisingly, contrary to the 
numerous reports on tissues that have been acellularized, characterization of the growth 
factors retained within acellular matrices has not been as thorough.  Only a few studies 
have demonstrated successful retention of bioactive growth factors within acellular 
matrices.  FGF-2 was identified through immunostaining after tracheas were acellularized 
in 4% sodium deoxycholate and DNase [156].  Quantitative measures of two growth 
factors, VEGF and PDGF-BB, demonstrated preserved bioactive factors among four 
different acellularization treatments of porcine bladder [154, 157].  FGF-2 and TGFβ 
have been extracted and identified from acellular SIS, and increased cell mitogenicity in 
vitro was noted due to extracted factors [158].  The most extensive growth factor 
characterization was performed on acellular bladder submucosa matrix (BSM), 
identifying nine growth factors and comparing the efficiency of different buffers to 
extract these growth factors from the acellular BSM and in a bioactive form so that they 
could enhance cell proliferation in vitro [159].  All together, acellular matrices have been 
shown to be non-cytotoxic, permit cell infiltration, and subsequently aid in healing a 
number of damaged tissues, however the mechanism by which these matrices enhance 
tissue repair has yet to be elucidated. 
 
Stem Cell Therapies for Cardiovascular Repair 
The first clinical report of cell transplantation for angiogenic therapy emerged in 
2002 from Tateishi-Yuyama et al.  Injecting bone marrow-derived mononuclear cells 
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intramuscularly into patients with leg ischemia resulted in an increase in vessel formation 
and blood flow and successful limb salvage [7].  Since then, numerous stem cell therapy 
approaches have observed increased blood perfusion, capillary density, and improved 
angiogenesis utilizing a variety of cell sources to stimulate revascularization, including 
bone marrow-derived cells [6, 160-165], endothelial progenitor cells [166-169], and 
embryonic stem cells [170, 171].  In a single injury model of angiogenesis, MSCs [172] 
and early progenitor cells from human cord blood [173-175] have all shown 
revascularization induction and cytoprotective effects on endogenous cells within the 
hindlimb ischemia model.  Additionally, differentiated cells derived from ESCs have 
been examined as a potential cell source for therapeutic cell transplantation, particularly 
ESC-derived ECs, since ECs are the primary cells involved in mediating angiogenesis 
and neovascularization.  Endothelial-like cells derived from ESCs facilitated 
revascularization and inhibited muscle degeneration in ischemic models in mouse 
hindlimb, myocardium, and brain [171, 176, 177]. 
Specific negative outcomes from transplanting cells have included increased 
atherosclerotic lesion formation due to circulating vascular progenitor cells [178] and 
increased calcification within myocardium following transplantation of unselected bone 
marrow cells [179].  The utilization of pluripotent ESCs in angiogenic cell transplantation 
therapies has been investigated; however, the risk of teratoma formation in vivo generally 
outweighs the potential benefits of ESC transplantation [19].  Undifferentiated ESC 
populations transplanted to stimulate tissue repair typically result in teratoma formation 
at the site of injection due to the lack of controlled differentiation cues presented in vivo, 
[180-182].  Furthermore, the success of transplanting ESC-derived vascular cells, or any 
20 
ESC-derived cell type, depends on the ability to obtain sufficient numbers of cells for 
transplantation.  Small rodent studies typically require on the order of 106 cells, which 
could translate to between 107 - 108 cells for human clinical trials, yet the efficiencies of 
directed differentiation protocols average < 5% of the total starting undifferentiated cell 
population.  Regardless of the number of studies exhibiting cell engraftment, many have 
observed low incorporation of transplanted cells that differentiate and repopulate the 
ischemic tissue [172, 180, 183-185].  These studies suggest that upon transplantation, 
early multipotent cells produced extracellular factors that aid in the survival of 
endogenous cells needed to build new blood vessels.  Thus, further studies examining the 
contribution of cellular versus extracellular factors during cell transplantation for tissue 
regeneration must be done to elicit more definitive modes of action of stem cell therapies 
that may lead to more innovative and effective therapies designed to target those 
mechanisms. 
 
Stem Cells’ Paracrine Mode of Action 
One means of delivering stem cell-secreted soluble factors to injured tissues is 
through the use of stem cell-conditioned media (CM).  To date, the release of paracrine 
factors into media by an array of stem cells has been characterized and analyzed for their 
effects on a variety of cell types and tissues.  Recently a number of reports describe high-
throughput analyses of extracellular molecules, or secretomes, produced by stem cell 
populations.  Characterization of secretomes from a variety of stem/progenitor cells, 
including adipose-derived stem cells [186], MSCs [187], and ESCs [188], reveal the 
21 
presence of numerous factors implemented in angiogenesis and tissue repair and provide 
insight into mechanisms by which these cells promote overall healing. 
Subsequent studies further assess the impact of stem/progenitor secretomes in 
vivo.  CM generated by amniotic fluid-derived stem cells contained several pro-
angiogenic molecules, such as stromal cell-derived factor (SDF)-1, IL-8, and VEGF, and 
promoted arteriogenesis in a murine hindlimb ischemia model [189].  Studies examining 
MSC-CM resulted in accelerated in vivo wound healing, attributed to the recruitment of 
macrophages and endothelial lineage cells [190], as well as improved left ventricular 
function after myocardial infarction [191].  Comparisons between MSC- and ESC-
conditioned media perfusion following global ischemia demonstrated greater 
cardioprotective effect and decreased expression of proinflammatory cytokines in rat 
hearts treated with the ESC-CM [192].   
Additional studies examining the effects of ESC-derived paracrine factors 
revealed positive influences on tissue regeneration.  In vitro, ESC-CM enhanced bone 
marrow progenitor cell survival and decreased apoptosis, potentially due to several 
secreted factors including macrophage-colony stimulating factor (CSF), stem cell factor, 
and VEGF [193]. Additionally, inhibition of cardiomyocyte apoptosis was mediated by 
tissue inhibitor metalloproteinase (TIMP-1) presented in ESC-CM [194].  Furthermore, 
soluble ESC-secreted molecules have demonstrated efficacy, potency, and long-lasting 
effects on endogenous cells, most notably rescuing embryonic lethal Id knockout mice 
[8].  Overall, the factors secreted by stem cells and harbored in conditioned media retain 
bioactivity to promote regenerative processes.  These cell-free examinations of stem cell-
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secreted paracrine factors motivate alternative methods to utilize the therapeutic potential 
of stem cells.   
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CHAPTER 3 
GENE EXPRESSION SIGNATURES OF EXTRACELLULAR 




For nearly three decades, embryonic stem cells (ESCs) have been used as a model 
of mammalian developmental morphogenesis in order to define and characterize 
mechanisms of self-renewal and differentiation of pluripotent cells [20, 21, 195].  The 
pluripotent differentiation potential of ESCs and derivation of human ESCs have also 
motivated the pursuit of regenerative ESC therapies to restore endogenous cells to tissues 
afflicted by traumatic injuries or chronic disease [19, 42].  In recent years, an increasing 
emphasis has also been placed on the potent paracrine morphogenic effects of molecules 
synthesized and secreted by stem cells, including ESCs [8, 194, 196].  In vitro, ESCs are 
commonly induced to differentiate via the spontaneous assembly of cell aggregates in 
suspension referred to as embryoid bodies (EBs) [44, 197].  The temporal sequence of 
ESC differentiation that occurs spontaneously within EBs recapitulates several aspects of 
early embryogenesis, including gastrulation to yield derivatives of the three germ 
lineages – ecto-, endo-, and mesoderm [42, 44].  While most studies of ESC 
differentiation have focused on the temporal expression changes of intracellular signaling 
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molecules and phenotypic markers that accompany differentiation, the complex patterns 
of extracellular molecule expression by differentiating pluripotent stem cells that can 
significantly influence cell phenotype(s) remain less well defined. 
 Exogenous administration of combinations and sequences of ECM and growth 
factor molecules has been attempted to direct the differentiation of stem cells in vitro to 
many cell phenotypes by precisely controlling the biochemical composition of the cell 
microenvironment.  This strategy, often based on well-established principles of 
developmental biology, has been successfully employed to direct pluripotent stem cell 
differentiation, but many protocols are not highly efficient.  For example, growth factors 
such as bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), and 
vascular endothelial growth factor (VEGF), as well as adhesive ECM proteins, such as 
fibronectin, collagens, and laminin, have been commonly applied to promote the 
differentiation of particular cell fates [198-201].  The development of high-throughput 
combinatorial array technologies can facilitate more rapid, parallel screening of ESC 
differentiation effects by a broad contingent of ECM and growth factor molecule 
combinations [202, 203].  Despite the wealth of information gained from studies of 
exogenously applied extracellular molecules, curiously much less is known about the 
inherent ECM and growth factors produced by ESCs as a consequence of differentiation.  
Some studies have begun to examine the gene expression profile of early EBs using 
microarrays [204-206], while others have investigated aspects of the EB transcription 
factor [207] and glycomics profiles [208].  In addition, the endogenous production of 
specific individual matrix molecules has been found to correlate with specific cell 
phenotypes [209-211], suggesting that the molecules produced locally within EBs can 
25 
influence ESC differentiation.  Thus, globally examining the temporal profile of 
endogenous ECM and growth factor expression by ESCs during the course of EB 
differentiation could yield new insights into the extracellular factors regulating the 
different stages of pluripotent stem cell differentiation.   
Microarrays have been widely used to screen for and identify key regulators in 
complex systems, resulting in the development of systems analysis approaches to dissect 
the molecular dynamics in cellular microenvironments.  In such dynamic systems, the 
often-studied temporal changes drastically increase the amount of data; as a result, 
typically only the most significantly changing genes are reported and dominate the 
subsequent forms of analysis, while many potentially equally important genes and classes 
of molecules remain buried within the massive wealth of data obtained.  As an 
alternative, microarrays have inspired the development of low-density array technologies 
that enable the investigation of a more focused subset of molecules while still capturing 
the dynamic changes of a system such as differentiating stem cells. 
In this study, initial single RT-PCR gene expression analysis focused on the 
spontaneous differentiation of EBs towards a cardiovascular lineage.  Previous studies 
have indicated that spontaneously differentiating EBs have the potential to differentiate 
towards more vascular cell types [50, 212].  Thus gene and protein expression analysis 
evaluated endothelial cell differentiation within EBs using phenotypic markers, in 
addition to the expression of growth factors, particularly angiogenic growth factors.  The 
differential expression of several individually assessed growth factor genes motivated a 
high throughout method to examine the expression of growth factors and other 
extracellular factors as EBs progressively differentiated over time.  Therefore, global 
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assessment of the dynamics of ECM and growth factor expression associated with the 
differentiation of ESCs within the EB microenvironment using low-density PCR arrays 
for gene expression and pathway analyses.  Gene expression of EB differentiation 
focused on ECM components, including cell adhesion molecules, matricellular proteins, 
integrins, and proteases, as well as growth factors, including members of the BMP, FGF, 
transforming growth factor β (TGFβ), and interleukin (IL) families.  Gene expression 
profiles were contrasted using hierarchical clustering, k-means clustering, and statistical 
mapping to identify different global patterns of expression, as well as shared profiles of 
independent molecules; the combination of these approaches enabled the identification of 
groups of molecules expressing either coincident or divergent expression patterns.  
Subsequent pathway analyses highlighted key signaling pathways acting on transcription 
factors regulating ESC phenotype at different stages of differentiation that were 
reconstructed solely from ECM and growth factor expression data.  Thus, characterizing 
the dynamic relationships between ECM/growth factor expression and EB differentiation 
using the novel analytical framework described provides new insights into the 
biochemical composition of the extracellular microenvironment regulating pluripotent 
stem cell biology and associated with early morphogenic differentiation events.  
 
Methods 
Embryoid body culture 
Mouse embryonic stem cells (ESCs; D3 cell line) were initially expanded on a 
feeder layer of mouse embryonic fibroblasts and were subsequently cultured feeder-free 
for several passages on 0.1% gelatin-coated 150 mm polystyrene cell culture dishes 
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(Corning) with Dulbecco’s modified eagle medium (Mediatech), supplemented with 15% 
fetal bovine serum (HyClone), 2 mM L-glutamine (Mediatech), 1x MEM non-essential 
amino acid solution (Mediatech), antibiotic/antimycotics (Mediatech), and 0.1 mM β-
mercaptoethanol (MP Biomedicals, LLC).  Undifferentiated cells were expanded prior to 
EB formation in the presence of 103 U/mL leukemia inhibitory factor (LIF) (ESGRO), 
which was added to the culture media upon each re-feeding.  Cells were passaged every 
two to three days before reaching ~70% confluence.  To initiate EB culture, ESCs were 
trypsinized from the gelatin-coated dishes using 0.05% Trypsin/0.53 mM EDTA 
(Mediatech).  A density of 400,000 cells/mL was used to inoculate 10 mL EB cultures in 
100 mm bacteriological grade polystyrene Petri dishes (Corning) using differentiation 
media (ESC media without LIF).  EB suspension cultures were maintained on rotary 
orbital shakers (Barnstead Lab-Line, Model 2314) at 40 rpm at 37°C in 5% CO2 for the 
entire duration of suspension culture.  Previous work from our lab has demonstrated that 
rotary orbital suspension culture methods result in greater yields of homogeneous 
populations of EBs [213].  EBs were cultured in suspension for up to 14 days and re-fed 
every other day after collecting independent EB cultures via gravity-induced 
sedimentation in 15 mL conical tubes.  Spent media was aspirated, and the cultures were 
replenished with 10 mL of fresh differentiation media before being placed back in the 
Petri dishes and returned onto the rotary orbital shakers. 
 
Microscopy and histological analysis 
 EB morphology was monitored daily by phase microscopy for up to 14 days of 
differentiation using a TE2000 microscope (Nikon) and a Spot Flex camera (Diagnostic 
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Instruments, Inc.).  For histological analysis, EBs collected at different stages of 
differentiation (4, 7, 10, or 14 days) were fixed with 10% formalin for 30 minutes and 
embedded in Histogel® (Richard-Allan Scientific).  Histogel®-embedded samples were 
either frozen or paraffin processed.  Samples for frozen embedding were soaked in 30% 
sucrose solution overnight at 4oC followed by embedding in OCT (Tissue-Tek) at -80oC.  
Samples in histogel were prepared for paraffin embedding with a series of xylene and 
alcohol rinses and embedded in paraffin.  Frozen sections (10µm) were obtained using a 
cryostat (Microm Cryo-Star HM 560MV), and paraffin sections (5µm) will be acquired 
using a microtome.  Prior to immunostaining, frozen sections were fixed in cold acetone 
for 10 minutes; paraffin sections were de-paraffinized.  Paraffin sections were stained 
with hematoxylin and eosin (H&E) using a Leica AutoStainer XL and coverslipped using 
low viscosity mounting medium (Cytoseal™ 60).  For immunostaining, slides were 
blocked and permeabilized simultaneously in 2% BSA and 0.05% TritonX-100, 
respectively, in PBS for 45 minutes at room temperature.  After 3 rinses (5 minutes each) 
in PBS, slides were incubated with either PECAM-1 or VE-CAD primary antibody 
(Santa Cruz Biotech) diluted (1:200) in blocking solution for 2 hours at room 
temperature.  Subsequent PBS rinses (3X) were followed by incubation with FITC-
conjugated secondary antibody (Southern Biotech) diluted (1:200) in blocking solution 
for 1 hour at room temperature, counterstained with Hoechst (1:100 dilution) for 5 
minutes at room temperature, rinsed in PBS with a final wash in dI H2O.  Slides were 
mounted and cover slipped using Gel/Mount™ with anti-fading agents (Biomeda Corp.).  
All slides were imaged on a Nikon 80i microscope equipped with a SPOT Flex Camera 
(Diagnostic Instruments). 
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Quantitative reverse-transcription polymerase chain reaction  
RNA was extracted from undifferentiated ESCs and EBs at days 4, 7, 10, and 14 
of differentiation (n ≥ 3 for each sample) using the RNeasy Mini Kit (Qiagen).  
Complimentary DNA was reverse transcribed from 1 µg of total RNA using the iScript 
cDNA synthesis kit (Bio-Rad), and real-time RT-PCR was performed using SYBR Green 
technology with a MyiQ cycler (Bio-Rad).  Beacon Designer software was used to design 
forward and reverse primers for pluripotency and differentiation markers as well as for 
the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (Gapdh), which were 
each independently validated with appropriate positive cell controls.  Relative levels of 
pluripotent gene expression were calculated compared to undifferentiated ESC samples 
and normalized to Gapdh using the ΔΔCt method [214], whereas gene concentrations for 
differentiated markers were calculated based upon standard curves and normalized to 
Gapdh expression levels [215].   
 For SuperArray RT2 Profiler™ PCR array analysis, cDNA synthesis was 
performed using the SuperArray RT2 First Strand kit (SABiosciences).  A genomic DNA 
elimination mixture was prepared by first mixing 0.5 µg RNA with 5x gDNA 
Elimination Buffer and RNase-free water and then incubating at 42oC for 5 minutes.  The 
RT cocktail (5x RT Buffer 3, Primer & External Control Mix, RT Enzyme Mix 3, and 
RNase-free water) was prepared and added to the elimination buffer mixture.  Each 
cDNA sample was synthesized in an iCycler Thermal Cycler (Bio-Rad) (15 minutes at 
42oC, 5 minutes at 95oC) and diluted with RNase-free water after synthesis was complete.  
RT-PCR was performed by first preparing the experimental cocktail (2x SuperArray RT2 
qPCR Master Mix, first strand cDNA synthesis reaction, and RNase-free water) and then 
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equally distributing the cocktail (25µL) into all of the individual wells of the PCR 96-
well array (Mouse Extracellular Matrix and Adhesion Molecules array or Mouse growth 
factors array).  Only one gene, secreted phosphoprotein 1 (Spp1), overlapped between 
both arrays besides the housekeeping genes and internal controls.  Each array was tightly 
sealed with optical thin-wall 8-cap strips and amplified in a MyiQ cycler (Bio-Rad) with 
a two-step cycling program (1 cycle, 10 minutes, 95oC; 40 cycles, 15 seconds, 95oC; 40 
cycles, 1 minute, 60oC).  Fold changes in gene expression were analyzed using the ΔΔCt 
method for quantification, whereby samples of EBs from different time points (days 4, 7, 
10, and 14) were compared relative to undifferentiated ESC values after individual 
sample values were normalized to internal Gapdh levels.   
 
Gene clustering analysis: hierarchical clustering and k-means 
 Gene expression changes by differentiating EBs were calculated as either fold 
change increases or decreases at each time point examined compared to ESCs, using 
Gapdh as the normalization gene as described above.  Initially, the results of the 
independent ECM and growth factor PCR arrays were separately analyzed by Genesis 
(Release 1.7.5) array analysis software.  Two-dimensional hierarchical clustering of the 
log2-transformed data sets was performed across the different genes and time points 
using Euclidean distance and average linkage clustering.  The clustering results were 
represented visually by a heat map dendrogram, with green indicating decreased 
expression and red indicating increased expression relative to undifferentiated ESCs.  The 
relative color intensity values corresponding to the magnitude of fold change (either an 
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increase or a decrease) were set between -7.0 and 7.0 to provide a distinct color range for 
all log-transformed magnitudes. 
 Prior to all further analysis, both ECM and growth factor array data were 
combined and no longer examined as distinct sets of genes.  The average fold change 
values of ESCs and EBs of each gene from the entire time course were analyzed using k-
means clustering analysis in Genesis software (version 1.7.5).  In order to determine the 
optimal number of k-means clusters that sufficiently captured the different distinct 
profiles of the entire data set, cluster number was varied between 4 and 20 and evaluated 
for a maximum of 300 iterations.  Analysis with fewer clusters (4-8) did not distinguish 
different patterns of expression as clearly, whereas larger numbers of clusters yielded 
some independent groups with as a few as 1-2 genes; therefore, subsequent k-means 
analysis was performed using 12 clusters.  In the k-means graphs, the x-axis at zero 
represents the undifferentiated ESC baseline, and the centroid of each cluster is indicated 
by a black line (Figure 3B-M).   
 
Statistics 
Significance testing was conducted using SYSTAT (Version 12) software.  For 
individual genes, expression fold change comparisons across time points were evaluated 
using a one-way analysis of variance (ANOVA) with subsequent post-hoc Tukey analysis 
to determine significance (p < 0.05).  Significant differences in expression fold change 
between consecutive time points were depicted with a branch schematic for all genes 
from the array, with increasing or decreasing slopes representing positive or negative fold 
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differences, respectively, while non-significant differences were illustrated as horizontal 
lines.  
 
Ingenuity Pathway Analysis (IPA) 
Pathway analysis of genes that exhibited significant changes over time was 
performed using Ingenuity Pathway Analysis (Version 7.5, Ingenuity® Systems) to 
examine the biological functions and signaling pathways that were implicated in EB 
development.  For each time point (days 4, 7, 10, and 14), fold changes (-46.25 to -1 and 
1 to +513.58) were filtered in IPA using a minimum 2-fold change threshold; from these 
genes, a list of “focus” genes was generated that contained molecules present in IPA’s 
knowledge database (78% of eligible molecules).  Based on the resulting eligible genes 
from the array (“focus genes”) and IPA’s database containing gene associations (via 
physical or biological interactions), the top biological functions and networks for each 
time point were assessed.  Biological functions were tested for significance (p < 0.01) 
using the Benjamini-Hochberg (B-H) multiple testing correction method to account for 
false-positives and were then ranked in order of most to least significant (–log (B-H p-
value); presented here according to day 4 EB ranking results).  Based on published 
literature reports, IPA generated networks that included interactions between the array 
molecules as well as connections between array molecules and other molecules present in 
the IPA database.  Each of the networks generated by IPA included up to 25 focus genes 
and was assigned a relative score by the software reflecting the probability that a given 
gene in a particular network was present by chance, with higher scores indicating a lower 





The time course of EB differentiation was examined morphologically and phenotypically 
prior to performing semi-global gene expression analysis.  Using rotary orbital 
suspension culture, the formation of EBs and maintenance of the EB population remained 
relatively uniform over the time course examined (Figure 3.1A-D), similar to previously 
published reports [213].  Evidence of progressive differentiation was indicated by 
changes in the organization and morphology of the cells within EBs (indicated by black 
arrows), as well as the increasing appearance of cystic cavities (red arrows) (Figure 3.1E-
H).  The eosinophilic (pink) staining apparent by day 10 and accumulating by day 14 was 
visible primarily in regions of EBs with a lower cell density, possibly suggesting an 
increase in matrix deposition by the cells.  Over time, the average fold change of Nanog, 
a pluripotent transcription factor (Figure 3.1I), decreased from 0.701 ± 0.18 at day 4 to 
0.136 ± 0.06 by day 14 of differentiation (compared to ESCs).  Conversely, the endoderm 
differentiation marker α-fetoprotein (Afp) was expressed at significantly increased levels 
by day 14 compared to all other time points examined (p = 0.001; Figure 1F).  In 
addition, several genes indicative of ectoderm (Nestin) and mesoderm differentiation 
(Gata4, Nkx2.5, myocyte enhancer factor-2c, alpha myosin heavy chain, myosin light 
chain-2 ventricle) increased over time (data not shown), thus further confirming the 






Figure 3.1.  Embryoid body morphology and differentiation.  (A-D) EBs cultured 
using rotary orbital culture maintained morphological homogeneity and increased in size 
over the course of differentiation.  (E-H) H&E staining of EBs exhibited changes in cell 
organization and morphology within EBs (black arrows) and increasing appearance of 
cystic cavities (red arrows).  (I) Gene expression of the pluripotent marker Nanog, 
relative to ESC levels, decreased as EB differentiation proceeded.  (J) Conversely, gene 
expression of Afp, a marker of endoderm differentiation, increased significantly by day 
14.  * ANOVA: p < 0.05 compared to all other time points. Results indicated are 
mean±standard deviation (n=3). 
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 The differentiation of EBs towards the endothelial lineage was examined over 
time using gene expression analysis of several phenotypic markers, including Vegf-a 
receptors Flk-1 and Flt-1, and cell adhesion molecules Pecam-1 and VE-cadherin.  Over 
time, gene expression levels of endothelial cell adhesion molecules Pecam-1 and VE-Cad 
increased from 3- and 5-fold at day 4 to 51- and 102-fold by day 10, respectively (Figure 
3.2A).  As for Vegf-a receptors Flk-1 and Flt-1, gene expression levels for both remained 
relatively similar between days 4 and 10; however, the magnitude of the fold changes 
(compared to ESCs) between each gene was considerable, with Flk-1 ~45-fold and Flt-1 
~7-fold increases.  Protein expression of both cell adhesion molecules PECAM-1 and 
VE-CAD was confirmed for EBs obtained at days 7 and 10, which exhibited the largest 
increases in gene expression during these time points.  Within day 7 EBs, 
immunostaining demonstrated the expression both proteins was diffuse throughout the 
EB; whereas by day 10 the expression of both proteins was localized to the perimeter of 
the EB (Figure 3.2B). The coincident decrease in pluripotency and increase in germ 
lineage marker expression and later stage differentiation markers, as well as the EB 
morphological changes that occurred over 14 days of suspension culture were consistent 
with previous studies from our laboratory [213, 216, 217] that indicated progressive 




FIGURE 3.2.  Expression of endothelial phenotypic markers and growth factors.  
(A) Gene expression of phenotypic markers of EC differentiation increased with EB 
differentiation.  (B) Protein expression of endothelial markers PECAM-1 and VE-CAD 
(FITC) with nuclei counterstain (Hoechst).  By day 10, EBs spatially regulate the 
expression of both endothelial markers.  (C) Gene expression of several growth factors 
generally increased during EB differentiation. Results indicated are mean±standard 
deviation (n=3). 
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Initial insight into the expression of extracellular factors, particularly growth 
factors, by ESCs differentiating within EBs was evaluated on a gene-by-gene basis, 
including a few angiogenic growth factors, Fgf-2, Vegf-a, and Pdgf-b, as well as more 
development-specific growth factors, Ifg-1 and Igf-2 (Figure 3.2C).  Fgf-2 and Vegf-a 
were expressed at similar levels (~1-fold and 2.5-fold, respectively) between 4 and 7 
days, yet increased in expression in day 10 EBs to ~2.5- and 9-fold, respectively.  Pdgf-b 
was present at a slightly lower level (0.75-fold) than ESCs at day 4 and continued to 
decrease between 7 and 10 days (~ 0.2-fold).  These three growth factors broadly affect a 
number of cells types, including specific roles in stimulating endothelial cells during 
angiogenesis.  The Igfs were also examined for changes in gene expression during EB 
differentiation, particularly due to reported favorable effects of Igf-1 on angiogenesis 
[218, 219] and the role of Igf-2 in up-regulating Vegfa and promting endothelial 
progenitor cell homing [220, 221].  Ifg-1 and Igf-2 expression levels steadily increased as 
EB growth progressed, starting from ~ 8.5- and 5-fold change at day 4 to 71-fold and 45-
fold by 10 days, respectively.  The diverse modulation of these different growth factors 
demonstrate the complex nature of EB differentiation within 10 days, which warranted a 
more global assessment of the differential expression of extracellular factors during ESC 
differentiation within EBs. 
 
Gene clustering based on expression profiles  
 In order to visualize the general gene expression patterns exhibited by EBs and to 
identify any subsets of molecules undergoing coincident expression changes over time, 
two-dimensional hierarchical clustering was performed independently for both the 
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extracellular matrix and adhesion molecules array (referred to subsequently as the ECM 
array; Figure 3.3A) and the growth factors array (Figure 3.3B) to initially assess the 
clustering of genes within each array.  In both the ECM and growth factor arrays, 
independent replicate EB samples examined at each of the individual time points 
clustered together; in addition, the earlier (4 and 7 days) time points clustered separately 
from the later (10 and 14 days) time points, altogether demonstrating the reproducibility 
of the independent experimental samples as well as distinct shifts in gene expression 
occurring over the course of differentiation.  For each array, increasing (red) and 
decreasing (green) patterns of gene expression over time were evident, while a number of 
genes also appeared relatively unchanged compared to undifferentiated ESCs over the 
period of time examined.  In the ECM array, ~18% of the molecules (16 genes) clustered 
together and appeared to decrease considerably over time relative to ESC levels, while 
~16% (14 molecules) consistently increased over the course of differentiation and 
clustered together.  The remaining 66% (59 molecules) exhibited nominal changes 
roughly equivalent to baseline values (similar to ESC levels).  In contrast to the ECM 
array, there were a greater number of genes from the growth factor array that clustered 
together due to their increasing (~29%; 26 molecules) or decreasing (~31%; 28 
molecules) expression patterns.  Within these relatively broad classifications, visibly 
distinct clusters emerged from both arrays, including five sharply increasing molecules in 
the ECM array that exhibited 46- to 513-fold increases compared to ESCs by day 14 
(indicated by the black bar, Figure 2A).  In contrast, 15 molecules in the growth factor 
array clustered together that exhibited as much as a 25-fold decrease compared to ESCs 
(black bar, Figure 2B).  Overall, a larger percentage of genes in the growth factor array 
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Figure 3.3.  Hierarchical clustering of ECM and growth factor genes.  Gene 
expression fold changes compared to undifferentiated ESCs were log2-transformed and 
analyzed using hierarchical clustering on Genesis software.  Of the 84 extracellular 
matrix genes analyzed (A), approximately 34% of the genes demonstrated either an 
overall decrease (green) or increase (red) in gene expression relative to undifferentiated 
ESCs, whereas approximately 60% of the 84 growth factor genes (B) resulted in overall 
expression changes relative to ESCs.  Black bars highlight noticeable gene clusters in 
each array set.  
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(~60%) exhibited either increasing or decreasing fold changes than genes contained 
within the ECM array (34%).  Identifying such groups of genes in any data set may lead 
to the classification of subgroups that are similarly regulated over the given condition, but 
changes in the magnitude of gene expression alone are not necessarily sufficient to 
accurately yield insights into the key regulators of the system.
 In addition to examining the ECM and growth factor arrays individually, a 
complete heat map of the entire set of experimental data from both arrays was generated 
using the average fold change values of each gene to examine how potential ECM and 
growth factors clustered together (Figure 3.4A).  Based on hierarchical clustering, five 
groups of genes (labeled I – V) were identified whose expression pattern increased or 
decreased to varying degrees compared to ESCs (Table 3.1).  Groups I and IV contained 
genes whose expression increased over the course of differentiation, while genes in 
groups II and V decreased, and those in group III remained relatively unchanged 
compared to ESCs.  In order to more clearly define the temporal expression patterns 
embedded within the data, k-means analysis of the log2-transformed fold changes was 
performed (Figure 3.4B-M).  Genes within the five groups identified in the heat map 
were represented in 12 k-means plots by the corresponding colors (red = group I, green = 
group II, grey = group III, orange = group IV, blue = group V), clearly showing the 
ability of k-means analysis to further distinguish subgroups embedded within the 
hierarchical clustering data set.  As described in the methods, k-means analysis with a k- 
value of 12 captured an array of different expression patterns with a range of 6-29 genes 
per cluster (Table 3.2).   
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Figure 3.4.  K-means clustering of combined array sets.  (A) The hierarchical cluster 
produced by merging data from both the ECM and growth factor arrays exhibits several 
identifiable clusters, indicated by groups I – V.  (B-M) K-means clustering of the 
combined data set highlights the subtle temporal changes in gene expression while 
clustering genes that follow similar patterns of expression over time.  The expression 
profile for each cluster (panels B-M) is indicated by the solid black line, which connects 
the centroid at each time point.  The colored lines in each panel correspond to genes in 
the color-coded groups (I – V) established by hierarchical clustering (A).   
 
42 
The k-means plots highlighted the dynamic nature of expression values associated 
with temporal changes, with few genes exhibiting continually increasing or decreasing 
profiles and only one centroid (black line) consistently increasing between each of the 
different time points examined (Figure 3.3M).  Genes associated with the four k-means 
clusters where the centroid tended to decrease throughout differentiation (Figure 3.3B-E; 
43 genes, ~25% of the total number of genes studied) came primarily from hierarchical 
cluster groups II and V, demonstrating the ability of k-means to distinguish additional 
specific groups of genes from the hierarchical clusters.  In addition, genes that appeared 
to change nominally over time by hierarchical clustering analysis (group III) were 
divided into four different k-means plots (Figure 3.3F-I; 71 genes, ~41%), each 
containing centroids that exhibited differing profiles between the examined time points.  
Similarly, genes that clustered in groups I and IV were primarily distributed amongst four 
k-means plots (Figure 3.3J-M; 58 genes, ~34%) that almost exclusively contained genes 
exhibiting larger increases at later stages (post-day 7) of differentiation.  Overall, the k-
means cluster analysis largely sub-divided the groups initially generated by hierarchical 
clustering into more distinct temporal expression patterns, and thereby enabling the 
identification of several groups of ECM molecules and growth factors that shared similar 
temporal expression profiles and may therefore play coordinated roles in differentiation.   
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Table 3.1. Genes in each cluster represented in Figure 3.3. 
 














































































































































































Table 3.2. Genes in each k-means plot represented in Figure 3.3. 


















































































































































































Parallel analysis of variance (ANOVA) significance testing 
Although hierarchical and k-means clustering analysis enabled the identification 
of subgroups of genes that were similarly expressed over the course of differentiation, the 
correlative relationships were based upon the magnitudes of fold change relative to the 
starting state (ESCs), but didn’t account for statistical changes occurring between each of 
the discrete time points examined.  Parallel independent ANOVA analysis for each gene 
was therefore performed to evaluate significant changes in gene expression over time 
(Figure 3.4).  In general, the number of genes exhibiting significant differences in 
expression between time points increased with the progression of development.  
Approximately 16% of the genes examined changed significantly between day 0 (ESCs) 
and day 4, 10% between days 4 and 7, ~22% between days 7 and 10, and ~44% between 
days 10 and 14.  By day 4 of differentiation, ~89% of the molecules that changed 
significantly exhibited decreases in gene expression compared to ESCs, whereas by day 
14, ~99% of genes that changed significantly increased compared to day 10.  These 
contrasting patterns suggest that decreased expression of a small subset of extracellular 
factors followed by increased expression of many matrix and growth factor morphogens 
accompany ESC differentiation within EBs.   
 The ANOVA results were depicted in the form of a statistical “tree” to distinguish 
the numbers of genes either increasing, decreasing or not changing significantly between 
each of the time points of differentiation examined (Figure 3.4A).  A third of the genes 
(58 out of 171 total) did not change significantly throughout the entire 14-day EB culture 
period (Figure 3.4B), including Fgf2, matrix metalloproteinase 2 (Mmp2), and the 
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Figure 3.5.  Parallel ANOVA analysis.  (A) ANOVAs were performed across each time 
point for individual genes from both ECM and growth factor arrays.  Results are depicted 
using a tree schematic, where the slope of the line between each time point indicates a 
significant increase (positive slope), significant decrease (negative slope), or no 
significant changes (zero slope). The number of genes in individual categories is shown 
on each line.  A majority of the genes analyzed do not change significantly by 14 days of 
EB culture; however, a large number of genes significantly increase in expression 
between days 10 and 14. (B-F) Each graph highlights individual profiles of statistical 
changes in gene expression, including the number of genes encompassed in the respective 
profile and a sample of specific genes. 
 
47 







3.5E Figure 3.5F 
57 genes 24 genes 10 genes 12 genes 47 genes 
Actb  Il18 Adamts8  Bmp4 Bmp5 Adamts1  Hapln1 
Adamts2 Il1a  Bmp4  Col1a1 Fgf10 Bdnf Igf1 
Amh   Il1b  Bmp8a  Csf1 Gdf11 Bmp1 Inha 
Artn Il2  Bmp8b  Ctgf Igf2 Bmp3 Itga2 
Bmp10  Il3  Col1a1  Fgf13 Kitl Bmp6 Itga4 
Cdh1 Il4  Csf1  Itga3 Rabep1 Cd44 Lama1 
Cdh2 Il6  Ctgf  Itgb3 Spock1 Cntn1 Lama2 
Cdh3  Il7  Fgf13  Itgb4 Tgfa Col3a1 Lamb2 
Cdh4 Inhba  Fgf17  Lamc1 Tgfb1 Col4a1 Lif 
Csf2  Itga5 Fgf18  Thbs1 Tgfb2 Col4a2 Mdk 
Csf3  Itgae  Hprt1   Timp2 Col5a1 Mmp11 
Ctnna1  Itgav Icam1   Zfp91 Col6a1 Mmp9 
Ctnnb1  Itgax  Inhbb     Ctnna2 Ntf5 
Egf  Itgb1 Itga3     Cxcl1 Pgf 
Ereg  Lefty2 Itgal     Cxcl12 Postn 
Fgf11  Lep  Itgb3     Ecm1 Tgfb3 
Fgf2  Mmp13  Itgb4     Emilin1 Tgfbi 
Fgf22  Mmp14 Lama3     Entpd1 Timp3 
Fgf6  Mmp2 Lamc1     Fbln1 Tnc 
Fgf7  Mmp8  Pdgfa     Fgf3 Vcam1 
Fgf9 Ncam1  S100a6     Figf Vcan 
Gdf10  Ngfb  Spp1     Fn1 Vegfa 
Gdf5  Ntf3 Syt1     Gdnf Vegfc 
Gdf8  Sele  Thbs1      Vtn 
Hc Sell          
Hgf  Sparc         
Hsp90ab1  Tff1          
Il11  Thbs3         
Il12a  Timp1           
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housekeeping genes heat shock protein 90kDa alpha (cytosolic), class B member 1 
(Hsp90ab1) and β-actin (Actb).  In the previous analyses, hierarchical and k-means 
clustering results similarly indicated that expression of both Hsp90ab1 (Figure 3.3A, F) 
and Fgf2 (Figure 3.3A, I) did not vary with time.  In contrast, the Mmp2 (Figure 3.3A, K) 
and Actb (Figure 3.3A,D) profiles generated by the clustering methods suggested 
increasing and decreasing expression over time, respectively, indicating that conventional 
clustering analyses alone may not accurately convey the truly significant differences that 
emerge with progressive differentiation.  Importantly, several distinct groups of genes 
that did change significantly during EB differentiation could be extracted from the 
statistical tree results, with each containing 4-27% of the total number of the molecules 
contained within the arrays (Figure 3.4C-F; Table 3.3).   
Interestingly, specific families of molecules often tended to appear within the 
same statistical “branches”, suggesting that related molecules may be coordinately 
regulated during the course of EB differentiation.  For example, cadherins (4/4 genes 
analyzed in the array), fibroblast growth factors (6/17 genes), interleukins (10/10 genes), 
and matrix metalloproteinases (4/12 genes) all appeared within the group of genes that 
did not change significantly between consecutive time points (Figure 3.4B), whereas 
members of the transforming growth factor (5/5 genes), laminin (3/6 genes), and collagen 
(5/8 genes) families exhibited coordinate changes, such as increasing significantly 
between days 10 and 14 (Figure 3.4E,F).  The increasing diversity of molecular 
expression profiles that appeared over the entire 14-day EB time course examined was 
presumably reflective of the complexity of the extracellular EB environment.  Mapping 
significant changes in gene expression over time provides a global view of matrix 
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signatures that can highlight subgroups of statistically related molecules, independent of 
magnitude changes, whose coordinated increase or decrease in expression may be related 
to the course of specific differentiation events. 
   
Pathway Analysis 
Network analysis was performed using only the genes that changed significantly 
over the course of differentiation (~67% of all genes examined) and that exhibited more 
than two-fold expression changes compared to ESCs.  Using the IPA database, biological 
functions represented by these genes were generated and ranked (only the highest- (A) 
and lowest-ranked (B) graphs are shown in Figure 3.6).  Interestingly, processes that 
typically occur during embryonic morphogenesis consistently appeared among the top 10 
functions for each time point, including “cell growth & proliferation”, “tissue 
development”, “cell movement”, and “cardiovascular system development & function”.  
In contrast, the lowest ranking functions (Figure 3.6B) largely included disease states not 
conventionally related with development, such as “auditory disease”, “metabolic 
disease”, and “renal and urological disease”; bars absent from the graph were indicative 
of functions where no array gene met the threshold criteria.  Altogether, the ranking order 
of these functions suggested that the gene expression analysis of extracellular factors 




Figure 3.6.  Biological functions related to global gene expression changes. Graphs of 
biological functions were generated using “focus” genes and the database of gene 
interactions present within Ingenuity Pathway Analysis software. (A) The ten highest-
ranked biological functions that were significant at different differentiation time points 
consisted of processes typically related to development, including morphogenesis and 
proliferation.  (B) In contrast, the ten lowest-ranked biological processes included disease 




The networks generated from the gene expression data highlighted the transition 
of the differentiating ESCs away from a pluripotent state (the top network for each time 
point is shown in Figure 3.7).  Across the networks, several “hub” genes exhibited at least 
six network connections, including array genes fibronectin (Fn1; day 4), Mmp9 (day 7), 
Vegfa (day 10), and insulin-like growth factor 1 (Igf1; day 14).  At day 4 (Figure 3.7A), 
the top network was generated with 15 genes from the array (probability of random gene 
placement = 10-23; i.e. score = 23).  Many of the molecules included in the top day 4 
network were related to the p53 transcription factor that acts to suppress the pluripotent 
marker Nanog and thereby induce differentiation [222].  The top network at day 7 (Figure 
3.7B) contained 17 of the array genes (score = 24) as well as several extracellular factors 
related to p53; however, there were several growth factors that act on p53 in the day 4 
network not present at day 7, indicating an emergence of different roles for growth 
factors by day 7.  Along with the greater number of genes significantly increasing over 
time, the number of genes included in the networks at later time points also grew such 
that the top networks for days 10 (Figure 3.7C) and 14 (Figure 3.7D) contained 22 (score 
= 35) and 25 (score = 39) array genes, respectively.  Interestingly, compared to earlier 
time points, the network at day 10 included several more nuclear factors, such as friend 
leukemia integration 1 (Fli1), TATA box binding protein-associated factor 4B (Taf4b), 
and cell division cycle 73 (Cdc73), linked to extracellular factors, but their connectivity 
was low (2-3 connections) compared to the number of connections formed to p53 at days 
4 and 7.  This increase in the number of nuclear factors present in the day 10 network is 
suggestive of fewer shared nuclear targets by the  
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 Figure 3.7.  Gene networks identified during early EB differentiation.  Network 
analysis using Ingenuity Pathway Analysis software was performed on genes that 
changed significantly over the course of differentiation and that exhibited at least a two-
fold expression change compared to ESCs.  The shift in the top networks between (A) 
day 4, (B) day 7, (C) day 10, and (D) day 14 demonstrates a progression from a more 
undifferentiated state (A) towards more differentiated ones (B-D).  Relationships are 
divided into direct (solid line) and indirect (dashed line, - - - - ) interactions, with arrow 
heads exhibiting the affected gene (    ), as well as several “hub” genes.  Varying 
intensities of green denote negative fold changes, while shades of red indicate positive 
fold changes over ESCs.  Grey genes represent genes with fold changes less than 2 that 
are related to other genes in the network, while genes with no color were not contained in 
the array data set. 
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differentiating cells, possibly indicating the onset of diverging cell phenotypes.  Overall, 
the physical and biological network connections generated using statistically significant 
array data highlight the ability of ECM and growth factor molecules alone to elucidate 
global trends in cell growth and differentiation as a function of time.  
 
Discussion 
A global view of the extracellular matrix and morphogen expression profiles of 
stem cells elicited the dynamic changes that occur coincidentally with differentiation.  
The individual assessment of specific genes of interest demonstrated the diverse 
expression profiles of a few genes as well as the necessity for analyzing the global 
changes in expression of extracellular factors.  Hierarchical clustering highlighted general 
patterns of expression, which is useful for quick detection of subsets of genes that 
generally increased, decreased, or remained similar to baseline levels (in this case, 
undifferentiated ESCs).  For the time-dependent data set presented here, two-way 
hierarchical clustering was useful for assessing whether non-consecutive time points 
exhibited any overall expression pattern similarities.  K-means analysis was able to 
further parse out the temporal relationship across genes by isolating subsets of groups 
with distinct expression patterns.  In order to statistically evaluate gene expression 
patterns, parallel ANOVAs were mapped to clearly highlight significant changes 
occurring between the different stages of differentiation.  Finally, performing pathway 
analysis identified links between molecules while highlighting key regulator genes within 
each network.   
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As ESCs differentiate within the 3D EB environment, the extracellular gene 
expression patterns dynamically change according to the phenotypic and morphological 
changes occurring within the cells.  Differentiation of ESCs within EBs is an increasingly 
complex process due to the heterogeneous differentiation of the cells to different 
phenotypes.  By analyzing a large number of molecules simultaneously, subtle changes in 
expression can be used collectively to analyze the system, in contrast to the traditional 
approach of focusing on the gene expression changes of one molecule at a time [209].  
However, results from individual gene analysis provided motivation to investigate a 
broad array of factors likely involved in differentiation. Importantly, ontological 
assessment of the extracellular genes (ECM and growth factors) included in the arrays 
provided links to intracellular genes, such as receptors and transcription factors, that were 
indicative of morphogenic changes occurring within the EB microenvironment.  Analysis 
based on existing relationships, thus highlight overlapping roles of molecules during 
development in ESC differentiation in vitro.   
 In the EB system, a combination of the described analyses has provided a higher-
level understanding of the influence of extracellular factors on morphogenic processes 
over the differentiation time course.  The molecules that appear in the day 4 network 
primarily act upon the transcription factor p53 that in turn decreases the pluripotent 
marker Nanog.  Together, these results indicate the importance that growth factors may 
have in the early stages of EB culture to prime the system for differentiation or that.  The 
ECM molecules present in the top day 7 EB network (Figure 3.7B) are largely proteases.  
By day 10 (Figure 3.7C), both ECM molecules and growth factors appear in the network, 
along with an increase in the number of connected transcription factors, suggesting the 
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onset of signaling related to a variety of differentiation events.  Finally, the increased 
expression of a number of integrins by day 14 (Figure 3.7D) emphasizes the onset of cell 
movement and signal transduction events. 
 Complementary information provided from different forms of expression analysis 
provides an overall more comprehensive characterization of the temporal regulation of 
EB differentiation than individual analyses alone.  Some molecules appear consistently 
throughout, but have different gene interactions, while others are unique to certain stages 
of differentiation.  As an illustrative example, consider the changes occurring with Vegfa.  
This gene, which clustered with genes such as Igf2 and Tgfb2 within the growth factor 
array (Figure 3.2B, Figure 3.3L), was also found to be highly related to expression 
patterns of matrix proteins such as Col3a1 and Emilin1 (Figure 3.3L) when the two sets 
of array data were analyzed collectively.  Furthermore, the ANOVA analysis upheld 
relationships with Vegfa when tested for statistical significance (Figure 3.4F).  When 
visualized as a dynamically changing network, however, several additional features of 
Vegfa’s role in EB differentiation emerge.  First, as indicated by the high degree of 
connectivity to other molecules in Figure 3.6A, signaling through this growth factor is 
likely important as early as day 4, even though its own expression was not higher than the 
2-fold change threshold.  Secondly, the high degree of clustering/statistical significance 
that emerges with other genes such as Tgfb2 and Col3a1 are due to regulation through 
common transcription factors (e.g. p53).  Finally, tightly clustered proteins induce 
common effector molecules (e.g. Fn1) and one another (Igf2 → Vegfa) to synergistically 
amplify extracellular cues associated with the EB differentiation process.  Through this 
manner, functional relationships emerge from the data that allow for new hypothesis 
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generation and testing regarding exogenous molecules capable of affecting ESC 
differentiation. 
 Just as each individual analysis lends insight when examining specific molecules, 
the range of analyses presented is critical for extracting a more global perspective.  
Researchers often rely on a single method for assessing large data sets, typically either 
hierarchical clustering or pathway analysis, which can potentially result in overlooking 
molecules important to the system.  For example, performing clustering (hierarchical or 
k-means) alone did not result in the identification of Fn1 as an important molecule in the 
examined EB system, due to the fact that it didn’t exhibit large fold changes over time.  
Further analysis using parallel ANOVAs shows that Fn1 increases significantly by day 
14 (Figure 3.5F), along with other key molecules such as Ctnna2, Postn, Hapln1, Col3a1, 
and Vtn that are highlighted in clustering analyses.  Pathway analysis demonstrated that 
Fn1 is a hub gene at both day 4 and day 14, suggesting its importance throughout the 
differentiation time course.  In contrast, consider Spock1, which is highlighted in 
hierarchical clustering as exhibiting one of greatest increases in expression over time 
compared to ESCs, along with Ctnna2, Postn, Hapln1, Col3a1, and Vtn.  K-means 
clustering also indicated an association between Spock1 and Postn/Vtn (Figure 3M, Table 
3.2), while ANOVA verified the gene’s significant increase after day 7 (Figure 3.5E).  
However, Spock1 was not included in the top networks at later time points of EB 
differentiation (days 7 – 14), although it was present in the top network at day 4 with a 
single connection.  Analysis displayed a relationship between Spock1 with Col18A1, a 
hub gene not included in the arrays, but highly connected to several ECM and growth 
factor genes contained in the arrays - Vegfa, Fgf2, and Itgb3, as well as other highly 
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connected genes - p53 and Fn1.  The aforementioned examples of Fn1 and Spock1 
demonstrate that a combination of analytical tools can identify potential key regulators in 
the differentiation system that would have otherwise been overlooked by single forms of 
analysis alone.  
 
Conclusion 
The overall objective of this study was to investigate gene expression patterns 
obtained from low-density PCR arrays using a variety of analytical tools and to explore 
the utility of these assays in understanding the importance of extracellular factors in 
embryonic stem cell differentiation.  ESCs undergo progressive differentiation within 
EBs and differentially express a number of ECM and growth factor genes.  Although not 
typically used to examine differentiation patterns, variations in ECM and growth factor 
expression were indicative of more global changes occurring within the EB 
microenvironment, such as decreased pluripotency, cellular proliferation, and tissue 
morphogenesis.  Low-density analysis of extracellular factors in dynamic environments 
highlights the importance of such endogenous molecules and their utility in assessing the 
temporal shifts in the system. 
The clustering, statistical, and gene mapping tools may be critical to further 
understanding the role of endogenous ECM and growth factors in differentiation.  Some 
studies have begun to elucidate the role that specific molecules play in ESC 
differentiation [209, 210, 223-226], although analyses that include a broader range of 
extracellular factors have thus far been somewhat limited [187, 208].  In order to analyze 
the wide spectrum of matrix molecules in this study, distinct methods were used that 
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either highlighted differences in expression patterns through clustering tools or focused 
on the relationships between the molecules via network analysis.  Subsets of genes with 
diverging expression values (gene groups that between multiple time points had opposing 
signatures) emerged from k-means and statistical analyses.  The simultaneous increase 
and decrease of different sets of molecules may be necessary for the onset of a particular 
differentiation event, and the identification of these sub-groups could be critical for 
further understanding the coincident cell phenotype specification.  Studies that examine 
individual molecules largely remain one-dimensional and may lose the global view that 
contributes considerably to the fundamental understanding of the system.  In contrast, the 
combination of clustering/statistical analyses with network mapping provides a multi-
faceted approach that enables a more in-depth understanding of the dynamic EB 
microenvironment.  Through these types of global analyses, the extracellular environment 
can further elucidate the ongoing biological process within EBs.  Moreover, 
characterization of the molecules secreted by ESCs differentiating in EBs may aid in 
establishing the impact of ESC-derived extracellular factors.  
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CHAPTER 4 
SOLUBLE FACTORS SECRETED BY DIFFERENTIATING 
EMBRYONIC STEM CELLS STIMULATE EXOGENOUS CELL 
PROLIFERATION AND MIGRATION* 
 
Introduction 
Tissue damage in adult mammalian species typically results in the formation of 
scar tissue that prohibits the recovery of normal tissue function, such as cutaneous 
wounds, brain and spinal cord injury, and myocardial infarction. Cellular infiltration, 
matrix deposition, angiogenesis, and remodeling events that transpire following tissue 
injury are intended to prevent further damage and preserve tissue function; however, such 
endogenous processes are typically insufficient to fully promote functional regeneration.  
Transplantation of cell populations with the ability to integrate and restore function to 
damaged tissues has been attempted to stimulate tissue regenerative processes in a 
number of different tissues [169, 227, 228], yet the percentage of cells that successfully 
engraft and persist within host tissues is typically very low (< 0.1-1%) [174, 229, 230].  
Despite the transient presence of exogenously delivered cells, persistent 
macroscopic beneficial effects have been commonly observed in a variety of different 
tissues.  The advantageous impact on the regenerative response is most likely due to the 
paracrine factors produced by the transplanted cells.  Several studies have investigated 
the influence of paracrine factors secreted by cells of interest to stimulate native tissue 
                                                
 
 
* Modified from: 
AV Ngangan, JC Waring, and TC McDevitt. Soluble factors secreted by differentiating embryonic stem 
cells stimulate exogenous cell proliferation and migration, in preparation. 
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function in the absence of cell integration, ranging from spinal cord injury to myocardial 
infarction [231-234].  The remodeling of injured tissues is mediated locally by a number 
of cell types, including fibroblasts and endothelial cells, which are either recruited to or 
activated at the site of injury via the secretion of chemokines.  Transplanting exogenous 
cells capable of secreting a potent combination of soluble factors can augment 
chemotaxis of host cells that participate in tissue remodeling [190, 235, 236].  Secreted 
factors released by a variety of cell types implemented in cell transplantation have been 
further characterized for growth factors and chemokines [191, 237, 238]. 
In addition to investigating adult stem and progenitor cells, pluripotent embryonic 
stem cells (ESCs) have also widely been examined for their potential to differentiate and 
repopulate compromised tissues following transplantation.  However, paracrine modes of 
action appear to provide stimulatory signals for promoting tissue regeneration for a 
variety of tissues [8, 192, 239].  Following the establishment of a paracrine mode of 
action, the extracellular stem cell environment, such as the secretome and glycome, has 
been of interest to the scientific community [188, 193, 240].  Injured embryonic tissues 
are generally able to endogenously regenerate normal function, indicating that factors 
present in the embryonic environment are unique to promote tissue regeneration.  In vitro 
differentiation of ESCs cells through the formation of small aggregates, termed embryoid 
bodies (EBs), mimics aspects of embryogenesis, including behaviors such as 
proliferation, migration, and differentiation [42, 44, 47].  As ESCs differentiate within 
EBs to form primitive tissues, the profile of morphogens secreted by these cells varies, 
and these molecules could impart a more embryonic environment that invokes 
endogenous tissue regeneration responses. 
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Hence, the objective of this study was to analyze the relative abundance of soluble 
factors secreted by ESCs as a function of differentiation and to elucidate the bioinductive 
potential of ESC-derived factors on exogenous cell types, specifically fibroblast and 
endothelial cells.  As ESCs differentiated within EBs, the secreted growth factor profile 
was modulated, while the EB-conditioned media differentially affected fibroblast and 
endothelial cell mitogenicity and motogenicity.  Characterizing the potency of growth 
factors secreted by differentiating ESCs on exogenous cell types may provide new insight 
into mechanisms of how ESC-derived cells can impact tissue regeneration. 
 
Methods 
Mouse embryonic stem cell culture 
D3 murine ESCs were cultured on 0.1% gelatin-coated plates in complete 
medium consisting of Dulbecco’s Modified Eagle Medium (DMEM, Mediatech) 
supplemented with 15% fetal bovine serum (FBS, Hyclone), 2mM L-glutamine 
(Mediatech), 1X non-essential amino acids (Mediatech), 100 U/mL penicillin 
(Mediatech), 100 mg/mL streptomycin (Mediatech), 0.25 mg/mL amphotericin 
(Mediatech), 0.1 mM β-mercaptoethanol (MP Biomedicals, LLC), and 103 U/mL 
leukemia inhibitory factor (ESCGRO, Millipore).  Cells were incubated in a humidified 
environment at 37ºC in 5% CO2 and passaged with 0.05% trypsin-EDTA (Mediatech) at 
approximately 70% confluence.  To initiate ESC differentiation, embryoid bodies (EBs) 
were formed from a single-cell suspension of 4x106 cells in 10 mL differentiation 
medium (complete medium without LIF) by spontaneous aggregation on a rotary orbital 
shaker.  EBs were cultured in 100 mm Petri dishes on a rotary orbital shaker (Lab-Line 
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Lab Rotator, Barnstead) held constant at 40±2 rpm [213].  Rotaries were calibrated every 
day to ensure constant speed throughout the course of EB culture, and medium was 
completely exchanged every 2 days after collecting EBs via gravity-induced 
sedimentation in 15 mL conical tubes.  
 
Collection of EB-conditioned media 
EBs differentiated for 4, 7, or 10 days were collected (as described above), rinsed 
three times with phosphate-buffered saline (PBS), and cultured for an additional 2 days 
with a modified serum-free differentiation medium, hereafter referred to as unconditioned 
media (uCM), consisting of phenol red-free, low-glucose (2.8 mM) Dulbecco’s Modified 
Eagle Medium (DMEM, Invitrogen), supplemented with 2mM L-glutamine, 1X non-
essential amino acids, 100 U/mL penicillin, 100 mg/mL streptomycin, 0.25 mg/mL 
amphotericin, and 1 mg/ml bovine serum albumin (BSA, Fraction V, MP Biomedicals).  
After 48 hours of conditioning, EBs were collected by gravity-induced sedimentation and 
the EB-CM (~10 mL) was transferred to a fresh conical tube.   The EB-CM was 
centrifuged for 5 minutes at 10,000 RPM at 4oC to remove cellular debris and the 
supernatant fraction was transferred to a new 15 mL conical tube and stored at -20 ºC 
prior to further analysis.  Conditioned media by 3T3s was also collected after 10 mL of 
uCM was cultured in a 100 mm plate of 3T3 fibroblasts for 48 hours. 
 
EB count 
Following EB-CM collection, EBs were washed twice with PBS and resuspended 
in 2 mL of PBS.  From this EB suspension, two successive serial dilutions were made in 
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PBS (between 1:5 and 1:10) in order to reduce the density of EBs for visual counting in 
multiple wells of a 24-well plate.  The number of EBs contained in the diluted 
suspensions was counted at 4X magnification using a Nikon TS100 microscope and the 
total number of EBs per plate was calculated based on the dilution factor used. 
 
RNA extraction and quantitative RT-PCR 
RNA was extracted from undifferentiated ESCs (day 0) and from serum-free EBs 
on days 6, 9, and 12 of rotary culture utilizing the RNeasy Mini Kit (Qiagen) and 
analyzed on the NanoDrop spectrophotometer (NanoDrop) for concentration and purity at 
260 nm and 280 nm.  Complimentary DNA was reverse transcribed using 1 µg of total 
RNA in conjunction with the iScript cDNA synthesis kit (BioRad) on the iCycler 
Thermal Cycler (Bio-Rad).  Quantitative RT-PCR was performed using SYBR Green 
with the MyIQ cycler (BioRad).  Primer sets were designed using Beacon Designer 
software for pluripotency (Octamer-4, Oct-4) and differentiation (α-fetoprotein, Afp) 
markers as well as for housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh). Additionally, growth factor primer sets were also designed, including bone 
morphogenetic protein-4 (Bmp-4), fibroblast growth factor-2 (Fgf-2), insulin-like growth 
factors 1 and 2 (Igf-1, Igf-2), platelet-derived growth factor B chain (Pdgfb), and vascular 
endothelial growth factor-A (Vegfa).  Each primer pair was independently validated with 
appropriate positive cell controls.  Relative levels of gene expression were calculated 
compared to undifferentiated ESC samples and normalized to Gapdh using the ΔΔCt 




EB-CM samples were analyzed using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE).  Samples of equal volume were combined with 4X SDS-
sample buffer consisting of 0.25 M Tris-HCl (pH 6.8), 8% sodium dodecyl sulfate, 40% 
glycerol, 8% β-mercaptoethanol, and 0.02% bromophenol blue to reach a final 
concentration of 1X.  These samples were then loaded into precast PAGEr 10-20% Tris-
glycine gels (Lonza).  The gels were run in 1X running buffer consisting of glycine, Tris 
base, and sodium dodecyl sulfate for 2 hrs at 125V.  Gels were fixed and stained using 
Coomassie Blue.  Images were then taken using a SONY DSC-W1 digital camera. 
 
EB-CM protein quantification  
Total protein content of EB-CM was analyzed using a bicinchoninic acid (BCA) 
assay kit (Thermo Scientific).  According to the manufacturer’s protocol, 25 µl of sample 
was incubated with 200 uL of BCA solution for 30 minutes.  Absorbance readings were 
taken at 562 nm using a Molecular Devices SpectraMax M2e microplate reader and 
SoftMax Pro v5 microplate data acquisition software.  The absorbance readings of the 
EB-CM samples were compared against a standard curve (0 µg/mL - 2,000 µg/mL) 
generated using bovine serum albumin (BSA) in order to calculate absolute protein 
concentrations.  To determine the amount of protein secreted by the EBs during 
conditioning, the protein content of unconditioned medium was subtracted from all EB-
CM samples.  
Enzyme-linked immunosorbent assay (ELISA) kits were used to quantify the 
amount of proteins of interest contained within the EB-CM, specifically BMP-4, IGF-2 
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and VEGF-A (DuoSet, R&D Systems).  Briefly, capture antibody was adsorbed onto a 
MaxiSorp™ Immuno 96-well plate (Nunc), followed by a blocking step, incubation with 
100 µL sample, and binding of analyte to a biotinylated detection antibody. The 
concentrations of capture and detection antibodies used were dictated by the DuoSet 
protocol for each protein: 2 µg/mL and 1 µg/mL for BMP-4, 4 µg/mL and 200 ng/mL for 
IGF-2, and 400 ng/mL and 100 ng/mL for VEGF-A.  Unconditioned medium was used as 
the diluent for the standard curve samples.  The amount of analyte was assessed using the 
colorimetric reaction of peroxidase and tetramethylbenzidine (TMB) with an absorbance 
reading at 450 nm.  The absorbances for each EB-CM sample were compared to the 
standard curve to establish the protein analyte content, which was normalized to EB 
number and reported as pg protein per 1000 EBs. 
 
Proliferation assay 
 NIH-3T3 fibroblasts were cultured on tissue culture dishes in 3T3 growth medium 
containing DMEM supplemented with 10% bovine growth serum (BGS), 4 mM L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin. 
Human umbilical vein endothelial cells (HUVECs) were cultured on gelatin-coated tissue 
culture dishes in endothelial cell (EC) growth medium, consisting of MCDB131 basal   
medium supplemented with 5% FBS, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin, 
2 mM L-glutamine, 1 mg/mL hydrocortisone (Sigma), 2 ng/mL FGF-2 (PeproTech), 10 
ng/mL epidermal growth factor (EGF, Gibco), 2 ng/mL IGF-1 (Gibco), 1 ng/mL VEGF-
A (Sigma), and 50 mg/mL ascorbic acid (Sigma). 
 66 
For proliferation studies, NIH-3T3 fibroblasts and HUVECs were cultured to 
approximately 50% confluence in 2-chamber glass slides (BD Bioscience), at which point 
growth media were removed and the cells were rinsed 3 times in PBS.  Cells were then 
starved overnight in low-serum media, followed by an 18-hour pulse with 10 mM 5-
bromo-2’-deoxyuridine in EB-CM from different time points as well as control media.  
After the 18-hours pulse, cells were rinsed with PBS and fixed in 70% ethanol with 2.3M 
HCl for 10 minutes at room temperature, rinsed in PBS 3 times, and incubated with 
mouse anti-BrdU primary antibody (Molecular Probes) for 1 hour at room temperature.  
Following primary antibody incubation, the cells were incubated with donkey anti-mouse 
secondary antibody conjugated to Alexafluor 488 (Invitrogen) for 2 hours at room 
temperature, counterstained with Hoechst, and then coverslipped using GelMount 
(Electron Microscopy Sciences). 
 Stained slides were imaged using a Nikon 80i upright microscope with a 
SPOTFlex digital camera and SPOT Advanced Software (Nikon) using both the FITC 
and DAPI filters.  Nuclei counts were performed on all images using the “nuclei count” 
application within MetaMorph (Molecular Devices).  The percentage of BrdU-positive 
nuclei (FITC) was calculated for all images taken (n=6 per chamber) to determine the 
amount of proliferation induced by the conditioned media samples compared to the 
control media samples. 
 
Transwell migration assays 
For migration studies, NIH-3T3 fibroblasts and HUVECs were each grown to 
~80% confluence, inactivated with 10 µg/mL mitomycin-C in serum-free media (2 hours 
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at 37oC in 5% CO2) and cultured overnight in growth media.  Cells were also 
fluorescently labeled in serum-free media with 1 µM CellTracker® Green (Molecular 
Probes) for 20 minutes at 37ºC, followed by a 30 minute incubation in growth media 
prior to initiation of the migration experiment. 
HTS Fluroblok transwell culture inserts (Falcon, 24-well, 8 mm pore size) were 
prepared with 300 µL single-cell suspension (7.5x104 3T3s or 1x105 HUVECs) in growth 
media (loaded in the top chamber).  The bottom of the transwell chamber was filled with 
800 uL of EB-CM sample or control media; cells’ respective growth media were used as 
positive controls, while uCM served as a negative control.  Transwell culture plates were 
incubated for 24 hours in 37oC at 5% humidity, and fluorescent microscopy images of the 
bottom of wells were taken every 6 hours using a Nikon TE 2000 inverted microscope 
with a SpotFLEX digital camera and SPOT software (Nikon).  The number of cells that 
migrated through the porous membrane were counted for each transwell sample (fields of 
view = 3) using ImageJ and normalized to a unit area (mm2).   
 
Scratch wound assay & image analysis 
In a 6-well tissue culture plate, 3T3 fibroblast cultures were allowed to reach 80% 
confluence before being treated with serum-free 3T3 media containing 10 µg/ml 
mitomycin-C for 2 hours at 37ºC in 5% CO2.  Following treatment, cells were cultured 
overnight in 0.5% BGS 3T3 media.  Next, the monolayer was scratched using the end of 
a 200 µl pipette tip, washed with DPBS to remove detached cell debris, and fed with 2 ml 
of EB-CM sample.  At 0, 12, 24, and 48 hrs media was removed and cells were rinsed 
with DPBS at which point phase images at 10X magnification were taken using a Nikon 
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TE 2000 inverted microscope with a SpotFLEX digital camera (Diagnostic Instruments, 
Inc.).  EB-CM was replaced following imaging. 
Phase images captured from scratch wound assays were analyzed using 
MATLAB (Simulink) programming language, in order to quantify the migration of cells 
across the scratch wound kinetically.  Images were captured with SPOT Advanced image 
capturing software (Diagnostic Instruments, Inc.) at 10X magnification using a Nikon TE 
2000 inverted microscope with a SpotFLEX camera at a resolution of 2048x2048 and 24-
bit.  Using ImageJ (NIH, Bethesda, MD), the original images were converted to an 8-bit 
image to enhance the contrast and subsequently converted to a binary image through 
threshold balance adjustment.  Next, using a MATLAB script with the executable 
command improfile, an intensity average plot from 0 to 1 was calculated for a predefined 
portion of the image.  Using the data displayed in the graph, the area under each curve 
was related back to the curve produced for a confluent monolayer to obtain a percent 
fractional coverage.  Relating that percent coverage back to the starting scratch curve, the 
approximate percent covered after 12, 24, and 48 hours post-scratch was determined. 
 
Statistical analysis 
All experimental samples were analyzed in triplicate, with data presented as mean 
± standard deviation.  Statistical significance was determined using SYSTAT 12 
(SYSTAT Software, Inc.) employing an analysis of variance (ANOVA) test with a post-
hoc Tukey analysis to determine significance (p < 0.05). 
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Table 4.1.  RT-PCR primer sequences. 
Primer Nucleotide Sequence (5’ – 3’) 
F  GCC TTC CGT GTT CCT ACC Gapdh 
R   GCC TGC TTC ACC ACC TTC  
F   CCG TGT GAG GTG GAG TCT GGA G Oct-4 
R   GCG ATG TGA GTG ATC TGC TGT AGG 
F   CAC ACC CGC TTC CCT CAT CC Afp 
R   TTC TTC TCC GTC ACG CAC TGG 
F  CTG GCC CGG AAG CTA GGT GAG TT Bmp-4 
R  GAG GGC CAG AGA CTG GAT CGC 
F   AGC GAC CCA CAC GTC AAA CTA C Fgf-2 
R   CAG CCG TCC ATC TTC CTT CAT A 
F   TCC GCC AGG TTG CCT CTA G Igf-1 
R   GGA AGC AGG TGG ATG GTC AG 
F   TCA AAG AGT TCA GAG AGG 
Igf-2 
R   CAA CCA TCA GTG AAT CAA A 
F   ATC GCC GAG TGC AAG ACG CG Pdgfb 
R   AAG CAC CAT TGG CCG TCC GA 
F  TGC ACC CAC GAC AGA AGG 
Vegfa 





Embryoid body morphology and differentiation 
Preliminary studies indicated that EBs failed to initially form well in serum-free 
media and did not survive very well past 72 hours after being switched to serum-free 
conditions, especially at earlier time points of differentiation.  Thus, a regimen of forming 
and maintaining EBs in serum-containing media before switching to serum-free media 
for conditioning was utilized (Figure 4.1A).  As is normally observed, EBs increased in 
size during the course of differentiation (~250 µm diameter at day 6 compared to ~500 
µm at day 12), with no significant differences in the size of EBs cultured in serum-free 
media for two days were observed compared to EBs in serum-containing media, thus EBs 
cultured for up to 48 hours with serum-free medium at different stages of differentiation 
were morphologically similar to their cohorts that remained in serum containing media 
for the same period of time (Figure 4.1B).  The number of EBs per 100 mm Petri dish (on 
average, approximately 5x103 EBs per plate) also did not vary significantly over time in 
serum-containing or serum-free media (Figure 4.1C).  Gene expression analysis for 
pluripotent and differentiation markers were also performed for EBs from both culture 
conditions on days 6, 9, and 12 of differentiation.  Oct-4, a pluripotent transcription 
factor, exhibited a similar pattern of decreasing expression for both EB culture conditions 
as differentiation proceeded (Figure 4.1D).  At early time points, day 6 and 9, Oct-4 gene 
expression levels were significantly different between serum and serum-free EB cultures 
(t ≤ 0.027).  By day 12, significant decreases in Oct-4 gene expression were evident 
compared to day 6 for both EB cultures (p ≤ 0.025).  Increasing levels of Afp gene 
expression, a marker of primitive and definitive endoderm, were similar at each of the 
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Figure 4.1. EB-conditioned media (EB-CM) collection and comparison of EB 
formation and differentiation in serum-containing and serum-free media.  (A) EBs 
were cultured on a rotary orbital shaker at 40 RPM for 4, 7, and 10 days in serum-
containing media, at which point the EBs were switched to serum-free media and 
cultured for two more days.  At the end of days 6, 9, or 12 of differentiation, EB-
conditioned media (CM 6, CM 9, CM 12, respectively) was collected for further analysis.  
(B) EBs cultured with (top row) or without (bottom row) appeared similar in size, shape, 
and morphology  at each of the time points examined.  Scale bars = 500 µm (panel) and 
100 µm (inset).  (C) The total number of EBs remained relatively constant (~5x103 
EBs/plate) throughout EB culture for both serum-containing and serum-free conditions.  
(D, E) Similar EB differentiation in both media conditions was confirmed by a significant 
decrease in the pluripotent marker Oct-4 by day 12 compared to day 6 and a significant 
increase in endoderm marker Afp by day 12 compared to day 6 for EBs cultured under 
both conditions.  Results indicated are mean ± standard deviation (n=6). ANOVA: *= p < 
0.05; Student t-test: # = t < 0.05. 
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time points examined between both EB culture conditions (Figure 1E).  For both EB 
culture conditions, a significant increase in Afp fold change resulted at day 12 compared 
to day 6 EBs (p ≤ 0.034).  Thus, the switch to serum-free medium for 48 hours prior to 
collection did not significantly alter the differentiation progress of EBs compared to 
serum-containing culture.  The similarities between the two EB culture conditions were 
examined using multiple parameters, thus suggesting minor differences during serum-free 
media conditioning. 
In contrast, the levels of Bmp-4, Fgf-2 and Pdgfb gene expression were 
significantly decreased in day 6 EBs compared to ESCs (0.3-fold, p = 9.99x10-5; 0.02-
fold, p = 0.002; 0.5-fold, p = 0.015, respectively) (Figures 4.2A, D, E).  Bmp-4 
maintained similar expression at days 6 and 12 compared to ESCs, yet at day 9 expressed 
a signifcantly lower gene expression level compared to ESCs (0.5-fold, p = 4x10-3).  At 
day 9, Fgf-2 gene expression remained significantly lower compared to ESCs (0.43-fold, 
p = 0.027), but increased by day 12 to approach a similar level to ESC expression level 
(Figure 4.2D).  Pdgfb gene expression continued to increase significantly in EBs between 
days 9 and 12 (~1-fold) compared to day 6 (p ≤ 0.001, Figure 4.2E) towards similar 
levels present in ESCs.  The fold changes for Pdgfb remained between 0.5- and 1.3-fold, 
while Fgf-2 remained between 0.2- and 1-fold.  Despite the vast differences in growth 
factor gene expression modulation, all of the aforementioned growth factors were 
expressed at increasing levels as ESC differentiation progresses, suggesting functional 
roles in biological processes involved in differentiation, including migration and 
proliferation as previously described in Chapter 3.  
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Growth factor gene expression analysis 
Overall, the gene expression levels of the six growth factors analyzed generally 
increased as EB differentiation progressed with serum-free media conditioning.  Growth 
factors with the largest changes in gene expression were Igf-1 and Igf-2: Igf-1 
significantly increased in fold-change by days 9 (~13-fold, p = 0.009) and 12 (~29-fold, p 
= 6.58x10-6) compared to ESCs (Figure 4.2B); whereas, Igf-2 demonstrated significant 
increase in expression at day 12 (~126-fold, p < 7.43x10-5) compared to ESCs (Figure 
4.2C).  As for Vegfa, the magnitude of gene expression was modest compared to the 
Igf’s, but did increase over EB differentiation time, with significant increases at days 9 
(~5-fold) and 12 (~5-fold) compared to both ESCs (p ≤ 6.37x10-6) and day 6 EBs (p ≤ 
9.19x10-6) (Figure 4.2F).  Increased expression of these growth factors progressed as EB 
differentiation continued, yet the magnitudes of the fold changes ranged greatly 
depending on the specific gene: Igf-2 between 7- and 127-fold, Igf-1 between 4- and 29-
fold, and Vegfa between 2- and 5-fold differences.  
 
Protein characterization of EB-conditioned media 
 The total protein content of EB-CM did not vary significantly between the 
different time points assessed, with a concentration range of 150-225 µg/mL  (Figure 
4.3B).  The SDS-PAGE analysis indicated slight differences in the EB-CM content based 
on molecular weight, especially between to 10 – 20 kDa range (Figure 4.3A).  
Contrastingly, specific growth factors that exhibited large fold changes in gene 
expression also exhibited differences in EB-CM protein quantities.  BMP-4 protein 
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Figure 4.2.  Growth factor gene expression by differentiating EBs.  Overall, the 
expression of several growth factors increased over time during ESC differentiation 
within EBs.  The relative values of expression are depicted as fold changes in EBs 
compared to the ESC starting population.  Results indicated are mean ± standard 
deviation (n=6). ANOVA: * p < 0.05, # p < 0.001, and † p < 0.05 compared to ESCs. 
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content in CM 9 was reduced by half compared to CM 6 and 12, yet the changes in BMP- 
4 protein in all CM samples were not significant (Figure 4.3C).  However, IGF-2 and 
VEGF-A both increased in protein content as EB differentiation progressed, which 
corresponded to their increases in gene expression (Figures 4.3D, E).  Between CM 6 and 
9, IGF-2 content was similar (~6 pg/1000 EBs), whereas the amount present in CM 12 
was significantly increased (23.78 pg/1000 EBs) compared to both CM 6 and 9 (p < 
0.0001).  The VEGF-A protein present in the EB-CM increased by later time points of 
EB culture, with a significant increase in protein expression in CM 12 (2.26 pg/1000 
EBs) compared to CM 6 (0.07 pg/1000 EBs; p = 0.029).  The growth factors analyzed 
vary greatly in the amount contained in the EB-CM, even when the concentrations were 
normalized to the number of EBs per dish.  Growth factors that demonstrated increased 
gene expression during EB differentiation, also exhibited increases in EB-CM protein 
content as EB differentiation progressed.  
 
Mitogenic potential of EB-CM 
 Bioactive molecules contained within EB-CM stimulated fibroblast proliferation 
compared to uCM, but not as robustly as fibroblast growth media.  CM 6 and 12 induced 
significantly more BrdU+ cells (~60% of fibroblasts) compared to uCM (~25%, p ≤ 
4.54x10-4) (Figure 4.4A), but significantly less than growth medium (p ≤ 0.004).  
Comparisons between the EB-CM samples demonstrated that CM 9 stimulated 
significantly less proliferation (~37% of fibroblasts) compared to CM 6 and 12.  As for 
proliferation effects on HUVECs, CM 6 and 9 elicited a similar amount of BrdU+ 




Figure 4.3.  Protein analysis of EB-CM.  (A) SDS-PAGE analysis illustrating the 
molecular weight distribution of proteins contained in EB-CM collected from different 
time points of EB differentiation. Proteins with differences in expression, particularly 
between 10-20 kDa, are highlighted within the dashed box region. (B) The total protein 
content of the CM collected at each time point examined did not significantly vary over 
time.  (C) BMP-4 protein slightly increased in content as EB differentiation progressed 
with time, but not significantly.  (D, E) Within EB-CM, IGF-2 protein increased 
significantly over time by CM 12 compared to CM 6 and 9; while, VEGF-A increased by 
CM 12 with significance compared to only CM 6.  Results indicated are mean ± standard 
deviation (n=6).  ANOVA: * p < 0.05 compared to CM 6 and CM 9, † p < 0.05 compared 






Figure 4.4.  EB-CM influences mitogenic induction of exogenous cell types.  (A) CM 
6 and CM 12 increased fibroblast proliferation significantly compared to uCM, but 
remained significantly less than standard growth media.  CM 9 elucidated significantly 
less motogenic response compared to CM 6 and CM 12.  (B) Early time points of EB-CM 
did not significantly induce endothelial cell proliferation compared to uCM; whereas, CM 
12 exhibited significantly greater proliferative response than uCM and CM 6 and CM 9. 
Results indicated are mean ± standard deviation (n=6).  Top row images: phase images, 
scale bar = 50 µm.  Bottom row images: fluorescent images, blue = Hoechst stain, green 
= BrdU-positive cells, scale bar = 50 µm.  % BrdU+ cells stimulated by the respective 
cell type’s growth media indicated as a dashed line (- - -). ANOVA: * p < 0.05 compared 
to uCM; # p < 0.05 compared to growth media; † p < 0.05 compared to CM 6 and CM 
12; ‡ p < 0.05 compared to CM 6 and CM 9. 
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media (~55% of cells, p ≤ 0.001) (Figure 4.4B).  However, the CM 12 stimulated 
significantly more HUVEC proliferation, ~42%, compared to the other EB-CM samples 
(p ≤ 0.002) and uCM (p = 1.43x10-4).  Phase images illustrate the confluency differences 
corresponding to the mitogenic induction by the various samples, while the fluorescent 
images easily discern between BrdU+ and BrdU- nuclei (Figures 4.4A, B bottom rows).  
Between cell types, in response to CM 9 there was less proliferation in fibroblasts 
compared to CM 6 and 12, whereas CM9 was only less than CM 12 for EC proliferation.  
CM 12 enhanced proliferation in both 3T3s and HUVECs, which suggests that CM 12 
contains molecular cues that can positively affect cellular proliferation.  These results 
suggest that factor(s) present in CM 9 may suppress fibroblast proliferation, while CM12 
contained factor(s) that induced EC proliferation.  Overall, the mitogenic response varied 
based on cell type as well as the state of ESC differentiation at which the bioactive 
factors were collected. 
 
Motogenic potential of EB-CM  
Chemotactic migration of fibroblasts and ECs were examined in response to 
factors present within EB-CM.  Fluorescent images of CellTracker-labeled fibroblasts 
(bottom-side of insert) qualitatively illustrated increased cell migration induced by EB-
CM compared to uCM (Figure 4.5A).  Quantitative analysis demonstrated that all CM 
samples stimulated significantly more cells (~27,000 – 30,000 cells) to migrate compared 
to uCM (~16000 cells, p < 0.05) and fibroblast growth medium (~7,000 cells, p < 0.05, 
data not shown) after 6 hours of incubation (Figure 4.5B).  CM samples from all time 
points continued to yield significantly greater migration responses than uCM (p < 0.05) 
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after 12 hours  (26,000 – 33,000 total migrated cells vs. 14,000 total cells).  Qualitative 
assessment of images taken at 24 hours further illustrated differences in EB-CM treated 
cells compared to uCM.  Fibroblasts appeared to be arranged in clusters with extended 
processes (stellate morphology) in EB-CM transwells compared to single rounded cells 
sparsely scattered in transwells containing uCM (Figure 4.5C).  The results from the 
transwell assay corresponded to those from the fibroblast scratch wound assay - each of 
the EB-CM samples enhanced wound closure by 24 hours compared to uCM (Figure 
4.5D).  Overall, EB-CM affected migration of fibroblasts, specifically modifying cell 
morphology and increasing the number of migratory cells towards the EB-CM compared 
to uCM. 
To further examine the paracrine effects of factors secreted differentiating EBs, 
the migrations response of endothelial cells, another cell type implicated in tissue 
remodeling, was evaluated.  According to transwell images, individual HUVECs in EB-
CM were more spread and clustered together compared to more rounded and separated 
HUVECs in uCM (Figure 4.6A).  Over the entire 24-hour period of migration, each of the 
EB-CM samples stimulated HUVEC migration compared to uCM, as quantified by the 
fluorescent images taken of the bottom of the transwells (Figure 4.6B).  All EB-CM 
samples significantly induced a greater number of migrated cells at each time point 
compared to uCM (p < 0.05).  Comparisons between each of the different EB-CM 
samples at 6- and 12-hour time points indicated similar motogenic induction since the 
numbers of migrated cells (~4000 – 4800 cells) were not significantly different. 
However, by 24 hours, CM 6 and 9 samples continued to decrease in migrated cell 




Figure 4.5. Fibroblast migration response to EB-CM.  (A) Fluorescent images of the 
migrated fibroblasts qualitatively exhibit differences in cell number (scale bar = 150 µm).  
(B) Quantified migration exhibited significant number of cells were stimulated by CM 
collected from different days of differentiation compared to uCM (n=6).  (C) At the final 
time point, CM influenced the appearance of fibroblasts in network structures compared 
to ones treated with uCM, which appeared more as single cells.  (D) Binary phase images 
and corresponding intensity profiles (below) exhibit scratch wound closure over time.  
Scale bar = 500 µm.  (E) The fractional coverage of the wound area was determined 
using MATLAB analysis on the corresponding intensity profiles.  Series: □ 10% BGS 
3T3 media, ◊ uCM.  Results indicated are mean ± standard deviation (n=6).  ANOVA: * 
p < 0.05 compared to 3T3-CM; † p < 0.05 compared to uCM, 3T3-CM, and 10% BGS 
3T3 media; # p < 0.05 compared to uCM and 3T3-CM; ‡ p < 0.05 compared to uCM, 




number of migrated cells (~4800 cells) to its number at the 6- and 12-hour time points.  
Thus, at the 24-hour time point, the total number of migrated cells induced by CM 12 was 
significantly greater than the number of cells induced by CM 6 (p = 0.004).  Upon 
examination of the HUVEC morphology after 24 hours, ECs in CM 12 were generally 
arranged in large clusters, while ECs in CM 6 and CM 9 remained as single cells or small 
clusters (Figure 4.6C). 
Despite similar concentrations of total protein in EB-conditioned media collected 
at all time points of differentiation, different cell types responded quite differently - the 
number of migrated 3T3 fibroblasts was about 10-fold higher than the amount of 
migrated HUVECs throughout the transwell study even though the transwells were 
inoculated with similar numbers of cells (7.5x104 3T3s, 1x105 HUVECs).  These 
differences may be due to fibroblasts having a mesenchymal phenotype, having the 
propensity to migrate, while endothelial cells have an epithelial phenotype, which are 
typically not migratory, unless provided with the proper cues [241].  This difference in 
cell phenotypes also may explain why EC growth media stimulated the majority of cells 
seeded in the transwell to migrate – the EGM-2 media is optimized and defined with 
growth factors, whereas fibroblast growth media consists of less undefined BGS.  Thus, 
the factors contained within the EB-CM are not as stimulatory as EGM-2, but did induce 
EC migration compared to uCM; however, EB-CM factors were more stimulatory than 
BGS resulting in greater number of migrated cells compared to fibroblast growth media.  
Overall, the results of the migration assays revealed that EB-CM collected at different 
stages of EB differentiation contained chemotactic factors capable of stimulating cell 




Figure 4.6.  EB-CM affects endothelial migration.  (A) EB-CM collections from 
various time points differentially affect migration of endothelial cells (scale bar = 150 
µm).  (B) EB-CM significantly stimulated more ECs in response all CM compared to 
uCM, yet significantly less than EC growth media.  (C) At 24 hours, uCM did not 
influence the appearance of endothelial cells, mostly shown as single cells, while CM 
treated cells prompted cells to exist in clusters. Results indicated are mean ± standard 
deviation (n=6).  ANOVA: * p < 0.05 compared to all EB-CM and uCM; † p < 0.05 




This study elicited a number of growth factors differentially secreted by 
differentiating ESCs, in addition to examining the impact of this complex mixture of 
factors captured within the EB-CM on different cell types.  ESC transplantation has been 
widely studied for the repopulation of tissues undergoing remodeling; however, the 
number of ESCs that integrate and differentiate within the host tissue is quite minimal 
[174, 185, 229, 230].  Several studies have demonstrated the potency of ESC-secreted 
molecules in inhibiting apoptosis, rescuing congenital defects, and providing a 
cardioprotective effect following myocardial infarction [8, 192, 239].  While ESC-
secreted factors have been reported in the literature, these reports typically examined 
paracrine actions of undifferentiated ESCs and in monolayer culture [188, 208, 242].  
When ESCs are transplanted into an injured tissue, the endogenous tissue environment 
will not maintain pluripotency, which will result in ESC differentiation and further 
modulate the paracrine factors released.  Despite the loss of pluripotency, the transplanted 
ESCs still positively affect damaged tissue repair [243]. 
In this study, the change in secreted factors as a result of differentiation was 
analyzed for protein content and bioactivity, specifically motogenicity and mitogenicity 
of fibroblasts and endothelial cells. The gene expression of EBs and protein profiles of 
EB conditioned media demonstrated differential representation of several growth factors 
as EB differentiation progressed.  Growth factors that decreased in gene expression 
relative to ESCs during EB differentiation, including Fgf-2 and Pdgfb, also resulted in 
low levels of protein in EB-CM, which were undetectable by ELISA (data not shown).  
On the other hand, other growth factors’ gene expression that increased steadily as ESC 
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differentiation progressed, particularly Igf-2 and Vegfa, correlated to increased content of 
each protein in CM 9 and 12.  The differential expression and secretion of proteins by the 
differentiating ESCs was elucidated not only by gene and protein analyses, but also by 
varied cell responses during proliferation and migration experiments comparing EB-CM 
collected at different days.  Overall, CM 9 continued to induce significantly more 
fibroblast migration than uCM over the entire 24-hour period, while significantly 
reducing the percentage of proliferating fibroblasts compared to CM 6 and 9.  Distinct 
fibroblast behavior in response to CM 9 demonstrates the unique combination of 
morphogens secreted by EBs after 9 days of differentiation – a secretome that stimulates 
fibroblast migration, but inhibits proliferation; whereas, days 6 and 12 EBs yield secreted 
factors that promote fibroblast mitogenicity.  This change in promoting different cellular 
processes may be a reflection on the aspects of embryogenesis being mimicked within 
EBs.  ESCs typically proliferate at a high rate, which helps establish a critical mass for 
EB formation.  At later time points of EB differentiation, typically around 5 – 10 days, 
epithelial to mesenchymal transition (EMT) occurs, which is characterized by the 
transition of non-migratory epithelial cells to migratory mesenchymal cells to initiate 
tissue formation and has been identified during EB development [211, 244].  Therefore, 
the factors captured in the EB-CM are capable of modulating exogenous cells’ responses 
in the same way ESCs are differentiating within the EBs.  Additionally, EB-CM can 
provide further insight into the progression of EB development,  
The factors secreted by later stage EBs were most effective in stimulating ECs, a 
more differentiated cell type than 3T3 fibroblasts.  The migration of ECs in response to 
all EB-CM collections was significant compared to uCM up to 12 hours, after which 
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point only CM 12 was significantly increased.  The proliferative capacity of ECs was also 
greater in response to CM 12 compared to CM 6 and 9.  This increased stimulation of 
ECs by CM 12, corresponds to the increased differentiation of ESCs within EBs towards 
a more cardiovascular lineage described in Chapter 3.  Day 10 EBs gene expression of 
endothelial markers was accompanied by increases in gene expression of angiogenic 
factors Fgf-2 and Vegfa as well as a ~70-fold increase in Igf-1.  Interestingly, IGF-1 
protein has been shown to stimulate in vitro EC migration [245].  Thus, the increased 
differentiation of day 10 EBs towards a cardiovascular phenotype may yield an EB 
secretome that contains factors effective in stimulating a more differentiated vascular 
phenotype, such as endothelial cells.   
The factors secreted into EB-conditioned media reflect the state of differentiation 
ESCs are undergoing, thereby providing molecular cues to which only certain cell types 
may respond. The expression of stimulatory molecules is typically juxtaposed with 
inhibitory molecules, and cellular responses are not purely based on concentrations of 
such factors. During the early stages of ESC differentiation EBs mimic aspects of 
embryogenesis: progenitors expand in number, followed by morphogenesis and cell 
expansion of more differentiated cell types.  The growth factor profile and bioactivity 
results for each of the EB-CM collections at various time points demonstrate the unique 
combination of factors that early differentiating ESCs secrete over time and are reflected 
in the distinct responses from the two different cell types. 
The growth factors detected in the EB-CM have been shown to promote tissue 
regeneration.  The persistence of BMP-4 protein in the EB-CM from days 6 through 12 
demonstrates the importance of this molecule during ESC differentiation, specifically 
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towards the mesoderm lineage, and has been shown to enhance vascular network 
formation within human ESC-derived EBs [198, 246].  VEGF-A is a well-documented 
growth factor for promoting angiogenesis in ischemic tissues [247-249].  Enhancing the 
re-vascularization of damaged tissues is necessary in order deliver cells and nutrients to 
establish a regenerating environment.  As for IGF-2, many studies have shown its 
implication in growth and differentiation within muscle and bone tissue [250, 251].  
Additionally, IGFs and BMP-4 have been shown to up-regulate VEGF expression to 
synergistically stimulate tissue repair.  BMP-4 in concert with VEGF treatment enhanced 
bone formation and healing compared to single factor treatment [252].  IGF-2 and VEGF 
together promote homing of endothelial progenitor cells to further stimulate angiogenesis 
[221], and the combination of IGF-1 and VEGF can target multiple regenerative 
processes: angiogenesis, reinnervation, and myogenesis [253].  Taken all together, 
specific growth factors work in concert to effectively induce biological processes, in 
particular angiogenesis, to improve tissue regeneration.  The increased production of 
these factors by EBs at days 9 and 12, suggests that early differentiating ESCs secrete 
factors that can promote tissue regeneration by potentially inducing angiogenesis. 
 
Conclusion 
Overall, this study demonstrates that factors secreted by ESCs undergoing 
morphogenic differentiation are capable of inducing proliferation and migration of 
exogenous cell types.  The complex mixture of molecules secreted contains a number of 
different growth factors and morphogens whose relative abundance varies as a function 
of EB differentiation.  Interestingly, the morphogenic events known to be associated with 
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EB differentiation, including cell proliferation and migration, are reflected by the 
endogenous expression of factors that comprise the soluble milieu.  Thus, analyzing the 
composition and bioactivity of molecules secreted by differentiating ESCs not only 
provides insights into the paracrine nature environment of EB environments, but also 
suggests potential trophic mechanisms whereby differentiated progeny from ESCs can 








 The pluripotency of ESCs makes them an attractive cell source for regenerative 
cell therapies to treat a broad array of degenerative diseases and traumatic injuries.  ESCs 
and ESC-derived cells have been transplanted into areas of damaged tissue where 
resultant cell repopulation and recovery of tissue function have been demonstrated [254-
259].  Use of ESCs as a delivery vehicle for trophic factors has also been shown to be 
effective in stimulating tissue regeneration in a number of tissues [8, 260].  Notably, 
Fraidenraich et al. discovered that ESCs rescued embryonic lethal knockouts via 
secretion of soluble molecules and not by cellular repopulation [8].  Hence, ESC-derived 
molecular cues appear to be effective in stimulating tissue regeneration by inducing 
endogenous healing. 
 Acellularization techniques provide a means to extract cells from tissues, thereby 
isolating the extracellular matrix (ECM) components.  The ECM provides a natural 
scaffold for structural support of tissues and harbors a complex assembly of biochemical 
cues comprised of proteins, glycosylaminoglycans, proteoglycans, and growth factors.  
Numerous tissues from various sources have been acellularized in order to create 
scaffolds for tissue regeneration, including small intestinal submucosa (SIS) [119], 
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esophagus [120], bladder [121], cardiac valve [123, 261], dermis [124, 125], nerve [126], 
placenta [127], and pericardium [128].  Several methods have been developed to 
acellularize these tissues using techniques that include solution-based treatments and 
mechanical disruption.  Solution-based methods typically combine chemical treatments, 
such as detergents [141-144, 262], alkaline or acid solutions [145, 146], and hyper- or 
hypo-tonic solutions [144], as well as enzymatic digests, including trypsin, 
endonucleases, and ectonucleases [147, 148].  While chemical and enzymatic methods 
effectively remove cellular content, they usually require multiple incubation and rinsing 
steps to ensure thorough removal or inactivation of acellularization reagents and may 
unintentionally remove desirable ECM components, such as GAGs, fibronectin, or 
laminins [141, 142].  On the other hand, mechanical methods of acellularization, 
including repeated freeze-thawing, sonication, or other physical means of disrupting 
cells’ plasma membranes [149, 150], provide a direct and rapid means of acellularizing 
tissues, but used alone, such methods are not capable of completely removing cellular 
content.  Thus, a combination of physical and chemical/enzymatic methods is needed to 
successfully acellularize tissues. 
 The primary criterion for acellularization is efficient inhibition of tissue viability 
coupled with preservation of native ECM composition and structure.  Lyophilization is a 
mechanical acellularization method that utilizes freeze-drying to permeabilize cell 
membranes, as a result of intracellular ice formation during the freezing process, and 
subsequent removal water molecules.  A number of tissues and acellular matrices have 
been lyophilized prior to therapeutic application, including bovine pericardium [263, 
264], bone matrix [152], amniotic membrane [153], and cardiac valves [261].  Another 
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mechanical acellularization option uses multiple freeze-thaw cycles, which entails 
repeated snap-freezing of tissue by submersion in liquid nitrogen followed by thawing at 
room temperature in phosphate-buffered saline.  Multiple freeze-thaw cycles have been 
utilized to render a variety of tissues acellular, including peripheral nerve grafts [149, 
265], meniscal tissue [266], embryonic chick knee [267], and human dermis [268].  The 
aforementioned studies demonstrated that mechanical cell disruption is a mild 
acellularization treatment that preserves tissue components for successive tissue repair, 
but thus far, such methods have only been used to acellularize somatic tissues in a 
homeostatic state. 
ESCs are commonly induced to differentiate in vitro by forming 3-dimensional 
cell spheroids, termed embryoid bodies (EBs), which recapitulate many of the molecular 
and cellular morphogenic events that occur during the normal pre-gastrulation stages of 
embryological development [41, 42, 47, 269].  Previously, our lab demonstrated that 
acellular matrices could be derived from EBs using solvent extraction methods in 
combination with DNase treatment [216, 270].  The objective of the present study was to 
examine the effectiveness of two separate mechanical methods, lyophilization and 
repetitive freeze-thaw cycles, as alternative means to efficiently acellularize matrices 
produced by differentiating ESCs within EBs.  Acellularization was assessed based upon 
quantitative assays of cell viability, DNA content, and protein content compared to 
untreated EBs, in addition to histological analysis of acellular EB matrix structure and 
exogenous cell repopulation of EB-derived matrices.  These studies establish novel 
methods by which mechanical disruption techniques effectively acellularize EBs to 
produce acellular matrices capable of supporting cell attachment and adhesion.  Coupled 
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with the ability of ESCs to promote endogenous tissue regeneration in vivo, these 
naturally-derived matrices provide a novel scaffolding material for future investigations 
of endogenous tissue repair and regeneration, in addition to elucidating mechanisms by 
which ESCs promote healing and morphogenesis via the production of unique 
combinations of factors constituting an embryonic microenvironment. 
 
Methods 
ESC culture and differentiation 
 D3 murine embryonic stem cells were cultured on 0.1% gelatin-coated plates in 
complete media consisting of Dulbecco’s Modified Eagle Medium (DMEM, Mediatech) 
supplemented with 15% fetal bovine serum (FBS, Hyclone), 2mM L-glutamine, 1X non-
essential amino acids, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.25 µg/mL 
amphotericin, 0.1 mM β-mercaptoethanol, and 103 U/mL leukemia inhibitory factor (LIF, 
Chemicon).  To initiate ESC differentiation, embryoid bodies (EBs) were formed from a 
single-cell suspension of 4x106 cells in 10 mL differentiation media (complete media 
without LIF).  EBs were cultured in 100 mm Petri dishes on a rotary orbital shaker (Lab-
Line Lab Rotator, Barnstead) held constant at 40±2 rpm [213].  EBs were re-fed with 
fresh media every 2 days by collecting individual plates of EBs via gravity-induced 
sedimentation in 15 mL conical tubes, aspirating the old media, and replacing with fresh 
differentiation media before transferring the EBs back to 100 mm Petri dishes.  Rotaries 




Acellularization of EBs 
 After 4, 7, or 10 days of rotary orbital suspension culture, EBs were harvested, 
rinsed in phosphate-buffered saline (PBS) prior to acellularization treatments, and 
divided into aliquots of approximately 2x103 EBs per sample.  To acellularize via 
lyophilization, EB samples in 1.5 mL microcentrifuge tubes were rinsed twice with 1 mL 
PBS and frozen in 1 mL dH2O at -80oC overnight.  Frozen samples were placed in the 
lyophilizer (Labconco) overnight and then removed for further processing.  Freeze-
thawed acellular samples were produced by aspirating PBS, immersing the entire tube 
with EBs into liquid nitrogen, and allowing the liquid nitrogen to boil off.  Once the 
liquid nitrogen was boiled off, 1 mL PBS was added to thaw the EBs while rotating the 
sample for 5 minutes (LabQuake Rotisserie) at room temperature.  EBs were then 
centrifuged for 2 minutes at 18,000 rcf at room temperature.  This process of freeze-
thawing was performed 1, 3, or 5 times for each sample to determine the optimal number 
of cycles.  For comparison purposes, chemical acellularization was performed, as 
previously described, by treating the EB samples with 1% Triton X-100 for 30 minutes 
while rotating [270].  Following Triton treatment, samples were centrifuged for 2 minutes 
at 18,000 rcf at room temperature and rinsed three times with PBS.  For DNase treatment, 
subsequent to mechanical and chemical permeabilization steps, samples were treated with 
0.5 mL of 1 mg/mL DNase for 15 minutes while rotating, centrifuged for 2 minutes at 





Scanning electron microscopy (SEM) 
 Samples not dried via lyophilization (i.e. hydrated samples) were fixed in 2.5% 
gluteraldehyde in deionized (dI) H2O for 1 hour while rotating.  Samples were rinsed 3 
times in dI H2O and rotated in 4% osmium tetroxide in dI H2O for 1 hour at room 
temperature.  After 3 rinses in dI H2O, samples were placed in acetone and dehydrated 
using an E3000 series critical point dryer (Quorum Technologies).  Liquid CO2 was 
allowed to permeate the samples for 1 hour and passed through the CO2 critical point 
(31.5oC, 1100 psi).  Subsequently, dried samples were mounted on stubs with carbon tape 
and sputter-coated with gold for 120 seconds using a Polaron Sputter Coater SC 7640 
(Quorum Technologies).  Scanning electron microscopy images were taken using a 
Hitachi S-800 FE-SEM with a 10kV acceleration voltage. 
 
Histology 
 Histological samples were fixed for 30 minutes in 10% formalin while rotating, 
washed 3 times in PBS, and embedded in Histogel®.  The embedded samples were 
paraffin-processed and sectioned into 5 µm sections.  Prior to staining, slides were de-
paraffinized in a Leica Autostainer XL.  Hemotoxylin and eosin (H&E) staining was 
performed using a Leica Autostainer XL, and slides were incubated with Hoechst dye 
(nuclear stain, 10 µg/ml) for 5 minutes.  Slides were mounted with coverslips using either 
Cytoseal™ 60 for H&E (Richard-Allan Scientific) or Gel/Mount™ (Biomeda Corp.).  
Brightfield and fluorescent images were captured using a Nikon 80i Upright Microscope 
and a SPOT Flex camera (15.2 64Mp Shifting Pixel, Diagnostic Instruments) in 
conjunction with SPOT Advanced v.4.5 (Diagnostic Instruments) software. 
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Cell viability 
 Cell viability was analyzed using 10% alamarBlue (Biosource) in serum-free 
complete media without LIF.  Acellular samples and untreated EBs were incubated for 2 
hours in 5% CO2 at 37oC, after which 25 µl aliquots were taken from the incubated 
samples, and fluorescence measurements were taken (ex: 545 nm, em: 590 nm) using a 
SpectraMax M2e plate reader.  Relative viability was determined by normalizing the 
acellular samples to the starting population of untreated EBs. 
 
DNA analysis 
 Viable and acellular EBs were solubilized by rotating samples at room 
temperature for 24 hours in 6M guanidine hydrochloride in order to assess DNA content.  
DNA content was quantified using the Quant-iT™ PicoGreen® dsDNA Assay kit 
(Molecular Probes); a 1:5 volumetric ratio of solubilized sample to a solution of 1X TE 
buffer and 0.5X PicoGreen dye was used.  The fluorescence reading (ex: 485 nm and em: 
528 nm) was taken on a SpectraMax M2e plate reader, and the absolute amount of DNA 
(mg/mL) was quantified against a lambda DNA standard curve (0 mg/mL - 5 mg/mL).  
The amount of DNA present following DNase treatment was compared to untreated EBs. 
 
Protein analysis 
Total protein content was analyzed using a bicinchoninic acid (BCA) assay kit 
(Pierce).  A 1:1 dilution of 6M guanidine hydrochloride solubilized sample (described 
above) in dI H2O was used, and 25 µl of sample was incubated with BCA solution for 30 
minutes.  Absorbance readings were taken at 562 nm using the aforementioned plate 
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reader.  The absorbance readings of the solubilized samples were compared against a 
standard curve (0 µg/mL - 2,000 µg/mL) generated using bovine serum albumin (BSA) in 
order to calculate absolute protein concentrations. 
Enzyme-linked immunosorbent assay (ELISA) kits were used to quantify the 
amount of proteins of interest harbored within acellularized EB matrices, specifically 
IGF-2 and VEGF-A (DuoSet, R&D Systems).  Acellular EBMs were solubilized using 
500 µL TPER buffer (Thermo) with rotation for 2 hours at room temperature followed by 
5 minutes of centrifugation at 14,000 RPM to remove particulate.  Briefly, capture 
antibody was adsorbed onto a MaxiSorp™ Immuno 96-well plate (Nunc), followed by a 
blocking step, incubation with 100 µL sample, and binding of analyte to a biotinylated 
detection antibody. The concentrations of capture and detection antibodies used were 
dictated by the DuoSet protocol for each protein: 4 µg/mL and 200 ng/mL for IGF-2 and 
400 ng/mL and 100 ng/mL for VEGF-A.  TPER buffer was used as the diluent for the 
standard curve samples.  The amount of analyte was assessed using the colorimetric 
reaction of peroxidase and tetramethylbenzidine (TMB) with an absorbance reading at 
450 nm.  The absorbances for each sample were compared to the standard curve to 
establish the protein analyte content, which was normalized to the mass of EBM (mg) 
and reported as pg protein per mg EBM. 
 
Endotoxin assay 
 The end point chromogenic limulus amebocyte lysate (LAL) endotoxin test  
(Lonza) was used to assay the levels of endotoxin present in the lyophilized acellular 
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EBMs.  Briefly, acellular EBM samples were resuspended in 500 µL sterile PBS, placed 
on a rotisserie for 30 minutes at room temperature, and centrifuged for 5 minutes at 
14,000 RPPM to remove particulate.  Endotoxin testing was performed as described in 
the product manual.  Briefly, test samples and endotoxin standards reacted with the LAL 
for 10 minutes, followed by the addition of a substrate solution and incubated for 6 
minutes, and then the reaction was stopped with stop reagent (25% glacial acetic acid 
solution). The entire reaction was performed at 37oC.  Absorbance readings at 405nm 
were taken using a SpectraMax M2e plate reader, and the endotoxin concentration 
(EU/mL) was calculated using the standard curve generated using the endotoxin standard 
supplied with the kit. 
 
Cell seeding 
 NIH-3T3 fibroblasts were cultured to 80% confluence on tissue culture-treated 
100 mm dishes in growth media containing DMEM supplemented with 10% bovine 
growth serum (BGS, Hyclone), 4 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL 
streptomycin.  Three hours prior to seeding, 3T3s were treated with mitomycin-C (10 µM 
in serum-free growth media) to inhibit cell proliferation for assessment of cell invasion 
into the acellular matrix.  Following acellularization treatments, acellular EB matrices 
were frozen at -80oC in 1 mL dI H2O overnight and freeze-dried.  Fibroblasts were 
trypsinized and seeded onto the lyophilized acellular matrices at a density of 106 cells/mL 
by placing the matrices into 1 mL of 3T3 single-cell suspension and allowing them to 
rotate.  After 3 hours of seeding in suspension, seeded matrices were gently spun down 
for 1 minute at 200 rcf, washed 3 times in PBS, and transferred to 48-well tissue culture 
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plates with 500 µl of 3T3 growth media.  The seeded matrices were re-fed every two days 
for up to 4 days, at which point, seeded matrices were rinsed with PBS and processed for 
histology as previously described. 
 
Statistics 
All statistical analyses were performed using Systat software (version 12).  
Viability comparisons across multiple experimental groups were performed using a one-
way analysis of variance (ANOVA) followed by post-hoc Tukey analysis to determine 
significant (p < 0.05) differences between the different groups.  Comparisons within 
DNA and protein content results were done using a two-way ANOVA with significance 
assessed using post-hoc Tukey analysis (p < 0.05). 
 
Results  
 Overall results exhibited efficient acellularization of EBs using mechanical 
permeabilization with DNase treatment.  Initial studies were performed varying the 
number of freeze-thaw cycles (1, 3 or 5) and examined on the basis of inhibition of cell 
viability and retention of total protein content.  Using EBs differentiated for 7 days, 
investigation of the number of freeze-thaw cycles indicated that 3 cycles was efficient at 
removing DNA while retaining protein in the final product (Figure 5.1).  Successive 
studies were performed to assess acellularization efficiency on EBs at various stages of 
differentiation.  Both mechanical methods, lyophilization and 3 freeze-thaw cycles, 
independent of EB differentiation time, significantly inhibited cell viability (p = 5.57x10-
6) compared to untreated EBs; retention of total protein among EBs at different stages of 
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differentiation after acellularization, however, was not significantly different (Figure 5.2) 
from untreated EBs.  Day 4 EBs generally exhibit relatively low gene expression of ECM 
molecules and growth factors, whereas a variety of ECM and growth factor gene 
expression levels begin to increase by day 7 of differentiation and continue to increase by 
10 days described in Chapter 3.  Thus, based on the earliest time point at which ECM and 
growth factors are increasingly expressed within EBs as described in Chapter 3, day 7 
EBs were used for all subsequent acellularization studies. 
 
Morphology & ultrastructure analysis 
The two different mechanical disruption methods attempted yielded acellular 
products with very different macroscopic properties.  Lyophilized EBs were maintained 
as distinct EBs with a “cottonball, powder-like” morphology (Figure 5.3B, C) while 
freeze-thawed EBs (FT) produced a single amorphous mass with a “gel-like” appearance 
(Figure 5.3D, E).  Handling the lyophilized EBs was similar to managing a dry powder 
with static interaction, while the congealed, freeze-thawed EB matrix could be 
manipulated by collecting the entire mass using a spatula.  EB matrices treated with 
DNase, both lyophilized (L+D) and freeze-thawed (FT+D), formed a more compact 
pellet compared to FT matrices and could be gently manipulated using a pair of tweezers. 
Compared to untreated EBs (Figure 5.4A, D), the lyophilized matrices appeared 
relatively smooth and largely porous (Figure 5.4B, E), whereas FT matrices consisted of 
a non-porous, dense particulate material, due to compaction from the centrifugation steps 
performed during acellularization (Figure 5.4C, F).  After DNase treatment and 
centrifugation retrieval of the material, L+D samples were less porous and more closely 
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resembled the structure of the FT ± D samples (Figure 5.5).  These results indicate that 
the sequence of the processing steps performed strongly affects the structural properties 




Figure 5.1.  Effects of freeze-thaw cycles on acellular EB content.  DNA content (A) 
and protein content (B) within acellular EB matrices was slightly (but not significantly) 
decreased after 3 or 5 cycles compared to a single freeze-thaw cycle.  Results shown are 




Figure 5.2.  Quantitative assessment of acellular matrices derived from EBs at 
different stages of differentiation.  (A) Significant inhibition of cell viability was 
achieved by mechanical acellularization of EBs at various days of differentiation. (B) The 
amount of protein remaining after acellularization did not change significantly after 
differentiation of the EBs for different periods of time.  One-way ANOVA was 
performed for samples at the same day of differentiation (* = p < 0.05).  Results shown 





Figure 5.3.  Overview of EB acellularization process.  EBs differentiated for 7 days 
were mechanically acellularized either by lyophilization (B&C) or multiple freeze-thaw 
cycles (D&E) followed by DNase treatment.  Phase image shows EBs cultured for 7 days 
(A).  Digital images macroscopically exhibit EB matrix following each of the mechanical 




Figure 5.4.  Acellular EB ultrastructure.  Sample SEM images were taken before and 
after mechanical permeabilization at 100X (scale bar = 200 mm) and 1000X (scale bar = 
20 mm) magnification.  EBs (A, D) and lyophilized EBs (B, E) retain separate EB 
structure; however, lyophilized EBs show a more apparent porous structure compared to 
untreated EBs.  Freeze-thawed EBs (C, F) no longer retained EB morphology and 






Figure 5.5.  Ultrastructure of acelluar EBs with DNase treatment.  Acellular sample 
SEM images were taken after mechanical permeabilization and DNase treatment at 100X 
(scale bar = 200 mm) and 1000X (scale bar = 20 mm) magnification.  L+D (A, C) and 





Several notable differences in the histological appearance of lyophilized and FT 
EBs were also apparent.  As indicated initially by SEM, lyophilized EBs were maintained 
as separate EBs that appeared similar in size and morphology to untreated EBs (Figure 
5.6A, B), while repeated freeze-thawing caused individual EBs to agglomerate and form 
a cohesive mass of indistinguishable EBs (Figure 5.6C), much like Triton- or SDS-treated 
EBs [216, 270].  Mechanical acellularization methods alone did not remove cellular 
content, since nuclei were present within the resulting EB matrices (Figure 5.6A-C; 5.6A-
C inserts), compared to Triton-treated samples which lacked distinct nuclei [270].  
Treatment with DNase after physical permeabilization methods resulted in acellular 
matrices without discrete nuclei by hemotoxylin staining (Figure 5.6E, F) and little to no 
detectable Hoechst staining for DNA content (Figure 5.6E, F inserts), demonstrating the 
effectiveness of DNase treatment.  In contrast, DNase alone was not able to effectively 
permeate untreated EBs (Figure 5.6D; 5.6D insert) to disrupt and remove DNA.  Thus, 
the mechanical acellularization protocols produced matrices with different compositions 
and varying extents of cell DNA removal. 
 
Quantitative analysis 
A multi-parametric set of analyses was performed to quantitatively assess 
differences in cell viability, DNA removal, and residual protein content resulting from the 
different acellularization treatments.  The viability of the cells (Figure 5.7A) was 
significantly inhibited to negligible levels by both mechanical acellularization methods (p 




Figure 5.6.  Histological analysis of mechanical acellularization.  EBs and acellular 
samples were stained with H&E and Hoechst (inset) to qualitatively compare acellular 
treatments.  Mechanical disruption alone (top row, A-C) was compared to mechanical 
disruption and DNase treatment (bottom row, D-F). 
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significant differences between the different permeabilization treatments were observed.  
Each of the relative values approached the lower sensitivity range of the assay, indicating 
successful complete inhibition of cell viability by each of the independent methods prior 
to DNase treatment.  The freeze-thaw method of permeabilization allowed the most 
efficient removal of DNA (removing 75.02 ± 8.06% DNA), exhibited by the significant 
difference (p = 1.35x10-5) in residual DNA between FT and FT+D samples (Figure 
5.7B).  DNA content remaining in L+D and T+D samples were not significantly reduced 
compared to lyophilized (p = 0.763) and Triton-treated (p = 0.336) samples, respectively.  
Prior to DNase treatment, overall protein content was not significantly reduced between 
mechanical permeabilization methods compared to untreated EBs, whereas, Triton 
permeabilization significantly decreased the amount of protein (p = 0.001) compared to 
untreated EBs (Figure 5.7C).  With DNase treatment, mechanically permeabilized 
products exhibited similar protein content to chemically permeabilized samples, 
indicating that residual protein removal was a result of the subsequent incubation and 
wash steps following DNase treatment.  Overall though, acellularization using 
mechanical disruption techniques with DNase was capable of producing acellular EB 
matrices with slightly increased protein content compared to acellularized EBs using 





Figure 5.7.  Quantitative analysis of acellular EB matrix components.  (A) Cell 
viability of permeabilized samples.  (B) Residual DNA concentration pre- and post-
DNase treatment.  FT permeabilization lead to significant removal of DNA following 
treatment with DNase.  (C) Total protein content pre- and post-DNase treatment.  Total 
protein before DNase treatment in Triton samples was significantly lower than all other 
treatments; whereas post-DNase treatment of mechanically permeabilized samples 
significantly decreased protein content compared to no DNase treatment.  One-way 
ANOVA (p<0.05): * significant compared to untreated EBs.  Two-way ANOVA 
(p<0.05): # significant compared to other pre-DNase samples, † significant compared to 
same permeabilization, post-DNase. 
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Acellular matrix protein characterization 
The concentration of endotoxin was quantified in lyophilized matrices of day 7 
and 10 EBs.  The amount of endotoxin contained within the lyophilized matrices ranged 
between 0.03 – 0.38 EU/mL depending on the batch of EBs assessed (Figure 5.8A), 
which was less than the FDA guideline of 0.5 EU/mL [271].  Further characterization of 
two specific growth factors, IGF-2 and VEGF-A, was performed on lyophilized acellular 
matrix with and without DNase treatment.  These samples were chosen for quantifying 
growth factor retention as a result of the total protein content after mechanical 
acellularization.  The VEGF-A harbored within the lyophilized acellular EBMs was 
approximately 2 pg/mg for both ± DNase treatment; however, the amount of IGF-2 
retained in the lyophilized EBM was 6 pg/mg, while the DNase treated EBM had 
undetectable levels of IGF-2 protein (Figure 5.8B).  Overall, theses results indicated that 
these acellular EB matrices contained low levels of endotoxin while preserving growth 
factors content following acellularization. 
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Figure 5.8.  Endotoxin and growth factor protein content.  (A) Endotoxin content 
present in lyophilized EB matrices remained below the FDA guideline level of 0.5 
EU/mL among various batches.  (B) The amount of certain growth factors retained within 
acellular matrices was affected the method of acellularization. Results indicated are mean 
± standard deviation (n=4). 
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Cell repopulation of acellular EB matrices 
Fibroblast (NIH-3T3) cell attachment to and repopulation of the resulting 
acellular EB matrices was examined 4 days after seeding the cells.  As previously 
demonstrated, negligible Hoechst staining was observed in the unseeded acellularized 
matrices following DNase treatment (Figure 5.6E, F).  Exogenously added fibroblasts 
were easily distinguished from any residual ESC nuclei based on the larger size of the 
fibroblast nuclei (Figure 5.9Ai, Aiv, Bi, Biv), roughly twice that of ESCs.  Auto-
fluorescence of the acellular matrix under the FITC channel (green) was used to 
distinguish the acellular matrix from the exogenously seeded cells (Figure 5.9Aii, Avi, 
Bii, Bvi).  Fibroblasts seeded onto lyophilized matrices attached primarily to the surface 
of individual lyophilized EBs, but did not appear to invade the acellular matrices (Figure 
5.9Aiii); similarly, FT matrices without DNase treatment did not exhibit much infiltration 
by 3T3 fibroblasts (Figure 5.9Biii). Although the bulk of fibroblasts were distributed 
throughout the exterior layers of the acellular matrices with DNase treatment, many cells 
were found within the acellular matrices as well (Figure 5.9Avi, Aiix, Bvi, Biix).  Thus, 
L+D and FT+D treatments of EBs both permitted fibroblast attachment, adhesion, and 





Figure 5.9.  Biocompatibility of acellular EB matrices.  Fibroblasts seeded on 
lyophilized and L+D treated matrices (A) and compared to cell seeding on FT and FT+D 
acellular matrices (B).  DNA was stained with Hoechst (blue; first column), while the 
acellular matrix was visualized via auto-fluorescence (FITC channel; second column).  
Additionally, seeded matrices were stained with H&E to demonstrate successful 
repopulation (fourth column).   
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Discussion 
The aim of this study was to develop mechanical acellularization methods to 
isolate ECM molecules produced by ESCs undergoing differentiation as EBs.  The use of 
mechanical disruption techniques was investigated as an alternative approach to 
previously reported solvent extraction methods used to acellularize EBs [216, 270].  EBs 
were deemed acellular based on inhibition of cell viability, removal of DNA, and 
retention of protein content, thereby producing an EB-derived matrix harboring growth 
factors and capable of supporting exogenous cell adhesion and survival.  Additionally, 
various batches of acellularized EBs consistently exhibited negligible amounts of 
endotoxin (< 0.5 EU/mL).  Extraction of proteins from acellularized EBs demonstrated 
the presence of IGF-2 and VEGF-A growth factors retained in the acellular matrix.  
Isolation of acellular matrices from EBs enables further characterization of the complex 
assembly of ECM molecules dynamically produced by ESCs as they differentiate.  These 
novel acellular matrices may be utilized as inductive or instructive biological scaffolds in 
order to determine the functional effects of ESC-derived ECM biomolecules on somatic 
cell phenotypes and repair and regeneration of acute and chronically wounded adult 
tissues. 
When stem cells are utilized for tissue regenerative applications, the lasting 
effects typically observed do not include engraftment and stem cell differentiation, 
suggesting that transplanted cells exert a transient impact on tissue morphogenic 
processes.  The transient effect could likely be due to secreted trophic factors produced 
by the transplanted cells that stimulate endogenous cells to repair the injured or 
degenerative tissue site.  Previous studies have shown the ability of diffusible ESC-
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secreted factors to enhance cell survival and rescue knockout phenotypes [8, 193]; 
furthermore, secreted factors produced by ESCs could be non-covalently associated with 
the ECM to modulate the local EB microenvironment.  In the current study, mechanical 
disruption techniques, such as lyophilization and repeated freeze-thaw cycles, combined 
with DNase treatment resulted in acellular matrices derived from EBs.  General 
compositional differences between acellular EB matrices and untreated EBs included the 
presence of intact cell nuclei in untreated EBs and indistinguishable morphology of 
individual EBs in most acellular matrices.  Further differences between lyophilized EBs 
and L+D treated EBs were evident in the amount of IGF-2 extracted from the matrices - 
L+D treatment had resulted in undetectable levels of IGF-2.  However, fibroblast seeding 
studies demonstrated successful cell attachment to, as well as repopulation of, the 
acellular EB matrices. 
Acellularizing tissues has produced several naturally-derived matrices that are 
currently being utilized for an array of different clinical applications.  Almost all existing 
acellularized matrices originate from adult tissues, which typically exhibit significantly 
less regenerative capacity than embryonic tissues.  Within the developing embryo, 
paracrine factors, particularly morphogens and mitogens, are secreted in latent and 
bioactive forms into the ECM of the local microenvironment to influence and direct 
subsequent cell and tissue morphogenesis.  As EBs differentiate, a similar cadre of 
morphogens and mitogens are produced within EBs, thus using EBs as the starting tissue 
source for acellularization provides a unique opportunity to harness complex assemblies 
of molecules directly from EBs mimicking embryogenesis in vitro.  By acellularizing 
EBs at various stages of differentiation using different types and combinations of 
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permeabilization and extraction, the biomolecules associated with the differentiation of 
EBs and secreted into the ECM can be effectively harnessed and subsequently analyzed. 
The development of acellular matrices derived from stem cells may obviate many 
of the potential complications encountered by using cell transplants or viable tissues 
constructs for tissue regeneration applications.  Matrices derived from cells and tissues 
provide a natural scaffold material for cell adhesion and a vehicle to present instructive, 
morphogenic cues to cells that repopulate the scaffold.  Acellular EB matrices could 
provide a unique, potent reservoir of morphogenic factors produced by ESCs 
differentiating in a 3D environment.  In the future, acellular EB matrices could even be 
tailored for specific tissue applications by directing ESCs within EBs to differentiate 
towards specific cell phenotypes, which in turn could yield “tissue-specific” extracellular 
matrices from a single cell source.  Overall, the results of this study demonstrate that 
mechanical acellularization of EBs is a novel route to directly obtain ESC-derived ECM 
molecules for potential regenerative medicine therapies.  
 
Conclusions 
The ability to harness ESC-produced molecules to stimulate tissue morphogenesis 
independent of the cells themselves is a novel approach in regenerative medicine.  
Acellularizing embryoid bodies using mechanical methods provided a means to analyze 
secreted molecules by ESCs in a matrix formulation that can be further tested in vitro to 
assess effects on migration, proliferation, and differentiation of exogenous cell types.  
Initial characterization revealed growth factor retention within the acellular EB matrix, 
however, global analysis of the composition of biomolecules present in the EB matrix 
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would elucidate the extracellular morphogens secreted by embryonic stem cells 
mimicking early stages of embryogenesis.  Thus, the molecular cues produced during EB 
differentiation and harbored within the extracellular matrix could have broad applications 
in tissue regeneration strategies. 
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CHAPTER 6 
ACELLULAR ESC-DERIVED MATRICES HARBOR BIOACTIVE 
FACTORS THAT AFFECT ASPECTS OF ANGIOGENESIS 
 
Introduction 
Cells secrete extracellular factors in order to regulate themselves in an autocrine 
manner or control surrounding cells in a paracrine manner.  This mode of paracrine 
action has been studied specifically regarding the regenerative effects of secreted 
molecules, specifically in cell transplantation and conditioned media studies.  
Transplanted cells grafted into compromised tissues have been shown to yield 
considerable regenerative effects, however, the number of engrafted cells within the 
transplantation site are minimal.  As of recent, there has been a wealth of literature to 
support the paracrine effects of transplanted cells.  Studies involving MSC transplantation 
in the infarcted myocardium demonstrate functional benefits within 72 hours of 
transplantation, due to MSC paracrine factors providing a cytoprotective effect rather 
than cell engraftment [185, 272].  In order to alleviate the issue of transplanting cells, 
such as cell sourcing and obtaining sufficient quantity of cells, several studies have 
investigated the effects of conditioned media as a cell-free method to deliver secreted 
factors from a number of cell types typically utilized for cell transplantation, including 
adipose-derived stem cells (ASCs) [186, 273], endothelial progenitor cells (EPCs) [274], 
and ESCs [192, 243].  Progenitor cell-conditioned media has been demonstrated to be 
effective in modulating cellular responses by promoting cell survival and inhibiting 
apoptosis, as well as stimulating endogenous tissues in order to regenerate specific tissue 
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function, such as myocardium and vasculature, and overall wound healing and 
angiogenesis [189, 236, 275, 276].  The factors generally involved in stimulating cells in 
a paracrine manner are growth factors and cytokines, which typically have short in vivo 
half-lives in a soluble state [277] and would potentially require multiple injections when 
examining conditioned media effects in vivo.  Additionally, the amount of factors 
generated in conditioned media is dilute and require concentrating down the volume to 
obtain growth factor concentrations at clinically relevant levels.  Furthermore, 
administering secreted factors via conditioned media may not be clinically applicable.  
However, delivering growth factors associated with ECM has been used in a number of 
clinical settings, such as becaplermin, a recombinant form of PDGF [94] in combination 
with collagen products [278].  In vivo, growth factors are naturally associated with the 
extracellular matrix, potentially in latent form, and upon activation by proteases are 
released from the ECM to bind cell surface receptors, whereas other growth factors can 
bind receptors in their matrix-associated state.  Therefore, the ECM acts as a reservoir for 
a variety of secreted growth factors by the residing cells, while the ECM proteins 
themselves provide binding domains for a number of adhesion receptors.  The myriad of 
ECM and growth factors is fundamental in tissue regeneration processes, especially 
wound healing and angiogenesis.  Several delivery strategies have been reported in order 
to control the release of growth factors from a variety of delivery systems, including 
fibrin matrices, bioartificial matrices, and decellularized tissues [279-281].  
Acellularizing tissues has been a means to harness naturally derived matrices that 
contain a complex milieu of ECM and growth factors.  Despite the number of acellular 
matrices derived from tissues, only a few studies have extracted and identified specific 
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factors retained within the matrix.  Growth factors have been extracted from the 
extracellular matrix from a variety of tissues, including SIS, ABM, BSM, and amniotic 
membrane, and have been shown to retain bioactivity in a number of assays, including in 
vitro and in vivo studies [157-159, 282].  With all the above mentioned, only a few 
studies have examined acellularizing more embryonic associated tissues, such as placenta 
or amniotic membrane [127, 282].  Embryonic environments yield morphogens that 
promote proliferation, migration, self-renewal, and differentiation (reviewed in [283]), 
which can impact the response of fetal wound healing [284] or suppress tumor 
phenotypes [285].  Previous studies within our lab have established the presence of 
extracellular factors such as hylauronan and versican [211], among others, as well as the 
methods to isolate EB matrices using acellularization techniques such as chemical, 
mechanical, and enzymatic treatments [216, 270].  Based on results from previous 
chapters, including EB differentiation profile and acellular matrix protein retention, this 
study aims to examine the extraction of growth factors retained in acellularized EB 
matrices (EBMs) derived using lyophilization techniques as well as the bioactive effects 




Mouse embryonic stem cells (ESCs; D3 cell line) were initially expanded on a 
feeder layer of mouse embryonic fibroblasts and were subsequently cultured feeder-free 
for several passages on 0.1% gelatin-coated 150 mm polystyrene cell culture dishes 
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(Corning) with Dulbecco’s modified eagle medium (Mediatech), supplemented with 15% 
fetal bovine serum (HyClone), 2 mM L-glutamine (Mediatech), 1x MEM non-essential 
amino acid solution (Mediatech), antibiotic/antimycotics (Mediatech), and 0.1 mM β-
mercaptoethanol (MP Biomedicals, LLC).  Undifferentiated cells were expanded prior to 
EB formation in the presence of 103 U/mL leukemia inhibitory factor (LIF) (ESGRO), 
which was added to the culture media upon each re-feeding.  Cells were passaged every 
two to three days before reaching ~70% confluence.  To initiate EB culture, ESCs were 
trypsinized from the gelatin-coated dishes using 0.05% Trypsin/0.53 mM EDTA 
(Mediatech) and formed in AggreWell™ 400 inserts (Stem Cell Technologies) for the 
first 24 hours [286, 287].  A density of 6x106 cells in 3 mL differentiation media (ESC 
media without LIF) was used to inoculate one AggreWell™ insert containing 6000 wells 
to form 1000 cell EBs.  After allowing the cells to settle for a few minutes, inserts and 
cells were centrifuged for 5 minutes at 200 x g.  After 24 hours of culture, EBs were 
transferred out of the AggreWell™ to rotary suspension culture with ~2500 EBs cultured 
in 1x100 mm bacteriological grade polystyrene Petri dishe (Corning) with 10 mL 
differentiation media.  EB suspension cultures were maintained on rotary orbital shakers 
(Barnstead Lab-Line, Model 2314) at 40 rpm at 37oC in 5% CO2 for the entire duration of 
suspension culture.  Previous work from our lab has demonstrated that rotary orbital 
suspension culture methods result in greater yields of homogeneous populations while 
preventing agglomeration of EBs [213].  EBs were cultured in suspension for up to 10 
days and re-fed every other day after collecting independent EB cultures via gravity-
induced sedimentation in 15 mL conical tubes.  Spent media was aspirated, and the 
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cultures were replenished with 10 mL of fresh differentiation media before being placed 
back in the Petri dishes and returned onto the rotary orbital shakers. 
NIH-3T3 fibroblasts were cultured on tissue culture dishes in 3T3 growth medium 
containing DMEM supplemented with 10% bovine growth serum (BGS), 4 mM L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin. 
Human umbilical vein endothelial cells (HUVECs, Lonza) were cultured on gelatin-
coated tissue culture dishes in endothelial growth medium (EGM-2), consisting of 
Endothelial Basal Media (EBM, Lonza) with the addition of the EGM-2 BulletKit™ 
consisting of 5% FBS, human EGF, hydrocortisone, gentamincin, amphotericin-B, 
VEGF, human FGF-2, recombinant IGF-1, ascorbic acid, and heparin. 
 
Acellularization of EBs 
 Acellular EB matrices (EBMs) were obtained from EBs after days 7 and 10 of 
rotary culture.  Day 7 and day 10 EBs were investigated based on the increased gene 
expression results, in particular the angiogenic growth factors, in Chapter 3 and 4.  
Lyophilization methods without DNase, previously described in Chapter 5 were used to 
acellularize these EBs.  Briefly, EBs were formed for 24 hours using microwells, 
transferred to rotary suspension culture at 40 RPM, and re-fed every other day with fresh 
differentiation media.  At days 7 and 10, EBs from all plates were collected as a single 
batch by sedimentation, rinsed 3 times with PBS, and resuspended in 1 mL of molecular 
biology grade water per plate of EBs.  To obtain separate samples of EB matrix, 1 mL of 
EB suspension was aliquoted into a microcentrifuge tube, EBs were gently centrifuged at 
1000 RPM for 1 minute at room temperature, and then frozen at −80oC prior to 
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lyophilization.  After lyophilizing samples for 24 hours, the mass of EB matrix was 
calculated by subtracting the mass of the tube alone from the mass of the EB matrix + 
tube.  Dried EBM samples were stored in a dessicator at room temperature. 
 
EBM extractions 
Extraction of morphogens from lyophilized EB matrices (day 7 and day 10) were 
examined using two different extraction buffers – tissue protein extraction buffer (TPER, 
Thermo) and serum-free media.  For both TPER and serum-free media EBM extractions, 
two different doses of EBM were examined for morphogen extraction - 3 mg/mL and 6 
mg/mL.  TPER buffer is mild enough that proteins can be assessed using reporter assays 
and immunoassays.  Serum-free media can be readily applied to any cellular activity 
assay without requiring dialysis or dilutions.  The appropriate volume of buffer was 
added to each EBM sample in a microcentrifuge tube, pipetted up and down, and placed 
on a rotisserie overnight at 4oC.  Serum-free media consisted of low glucose, phenol red-
free DMEM and 0.1% bovine serum albumin (BSA, Fraction V) supplemented with 4 
mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25µg/ml 
amphotericin.  Additionally, serum-free media extractions samples were heat treated at 
95oC for 5 minutes to compare bioactivity with and without heating.  Before treating cells 
with EBM extractions, all samples (n=4 per group) were centrifuged to remove insoluble 




Protein quantification assays 
The total protein content of day 7 and day 10 EBMs was determined using a 
bicinchonic assay (BCA, Thermo) for EBM extractions after 24 hours, as described 
previously.  All samples were prepped and analyzed for total protein content according to 
the protocol provided by the BCA manufacturer.  Absorbances were read on a 
SpectraMax M2e plate reader at 562 nm, and protein concentrations were calculated 
based on a BSA protein standard curve (0 – 2000 µg/mL). 
As for quantifying specific growth factors extracted using TPER and serum-free 
media, enzyme-linked immunosorbent assays (ELISA) were performed for four growth 
factors: BMP-4, FGF-2, IGF-2, and VEGF-A (DuoSet, R&D Systems).  FGF-2 ELISA 
kit was for human FGF-2, thus the cross-reactivity with mouse FGF-2 was ~30%, as 
reported by the manufacturer, and the results are the direct result of the ELISA.  TPER 
extractions were not compliant with the BMP-4 ELISA kit, determined after several 
ELISA runs resulted the standards having a very small dynamic range unlike what is 
described in the product manual and the serum-free media extractions, thus BMP-4 was 
not analyzed for TPER extractions.  Appropriate diluents (TPER or serum-free media) 
were used for the standard curve samples depending on the sample set, either serum-free 
media or TPER buffer.  The amount of analyte was assessed using the colorimetric 
reaction of peroxidase and tetramethylbenzidine (TMB) with an absorbance reading at 
450 nm.  The absorbances for each sample were compared to the standard curve to 





For proliferation studies, NIH-3T3 fibroblasts and HUVECs were cultured to 
approximately 50% confluence in 2-chamber glass slides (BD Bioscience), at which point 
growth media were removed and the cells were rinsed 3 times in PBS.  Cells were then 
starved overnight in low-serum media, followed by an 18-hour pulse with 10 mM 5-
bromo-2’-deoxyuridine (BrdU) in EBM extractions with the respective serum-free media 
as well as control media, including respective growth media (positive control) and serum-
free media (negative control) (n=4 per treatment group).  Matrix extractions utilized for 
3T3s were conducted in serum-free 3T3 media consisting of low glucose, phenol red-free 
DMEM and 0.1% bovine serum albumin (BSA) supplemented with 4 mM L-glutamine, 
100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin; whereas, 
EBM extractions for HUVECs used serum-free EC media which consisted of EBM and 
0.1% BSA supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 
µg/ml amphotericin.  After the 18-hours pulse, cells were rinsed with PBS and fixed in 
70% ethanol with 2.3M HCl for 10 minutes at room temperature, rinsed in PBS 3 times, 
and incubated with mouse anti-BrdU primary antibody (Molecular Probes) for 1 hour at 
room temperature.  Following primary antibody incubation, the cells were incubated with 
donkey anti-mouse secondary antibody conjugated to Alexafluor 488 (Invitrogen) for 2 
hours at room temperature, counterstained with Hoechst, and then coverslipped using 
GelMount (Electron Microscopy Sciences). 
 Stained slides were imaged using a Nikon 80i upright microscope with a 
SPOTFlex digital camera and SPOT Advanced Software (Nikon) using both the FITC 
and DAPI filters.  Nuclei counts were performed on all images using the “nuclei count” 
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application within MetaMorph (Molecular Devices), which counted the number of 
events, between ~ 5 – 30 pixels in diameter, that were above the set intensity level.  The 
percentage of BrdU-positive nuclei (FITC) was calculated for all images taken (n=6 
fields of view per chamber) to determine the amount of proliferation induced by the EBM 
extraction samples compared to the heat inactivated EBM extractions as well as the 
control media samples, growth and serum-free media. 
 
Migration assays 
For migration studies, NIH-3T3 fibroblasts and HUVECs were each grown to 
~80% confluence, inactivated with 10 µg/mL mitomycin-C in serum-free media (2 hours 
at 37oC in 5% CO2) and cultured overnight in growth media.  Cells were also 
fluorescently labeled in serum-free media with 1 µM CellTracker® Green (Molecular 
Probes) for 20 minutes at 37ºC, followed by a 30 minute incubation in growth media 
prior to initiation of the migration experiment. 
HTS Fluroblok transwell culture inserts (Falcon, 24-well, 8 mm pore size) were 
prepared with 300 µL single-cell suspension (7.5x104 3T3s or 1x105 HUVECs) in growth 
media (loaded in the top chamber).  The bottom of the transwell chamber was filled with 
800 uL of EBM extractions in the appropriate media for each cell type (non-heat-
inactivated or heat-inactivated), as described above, or control media, including cells’ 
respective growth media (positive control) and serum-free media (negative control).  
Transwell culture plates were incubated for 24 hours in 37oC at 5% humidity, and 
fluorescent microscopy images of the bottom of wells were taken at 0, 3, 6, 12, and 24 
hours using a Nikon TE 2000 inverted microscope with a SpotFLEX digital camera and 
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SPOT software (Nikon).  Additionally, fluorescence measurements of each transwell as 
well as a range of known number of CellTracker™–labeled cells were taken (ex: 492 nm, 
em: 515 nm) using a SpectraMax M2e plate reader.  The number of cells that migrated 
through the porous membrane was calculated based on a fluorescent cell standard curve 
generated for each cell type labeled with CellTracker™ ranging between 0 - 200,000 
cells with cell number plotted against relative fluorescent units.  At each time point, the 
change in relative fluorescent units from 0hr was calculated and used to determine the 
number of cells that migrated during that time period from the cell standard curve. 
 
HUVEC network formation assay 
Network formation assay was performed using HUVECs plated on growth factor-
reduced Matrigel™ (GFRM, BD Biosciences).  Two different methods of treating 
HUVECs on GFR Matrigel™ with EBM were studied – extracted EBM factors and 
lyophilized EBM.  For both studies, HUVECs were each grown to ~80% confluence, 
fluorescently labeled in serum-free media with 1 µM CellTracker® Green (Molecular 
Probes) for 20 minutes at 37ºC, followed by a 30 minute incubation in growth media 
prior to trypsinization. 
The first method introduced soluble factors contained in serum-free EC media 
EBM extractions (3 mg/mL and 6 mg/mL), previously described in the proliferation and 
migration assay.  GFR Matrigel™ (200 µL per well) was allowed to gel for 30 minutes at 
37oC in a 24 well plate.  Treatment groups included EBM extractions from either day 7 or 
day 10 EBM at 3 mg/mL, with a corresponding heat-inactivated sample, which was 
heated to 95oC for 5 minutes.  Prior to adding the cells to each extractions, all samples 
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were centrifuged for 5 minutes at 14,000 RPM.  HUVEC growth media (EGM-2) was 
used as a positive control, while serum-free EBM was used as a negative control.  After 
HUVECs were trypsinized and rinsed in PBS, a 1.92x106 cells/mL cell suspension in 
serum-free EBM was used to add 48,000 HUVECs (25µL volume) to 275 µL of sample 
media, resulting in 300 µL total volume of sample added per well of Matrigel.  
The second method assessed the EBM as a whole by embedding the lyophilized 
matrix into the GFR Matrigel.  EBM obtained from days 7 and 10 EBs, in addition to 
heat-inactivated EBM from both time points, was used in the network formation assay.  
On ice, approximately 3mg of each type of EBM (n=3) was mixed with 50 µL of PBS to 
hydrate the powdery matrix followed by 150 µL of GFR Matrigel, while 50 µL of PBS 
with no matrix was used a control.  The 200 µL mixture of Matrigel and EBM+PBS or 
PBS alone was added to a well of a 24 well plate and allowed to gel for 30 minutes at 
37oC.  After HUVECs were CellTracker-labeled and trypsinized, a cell suspension of 
160,000 cells/mL was prepared in EGM-2 and distributed among the wells at 48,000 cells 
(300 µL) per well.   
For both network formation assay methods, fluorescent microscopy (FITC) was 
utilized to analyze the extent of HUVEC network formation after 18 hours using a Nikon 
TE 2000 inverted microscope with a SpotFLEX digital camera and SPOT software 
(Nikon).  Images taken at 4X (n=4 per treatment) were quantified using the “Angiogensis 
Network Formation” application within Metamorph software (Molecular Devices) using 
the following parameter settings: “minimum tube width” = 1 pixel, “maximum tube 
width” = 7 pixels, and “grey level intensity threshold” = 16.  All quantified images were 
assessed individually by visual inspection; if quantified images did not detect aspects of 
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the original image accurately, parameters were adjusted to highlight the tubes in the 
original image.  A variety of network formation measures were expressed as a fold 
change compared to GFRM only controls.  One-way analysis of variance (ANOVA) was 
used to test significance followed by a Dunnett’s test (p < 0.05) of the treatment measures 
compared to control (GFRM only) measures. 
 
Quail chorioallantoic membrane (CAM) assay  
Corturnix quail eggs were obtained from Ozark Egg Company (Stover, MO) and 
labeled “day 0” upon arrival in the lab.  Eggs were incubated overnight at 37oC in a 
humidified chamber.  On day 1, in a laminar flow hood, each egg was opened using small 
scissors, transferred to a well in a 6-well plate, and incubated for 7 days at 37oC in a 
humidified incubator.  Instruments used to open and transfer each egg were sonicated in 
70% ethanol for ~1 minute and flamed, while each egg was sprayed with 70% ethanol 
prior to opening.  After 7 days of incubation, each CAM was treated randomly with two 
samples.  EBM isolated from day 7 and 10 EBs as well as respective heat-inactivated 
samples (negative control) and GFRM samples (positive control) were analyzed.  To 
preserve the sterility of the EBMs and GFRM, the amount of sample for each treatment 
was determined prior to lyophilization.  The amount of EBM per sample was normalized 
to a single plate of EBs, which corresponded to a dry EBM mass approximately between 
1 - 2 mg, while the amount of GFRM used was similar in volume to the EBM samples, 
yet corresponded to a dry mass approximately half that for EBM, between 0.5 – 1 mg.  
Areas of the CAM with sparse vessel growth were chosen in order to easily visualize the 
progression of any angiogenic response.  Digital images were captured at 1.25X 
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following sample placement at times 0, 24, and 48 hours using a Leica M165 stereoscope 
coupled to a Nikon Coolpix digital camera.  After 48 hours of treatment, CAMs were 
fixed using 4% paraformaldehyde and 2% gluteraldehyde for 48 hours at 4oC.  The 
CAMs were isolated and transferred into a 35mm Petri dish and rinsed with PBS for 48 
hours.  Using a 10mm biopsy punch, treated areas of the CAM were isolated and placed 
on a microscope slide and imaged at 2X magnification using the stereoscope setup 
previously mentioned. 
 
CAM image analysis  
CAM images taken at 0, 24, and 48 hours prior to fixation were analyzed by 
quantifying the number of radiating, or anisotropic, vessels around the area of matrix 
treatment.  In LabView’s Vision Assistant software, digital RGB images were split into 
the three color channels (red, green, blue); the green filter was extracted and used for the 
vessel counts.  Using the green filter images, concentric circles with two different 
diameters (6mm and 10mm) surrounding the matrix sample were created in Adobe 
Fireworks software and then imported into ImageJ to count the number of intersecting 
primary (large) and secondary (branching off of the primary) vessels with each of the 
circles.  For each treatment, the Poisson count data between time points was tested for 
significance using the Poisson model with the Pearson’s test statistic to determine if the 
means were equal [288].  If the means among the three time points were not equal, with a 
Pearson’s test statistic of p < 0.05, then comparisons between each time point were 
conducted with a Bonferroni correction for alpha, such that significance between time 
points were determined with p < 0.01.   
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Additionally, semi-quantitative analysis was performed on fixed CAMs after 48 
hours of treatment from digital images capture using a stereomicroscope, as described by 
Ribatti et al. [86].  Briefly, the angiogenic response was scored on graded scale between 
0 – 5, where 0 indicates no response to the graft, 5 refers to dilated, branching vessels in a 
dense “spoke-wheel” pattern, and scores 2 -5 represent gradual increases in vessel density 
and branching resembling a “spoke-wheel” pattern.  These scores can then be used to 
obtain a coefficient of angiogenesis by summing the scores and dividing by the highest 
sum possible (5 x #CAM images), thus resulting in a coefficient value between 0 and 1 
[289].  
Images of fixed CAMs were converted from .NRW to .TIFF format using Nikon 
ViewNX software.  A custom LabVIEW 2010 .vi was created to isolate the vasculature 
from the image background and calculate the total percent vessel area.  The images were 
converted from 32-bit RGB to 8-bit grayscale by isolating the green color plane.  Further 
image thresholding was applied to the grayscale image using Niblack's local thresholding 
method in order to generate a binary image [290].  Niblack's method determined if the 
intensity of a pixel exceeded the mean kernal (default setting = 48 pixels x 32 pixel area).  
If the pixel did exceed this value, it was kept in the image; if not, it was removed.  Based 
on visual assessment through trial and error, the default setting was used rather than a 
user-defined setting.  Next, the resulting binary image was dilated using a 3x3 dilation 
matrix followed by a series of proper open and proper close algorithms, each using a 3x3 
matrix.  The open/close series are most easily represented in terms of their logical 
definitions [291]: 
Open: A • B = (A Ø B)  B 
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Close: A ··· B = (A  B) Ø B 
 = dilation and Ø = erosion 
Where ‘A’ is a defined region (3x3 matrix) and ‘B’ is the structure by which ‘A’ is 
eroded or dilated.  Essentially this series of dilations and erosions fill in the holes created 
within a continuous vessel in the binary image resulting from the Niblack’s local 
thresholding without exaggerating the vessel structures.  The open/close series was 
followed by a single iteration low-pass particle filter, which removed all particles with 
dimensions below 5x4 pixels from the image, to produce a "clean" image.  Due to the 
nature of the Niblack local thresholding, the centers of large vessels were deleted during 
the thresholding process.  To correct for this loss, images were touched up manually in 
ImageJ; original images were used as a reference, and the centers of large vessels were 
filled in by hand.  Images were also cropped to ensure that only the membrane area (10 
mm diameter) was included.  Vessel area fraction was calculated using ImageJ's 
histogram function (white pixels = 255 or black pixels = 0), such that: 
Vessel Area Fraction = # Pixels255/ Total # Pixels(255 + 0) x 100 
 
Statistical analysis 
All experimental samples were analyzed with n ≥ 3, with data presented as mean 
± standard error.  Unless otherwise stated, statistical significance was determined using 
SPSS® Statistics (IBM) employing an one-way analysis of variance (ANOVA) test.  
Levene’s test was used to determine the equality of variance (p < 0.05) in the samples.  
When the Levene’s test was significant, Games-Howell post-hoc analysis was used to 
determine significance (p < 0.05), but when the Levene’s test was not significant, thus 
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equal variances among samples, Tukey post-hoc analysis was used to determine 
significance (p < 0.05). 
 
Results 
Growth factor protein extraction from acellular EBMs 
In order to readily quantify several growth factors retained in the EBM and 
further compare the differential protein content between matrices obtained from EBs at 
later stages of differentiation, proteins were extracted from EBM using two different 
solutions – TPER buffer and serum-free media.  Preliminary studies examining the use of 
other solutions are described in Appendix A.  TPER buffer was the less mild of the two 
buffers used since it contained a proprietary mixture of salts and a mild detergent.  To 
examine the efficiency of each buffer to extract proteins in general, total protein content 
was quantified.  For TPER buffer, neither mass nor day of differentiation affected the 
extraction of total protein from the EBMs, since there was no significant difference 
between samples (~400 µg/mL, Figure 6.1A).  As for serum-free media (SFM) 
extractions, total protein content was similar across EBM days and doses with ~400 
µg/mg total protein extracted, except day 10 at 3 mg/mL yielded approximately 3-fold 
more total protein (~ 1000 µg/mg) (Figure 6.2A).  Heat treatment (HT) of SFM 
extractions resulted in significantly less detection of total protein compared to non-HT 
counterparts, which indicated that heating the SFM extractions did impeded the detection 
of a significant amount of proteins present in the non-HT extractions (Figure 6.2A).  
Since TPER extractions were not further investigated in subsequent in vitro assays and 




Figure 6.1.  TPER buffer extraction from EBM.  (A) Total protein extracted from 
EBM after 24 hours.  (B-D) Specific growth factor protein components present in the 
TPER extraction.  Results shown are mean ± standard error (n=4). ANOVA: † p < 0.05 
compared to all other samples; ‡ p < 0.05 compared to 6 mg/mL day 7 and 10; *p < 0.05 




were not heat-treated.  Nonetheless, with the exception SFM extraction of 3mg/mL day 
10 EBM, there appeared to be a limit to the extractable proteins from EBM using mild 
solutions - ~400 µg/mg which is approximately 40% of the total matrix mass.  Overall, 
between the non-HT extractions, TPER and SFM both resulted in similar amounts of total 
EBM extracted protein. 
In contrast to the total protein results, the extraction of specific growth factors 
from the EBMs for each buffer varied depending on matrix mass, day of differentiation, 
and heat treatment.  TPER buffer extracted similar levels of FGF-2 from each matrix 
dose for day 7 and EBM (~8 and14 pg/mg, respectively), while day 10 at 6 mg/mL 
resulted in significantly more extracted FGF-2 compared to all other EBM samples.  
These data suggest a maximum extractable amount of FGF-2 present TPER extractions 
for day 7, but day 10 increases with EBM dose (Figure 6.1B).  On the other hand, 
increases in matrix mass did affect TPER extraction of IGF-2 and VEGF-A (Figure 6.1C, 
D).  For IGF-2, the increase in matrix mass, from 3 mg to 6 mg, resulted in significant 
increases (~2X) in the amount of IGF-2 extracted from both days 7 and 10 EBM.  
Furthermore, IGF-2 contained in TPER extractions from day 10 EBM were significantly 
more than day 7 EBM TPER extractions at both doses, demonstrating that day 10 EBs 
expressed more IGF-2 than day 7 EBs.  As for VEGF-A, increases in matrix mass 
resulted in significant decreases (~4-fold) in TPER extraction of VEGF-A from both day 
7 and 10 EBM: at 3 mg/mL both day 7 and 10 EBM extractions contained ~20 pg/mg, 
while at 6 mg/mL extracted VEGF-A was ~5 pg/mg for both day 7 and 10 EBM (Figure 
6.1D).  This decrease in VEGF-A extraction implies that the increased presence of certain 
 134 
EBM molecules may inhibit VEGF-A extraction, i.e. ECM proteins that bind VEGF-A 
and render it insoluble.   
Compared to TPER extractions, the content of specific growth factors in non-HT 
serum-free media (SFM) extractions were generally similar (Figure 6.2C-D).  Due to 
ELISA incompatibility, BMP-4 could not be determined in TPER extracts; however, the 
amount of non-HT SFM extracted BMP-4 across all samples (mass and time point) was 
similar, ~40 – 57 pg/mg; following HT, the amount of BMP-4 was significantly lower, 
between 5 – 10 pg/mg, in each HT extraction compared to their respective non-HT 
sample, yet not significantly different among all HT SFM extractions (Figure 6.2B).  This 
result indicated that a maximum extractable amount of BMP-4 was present in non-HT 
SFM extractions, and upon heating SFM extractions, detection of BMP-4 was hindered.  
Another growth factor that was present in significantly higher amounts in non-HT SFM 
extractions compared HT ones was FGF-2 (Figure 6.2C).  Between non-HI SFM 
extractions, similar amounts of FGF-2 (12 – 21 pg/mg) were present and also comparable 
to FGF-2 levels in TPER extractions, with the exception of significantly higher levels 
(36.56 pg/mg) of extracted FGF-2 from day 10 EBM at 3 mg/mL compared to all other 
non-HI samples.  The FGF-2 present in the HT SFM extractions were all significantly 
reduced (< 1 pg/mg) compared to their respective non-HI samples, which again exhibits 
the effect of heating on FGF-2 detection via ELISA.  Due to the lowered cross-reactivity 
of mouse FGF-2 and human FGF-2, for which the ELISA was based on (~30% cross-
reactivity), the ELISA extraction results may be more than the amount detected.  On the 
other hand, detected levels of IGF-2 were significantly increased, by at least 2-fold, in all 




Figure 6.2.  Growth factor protein extracted with serum-free media.  Overall, the 
amount of several growth factors extracted was dependent on the time point at which the 
EBM was isolated as well as the matrix mass and the heat treatment.  Protein content was 
normalized to EBM mass.  Results indicated are mean ± standard error (n=4).  One way 
ANOVA comparing among samples within the same heat treatment  - ¥: p < 0.05 
compared to all other samples, †: p < 0.05 compared to day 7, 3 and 6 mg/mL, #: p < 0.05 
compared to 6 mg/mL day 7 and 10 EBM, ‡: p < 0.05 compared to day 7 at 3 mg/mL, §: 
p < 0.05 compared to day 7 at 6 mg/mL.  Student t- test comparing between non-HT and 
HT samples * indicates p < 0.05. 
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heating SFM extraction increased the release of IGF-2 from EBM (Figure 6.2D). Also, 
HT SFM extractions showed comparable levels of extracted IGF-2 to TPER extractions. 
The increase in matrix mass yielded significantly more extracted IGF-2 from non-HT day 
7 EBM, yet there was no change between non-HT or HT day 10 EBM.  The comparable 
levels of extracted IGF-2 within the same heat treatment demonstrates that the amount of 
extracted IGF-2 from day 10 EBM was at maximum capacity, especially since the total 
protein amount for 3 mg/mL, day 10 EBM was ~3-fold more than 6 mg/mL. The effect of 
heat inactivation on SFM extracts also significantly increased (~2-fold higher) the level 
of VEGF-A present compared to non-HT SFM extracts, but only at 3mg/mL (Figure 
6.2E). At higher matrix mass, SFM extracted VEGF-A levels were significantly lower 
compared both day 7 and day 10 EBMs of the same heat treatment.  This decrease in 
VEGF-A extraction at high matrix mass, for both non-HT and HT, was also analogous in 
TPER extractions, which further supports the implication of particular molecules 
hampering the extraction of VEGF-A at higher matrix doses.   
 Overall, non-HT SFM extractions and TPER extractions resulted in comparable 
amounts of the majority of growth factors measured, which justified using only SFM 
extractions for subsequent bioactivity studies, along with the fact that undiluted TPER 
samples would not be conducive for cell survival compared to undiluted SFM.  The 
differences in extraction content between matrix mass were most dramatic for VEGF-A 
quantities, which is a potent angiogenic factor, thus motivating the use of both matrix 
doses in subsequent in vitro assays.  Moreover, the differences in SFM extractions 
obtained from EBMs derived from EBs at days 7 versus day 10 are parallel to the 
changes in quantified proteins within the EB-CM in Chapter 4 (Figure 4.3) - BMP-4 
 137 
content did not change between CM9 and CM12, while IGF-2 content was significantly 
increased in CM12 compared to CM9.  All together, not only did EBs actively secrete 
growth factors, but also they were retained within acellular EBMs and capable of being 
extracted in varying amounts depending on the time point at which the EBM was 
obtained. 
 
Effects of EBM extraction on cell proliferation 
The bioactive effects of the growth factors and other molecules extracted from 
EBMs with serum-free media, based on the extraction data previously discussed, were 
analyzed for their mitogenic stimulation of both fibroblasts and endothelial cells (Figure 
6.3).  Fibroblast proliferation in response to bioactive factors present in the EBM 
extractions exhibited slightly increased proliferative effects compared to SFM alone 
(~5%), yet significantly less than cells in fibroblast growth media (~53%) (Figure 6.3A, 
B).  Among EBM extraction treatments, there were similar percentages of BrdU+ cells 
between the non-HT and HT treatments from both day 7 and 10 EBMs at 3 mg/mL (10 – 
12%).  However, differences in proliferation were present at 6 mg/mL EBM for both HT 
day 7 (19%) and day 10 (21%) compared to the non-HT, with a significantly higher 
proliferative response of fibroblasts from the HT treatment.  This significant increase 
between non-HT and HT indicate, despite no significance compared to controls, suggests 
either the inactivation of mitogenic inhibitors of fibroblasts or the increased extraction of 
factors that stimulate proliferation as a result of HT.  
The response of endothelial cells to the complex mixture of factors contained 





Figure 6.3.  EBM effects on cell proliferation.  (A, B) Fibroblast proliferation was 
differentially affected by EBM treatments at higher doses between the non-HT and HT 
matrices.  (C, D) Endothelial cell proliferation was inhibited by factors contained within 
the non-HT treatments.  Scale bar = 50 µm.  Green: BrdU+ cells, blue: Hoechst. Results 
indicated are mean±standard deviation (n=4). One-way ANOVA comparing among 
samples within the same heat treatment  - §: p < 0.05 compared to all other samples, ¥: p 
< 0.05 compared to day 7 at 3 mg/mL and 6 mg/mL (± HT), day 10 at 3 mg/mL, †: p < 
0.05 compared to day 7 at 6 mg/mL and day 10 at 3 mg/mL.  Student t- test comparing 
between non-HT and HT samples * indicates p < 0.05. 
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significantly less than growth media (42%) compared to non-HT day 7 (3 and 6 mg/mL) 
and day 10 (3 mg/mL) EBM, as well as HT day 7 (6 mg/mL) EBM (Figure 6.3C, 
D).Similar to the mitogenic response of fibroblasts to 6 mg/mL of day 7 EBM, HT 
stimulated significantly more (~2X) mitogenic cells compared to non-HT - an increase 
from 7% BrdU+ cells (non-HT) to 17% (HT).  The change in mitogenic response of both 
fibroblasts and ECs to non-HT versus HT day 7 EBM 6 mg/mL suggests that the 
potential inhibitors or activators of proliferation affected by HT were not specific to 
either cell type. Contrastingly, significantly higher percent of BrdU+ ECs in response to 
day 10 EBM at 6 mg/mL compared to day 7 EBM 6 mg/mL was specific to ECs. This 
distinct result corresponded to significantly more IGF-2 extracted from day 10 EBM 
compared to day 7 (Figure 6.2D), which has been reported to stimulate angiogenesis by 
up-regulating Vegfa gene expression [292, 293].  Despite the few significant differences 
in EC mitogenicity in response to EBM extractions, the mitogenic bioactivity of SFM 
extractions was remarkably stimulating, potentially due to low concentrations of soluble 




Cellular migration of two different cell types was investigated in response to 
potential bioactive factors present EBM extractions.  The results indicated that non-HT 
EBM extractions stimulated chemotaxis in fibroblasts compared to HT EBM extracts 
(Figure 6.4A-C). Initially, 6 mg/mL treatments of day 7 and day 10 non-HT EBM 
stimulated the largest number of cells, ~8,700 and ~10,000 cells respectively, to migrate 
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by 3 hours and appeared to maintain a similar number of migrated cells throughout the 
24-hour period.  Fibroblast chemotaxis was stimulated significantly at 6 hours in 
response to non-HT, 6 mg/mL day 10 EBM extraction (16,000 cells) compared to growth 
media control and all HT samples (Figure 6.4B, C).  By 12 hours, each of non-HT EBM 
extractions from both days and doses of EBM, ranging from ~7,500 to ~18,000 cells, 
stimulated slightly more cells than both media controls (~175 cell for serum-free media, 
~1,200 cells for growth media) and HT EBMs (~1,200 - ~1,700 cells).  The morphology 
of the cells treated with non-HT EBM extracts appeared to be larger and more stellate 
than the cells treated with HT EBM extracts, potentially suggesting activation of cells to 
migrate. (Figure 6.4A).  The 3 mg/mL doses of day 7 and day 10 non-HT EBM steadily 
increased in the total number of migrated cells throughout the 24-hour time period, with 
significantly more cells migrating as an effect of 3 mg/mL of day 10 EBM (~13,500 
cells) compared to serum- free media.  As for HT EBM extracts, each treatment resulted 
in similar numbers of migrated cells compared to serum-free and growth media and 
continued to increase slightly in number over 24 hours.  After 24 hours, 6 mg/mL day 7 
EBM extraction significantly induced more fibroblast migration (~19,000 cells) 
compared to all other HT samples, except 6 mg/mL, HT day 10 EBM extract (Figure 
6.4B, right).  Overall, the factors present in the HT EBM had a minimal effect on 
fibroblast migration compared to the factors retained in the non-HT EBM, which induced 
fibroblast migration faster than the control media. 
Conversely, endothelial cell migration was inhibited by factors contained in non-
HT EBM extracts, while HT EBM yielded similar chemotaxis response to serum-free
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FIGURE 6.4.  EBM-induced effects on cell chemotaxis.  Fibroblast (A) and endothelial cell (C) morphology differences at 12 hours 
between non-HT and HT EBM treatments.  Chemotaxis was measured by the total number of migrated fibroblasts (B) or endothelial 
cells (D) during 24 hours in response to EBMs (left); significance testing was conducted on the total number of migrated cells at early 
(6 hours) and late (24 hours) time points (right). Results indicate mean±standard error (n=4).  One-way ANOVA: * p < 0.05 compared 
to all HT samples;  p < 0.05 compared to all HT samples except 6 mg/mL, HT day 10 EBM; ‡ p < 0.05 compared to growth media 
control; # p < 0.05 compared serum-free media control; § p < 0.05 compared to all non-HT samples. 
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media (Figure 6.4C, D).  Initially between 3 – 6 hours, EC growth media stimulated 
significantly more endothelial chemotaxis (~82,000 cells) compared to non-HT EBM 
extracts (0 - ~5,000 cells) and serum-free media (~30,000 cells); HT EBM extractions 
and serum-free media stimulated a gradually increasing number of cells up to 6 hours and 
continued to maintain a comparable number of cells throughout 24 hours (Figure 6.4D, 
left).  By 12 hours, the growth control decreased in the number of migrated cells 
(~61,000), and the non-HT EBM extractions continued to minimally stimulated 
chemotaxis (~2,100 – ~8,800 cells).  Microscopy images taken at 12 hours validate the 
lack of chemotaxis in response to non-HT EBMs, and exhibit normal endothelial cell 
morphology of the migrated cells (Figure 6.4C).  At the end of 24 hours, the number of 
migrated endothelial cells treated in growth media had declined (~49,000 cells) to 
chemotaxis levels similar to HT EBMs (~42,000 – 46,000 cells) and serum-free media 
(~36,000 cells).  Furthermore, 6 mg/mL, HT day 7 EBM and 3 mg/mL, HT day 10 EBM 
had significantly stimulated a larger number of cells, ~44,000 cells each, compared to all 
non-HT EBMs (~2,200 – 8,900 cells) after 24 hours (Figure 6.4D, right).  Interestingly, 
the morphogens harbored in the non-HT EBM extracts prohibited the chemotaxis of ECs 
over the entire 24-hour experiment; whereas, HT EBM extracts elicited similar levels of 
chemotaxis compared to serum-free media, suggesting the inactivation of a potential 
inhibitory molecule(s) for endothelial migration. 
 
EBM impact on endothelial network formation  
A more specific in vitro assay to specifically assess angiogenic stimulation of ECs 
is via Matrigel network formation assay.  The formation of tubular networks by 
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endothelial cells was examined in response to potential bioactive factors harbored by the 
EBMs, particularly the soluble fraction of molecules extracted from the EBM in serum-
free media in comparison to the entire matrix-associated EBM.  In analyzing the soluble 
fraction of molecules from the EBM, non-HT and HT extractions at 3 mg/mL previously 
investigated in cell proliferation and migration assays were examined.  In the EC network 
formation assay the 3 mg/mL dose was chosen based on the combination of results from 
extracted growth factor quantification and previously discussed EC bioactivity assays.  
Qualitative assessments exhibited that the formation of tubular structures was evident in 
the control samples of growth media and serum-free media (Figure 6.5E, F); however, 
network formation in day 7 (Figure 6.5A, B) and 10 (Figure 6.5 C, D) EBM extracts, 
non-HT. and HT, was not observed compared to the controls.  Additionally, there were 
more rounded single ECs present in each of the EBM extracts compared to control 
treatments.  
Overall, the soluble fraction of factors contained within EBM extractions 
inhibited the formation of endothelial network formation on GFR-Matrigel.  These results 
correspond to previous EC bioactivity assays examining EBM extracts – no enhancement 
of EC proliferation compared to SFM only, as well as significant inhibition of EC 
migration in response to non-HT EBM extracts compared to SFM only.  Unlike the 
previous EC bioactivity studies, the HT EBM extracts did not appear to result in similar 
levels of network formation as SFM only, thus suggesting that the inhibiting factors 




Figure 6.5.  EBM extracts inhibit endothelial cell network formation.  After 18 hours, 
the molecules in SFM extractions from in both day 7 (A, B) and day 10 (C, D) EBM 
elicited less network formation on GFR-Matrigel compared to both serum-free and 
growth media controls (E, F).  Scale bar = 500 µm 
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 In contrast to treatments with soluble factors extracted from EBMs, network 
formation was elicited upon addition of entire EBM (~3mg) embedded into GFR-
Matrigel (GFRM) (Figure 6.6).  The EBM mass of 3mg was utilized to be consistent with 
the 3mg/mL dose used in the EBM extracts.  In addition to heating EBMs to 95°C for 5 
minutes (HT95 EBM), EBMs were also heat inactivated at 120°C for 20 minutes (HT120 
EBM) in order to obtain a matrix that almost completely inactivated.  Qualitative 
evaluation of the acquired microscopy images revealed that non-HT EBM from both day 
7 and 10 EBs (Figure 6.6 A, D) prohibited network formation after 18 hours compared to 
the various controls, including GFRM+DBM (a non-embryonic acellular matrix), 
GFRM+VEGF-A, and GFRM alone (Figure 6.6G-I).  Qualitative comparisons of 
resultant tubular networks exhibit that the extent of structures formed on HT95 EBMs 
from both days 7 and 10 (Figure 6.6B, E) appeared similar to ones formed on 
GFRM+VEGF-A (Figure 6.6H) - a robust network of tubes and nodes compared to 
GFRM+DBM and GFRM only (Figure 6.6G, I).  Whereas the degree of network 
formation on HT120 EBM (Figure 6.6C, F) was observed to be comparable to the 
frequency of nodes and tubes formed on GFRM only (Figure 6.6G, I).  The qualitative 
differences examining the extent of network formation seen between non-HT EBMs and 
HT EBMs indicated the inactivation of inhibitory molecules following HT.  Furthermore, 
the differences between HT95 EBM and HT120 EBM illustrated potential increase in 
stimulatory bioactive molecules in HT95 EBM and then subsequent inactivation of the 
stimulatory bioactive factors in HT120 EBM due to increased temperature and duration of 





Figure 6.6.  Heat-inactivated EBM-associated factors promote endothelial network 
formation.  The formation of tubular structures was inhibited as a result of non-HT 
EBMs obtained from day 7 and day 10 embedded within the GFRM (A, D).  
Contrastingly, HT EBMs from either day 7 (B, C) or day 10 (E, F) induced network 
formation comparable to controls (G – I).  Scale bar = 100 µm. 
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A more quantitative analysis of network formation in response to EBM treatments 
was conducted by analyzing microscopy images captured at 18 hours, including 
measurements of mean node and tube area, total percent area of nodes and tubes, and the 
number of nodes and branch points all relative to the GFRM only control.  The 
GFRM+DBM and GFRM+VEGF-A controls both resulted in similar mean node and tube 
measures compared to GFRM only (Figure 6.7A).  Among all the HT EBM treatments, 
the mean tube area for each treatment was similar to GFRM control (fold change ~1), yet 
the mean node area was larger than GFRM for all HT EBM treatments, with significantly 
increased mean node area from both day 7 HT95 EBM (2.4-fold) and HT120 EBM (1.8-
fold) and day 10 HT95 EBM (2.1-fold) compared to GFRM (Figure 6.7A).  In conjunction 
with the larger mean node area, day 10, HT95 EBM yielded significantly more total nodes 
(1.4-fold) and branch points (1.3-fold) compared to GFRM (Figure 6.7B).  Despite the 
larger mean node area, day 7 HT120 resulted in significantly less number of total nodes 
(0.8-fold) and branch points (0.4-fold) compared to GFRM.  The overall percent total 
area for each of these structures correlated to the differences observed for mean area per 
structure.  Day 7 HT95 EBM and day 10 HT95 EBM treatments, along with controls, were 
not significantly different from GFRM only for total tube percent area, while day 7 HT120 
EBM was significantly decreased by 0.4-fold (Figure 6.7C).  As for total node percent 
area, all treatments were comparable to GFRM, except for significantly more node 
percent area resulting from day 7 HT95 EBM (2.7-fold) and day 10 HT95 EBM (3.0-fold) 
relative to GFRM.  These significant differences demonstrated that day 7 HT95 EBM 
yielded greater node size and less tube area without affecting frequency; whereas, day 10 





Figure 6.7.  Quantitative assessment on EC network formation.  The effective 
stimulation of network formation by ECs was measured by changes in mean structure 
area of nodes and tubes (A) as well as the frequency of nodes and branch points (B).  All 
these aspects determine the total percent area of the EC network (C).  Dashed line (---) 
indicates fold change = 1, results indicate fold change of the treatment mean/GFRM 
mean.  Using ANOVA followed by Dunnett’s test, comparisons were made between 
treatment measurements (n=4) and control (GFRM only) measurements (n=4), * denotes 
p < 0.05 compared to GFRM. 
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along with significantly more branch points to effectively stimulate endothelial network 
formation, thus demonstrating a significant angiogenic response compared to GFRM.  
Heating EBMs to 120°C for 20 minutes effectively inactivated the increased bioactive 
factors released in HT95 EBM.  Embedding the EBMs within the GFRM remarkably 
stimulated more network formation than the EBM extracts and provided a means to 
effectively deliver the entire EBM.  Overall, these EC network formation results 
indicated that the combination of ECM and its associated factors, rather than the soluble 
factors alone, is essential to impart a synergistic effect on in vitro formation of networks 
by endothelial cells.  
 
CAM analysis 
The angiogenic response of the vascular tissue to the lyophilized EBM was 
examined using the CAM assay.  The entire EBM matrix, non-HT and HT, was grafted 
onto CAMs to observe the angiogenic stimulation of blood vessels over 48 hours.  The 
use of the lyophilized EBM rather than EBM extractions resulted from the considerable 
differences in EC tube formation elicited by the EBM delivered with the GFRM.  The 
angiogenic effects elicited by the matrix grafts was typically illustrated by the appearance 
of blood vessels radiating from the graft in a “spoke-wheel” pattern, with an increased 
density of vessels implying pronounced response, as well as changes in blood vessel 
morphology, including more tortuous vessels and extensive branching.  
Over the 48-hour treatment, the blood vessel changes surrounding the graft area 
on the CAMs were assessed visually inspected (Figure 6.8).  CAMs treated with GFRM 
or EBMs generally resulted in vessel morphologies that were indicative of angiogenesis, 
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such as tortuous vessels, smaller radiating vessel protruding adjacent to the graft, and 
extensive branching vasculature comprised of tiny vessels (Figure 6.8, bottom row).  
Vessel counts over 48 hours exhibited increased frequency of radiating vessels from 
EBM grafts (Figure 6.9).  Significant differences in vessel counts at the 6mm diameter 
were observed over time in EBM-treated CAMs, particularly after 48 hours in the 1° and 
2° vessels (Figure 6.9A), which generally corresponded with the presence of radiating 
vessels from the EBM graft (Figure 6.8).  Day 7 EBM stimulated significantly higher 
number of 1° vessels by 48 hours compared to all other time points, while 2° vessels were 
increased at 48 hours compared to 24 hours, at 6mm.  While day 10 HT EBM increased 
the number of vessels at 6mm by 48 hours compared to 0 hours.  At the 10mm diameter, 
day 7 EBM had a significant increase in both 2° and 3° vessels at 24 and 48 hours 
compared to 0 hours; whereas day 10 HT EBM demonstrated a higher number of 3° 
vessels only at 24 hours compared to 0 hours, yet resulted in significantly more 2° and 3° 
vessels at 48 hours compared to 0 hours.  The increased counts of 1° and 2° vessels 
suggests directional changes of the existing vascular network, while increases in tertiary 
vessel counts suggest more branching of the higher-order vessels, which are both features 
of angiogenesis.  These results indicated that delivery of these ECM-associated factors 
stimulated vessel changes within 48 hours, and the EBM bioactive factors were able to 
affect aspects of angiogenesis within a distinct radial distance.  
Fixed CAM images qualitatively demonstrated the angiogenic response of the 
vessels within the CAM as an effect of EBM treatment after 48 hours.  Binary images 
derived from the grayscale images of fixed CAMs were used to quantify the vessel 
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Figure 6.8.  Angiogenic response of CAMs due to EBM grafts.  Representative images 
of CAMs treated with EBMs or GFRM taken at three time points: 0 hours (top), 24 hours 
(second row), 48 hours (third row).  Morphological changes in blood vessels indicative of 
angiogenesis (bottom row): tortuous vessels (blue arrow), extensive branching of tiny 





Figure 6.9.  Radiating vessel counts in response to matrix grafts.  The change in 
radiating vessel number at 0, 24, and 48 hours within a 6mm diameter (A) and 10 mm 
diameter (B).  Tertiary (3°) vessels branched off secondary ones (2°) that sprouted from 
primary (1°) vessels that appeared unconnected to other vessels in the field of view.  
Results indicate mean count (n=7). Significance tested with Pearson’s test statistic, p < 
0.01: ‡ compared to all other time points, † compared to 24 hours, * compared to 0 hours.  
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density for each CAM treatment (Figure 6.10, bottom row); results ranged from ~13 to 
17%, with GFRM images generating the highest total vessel area percentage (Table 6.1).  
The non-HT EBM images yielded higher total vessel percent areas among EBM-treated 
groups compared to HT EBM treatments.  One caveat to measuring the total vessel 
percent area is that even though similar image areas were quantified, graft area size 
varied between CAMs, since the amount of matrix was normalized to starting EB 
material.  Hence, grafts with larger areas typically resulted in less total vessel area.  The 
differences in total vessel area were small, less than 5%, between each of the treatments, 
thus it was difficult to determine which EBMs were more effective at eliciting an 
angiogenic response, which suggests that total percent area alone was not an effective 
indicator of angiogenesis.  However, taken together with other CAM data total percent 
vessel area could support other analytical outcomes.  
Despite the previous quantitative and objective measure of angiogenesis, vessel 
directionality and morphology were not evident from total vessel area calculations. A 
more semi-quantitative image analysis readily compared the angiogenic response 
differences between treatments and took into account the vessel density, directionality, 
and morphology surrounding the grafts by calculating a coefficient of angiogenesis 
(Figure 6.10, top row).  Treatment with GFMR (positive control) resulted in the highest 
coefficient at 0.725 (Table 6.1).  Day 7, HT EBM and Day 10, non-HT EBM yielded the 
same coefficient (0.425), while Day 7, non-HT EBM was slightly higher at 0.467 and day  
10, HT EBM produced the highest coefficient (0.520) compared to the other EBMs.
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Figure 6.10.  Fixed CAM images.  (Top) Representative images capturing the first few millimeters surrounding the graft after 
fixation and used to score for angiogenesis coefficient.  (Bottom) Representative binary images as a result of image processing and 










Treatment GFRM Day 7 EBM Non-HT 
Day 7 EBM 
HT 
Day 10 EBM 
Non-HT 
Day 10 EBM 
HT 
Total %  
vessel area 
(mean ±  std. err) 
16.59 ± 1.94 14.24 ± 1.13 13.60 ± 0.58 15.33 ± 1.39 12.93 ± 0.591 
Coefficient of 
angiogenesis 0.725 0.467 0.425 0.425 0.520 
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Although this scoring method is not ideal by relying on the human eye, blinded scoring 
was used to eliminate bias.  Furthermore, the human eye can detect smaller changes in 
vessel appearance that may go unnoticed with computer-aided analysis, especially with 
small vessels that may be filtered out as noise. 
Overall, CAM assay analyses demonstrated that EBMs did not significantly 
inhibit or stimulate angiogenesis, thus the influence of EBM on inducing angiogenesis is 
inconclusive.  In relation to GFRM treatment, EBM was less effective at stimulating 
angiogenesis, since the mass of GFRM applied to the CAM per sample was 
approximately half that of the EBM samples.  The day 7 EBMs may contain some 
angiogenic factors due to the notable vessel changes in response to non-HT compared to 
day 10 non-HT, while day 10 HT EBM exhibited changes in vessel response over time 
compared to non-HT day 10 EBM.  Altogether, these results demonstrate that EBMs are 
capable of eliciting morphogenic responses from exogenous tissues, due to the complex 
mixture of factors harnessed in the EBM.  
 
Discussion 
The bioinductive capacity of an embryonic stem cell-derived matrix was 
investigated for its effects on cell proliferation, chemotaxis, and structure formation as 
well as tissue morphogenesis, particularly CAM angiogenic induction.  Protein 
extractions from EBM revealed that growth factors were harbored within the matrix and 
extracted in their active form based on the stimulatory and inhibitory in vitro bioactivity 
results.  The reaction of fibroblasts to EBM extractions was typically enhanced compared 
to basal level controls, contrary to the inhibition of endothelial cells in response to EBM 
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extractions.  Endothelial cells were stimulated only after EBM extractions were heat-
treated, particularly during migration and tube formation assays, but only to levels similar 
to serum-free media only.   
The influence of EBM on CAM angiogenesis based on the quantitative results 
was not as robust of a response compared to the significant inhibition of EC migration 
and tube formation.  Notable angiogenic responses were consistently observed in GFRM, 
yet were not as consistent in response to EBMs, yet there were noticeable changes in 
blood vessel appearance.  These observed variations seemed to affect EBM quantitative 
analysis, thus yielding results that were not as obvious as other bioactivity studies.  
Additionally, the results of different CAM analyses did not elicit any significant 
differences between treatments, which led to an inconclusive result as to the EBM effects 
on angiogenesis.  Altogether, the EBM did not inhibit nor did it stimulate robust 
angiogenesis, which could be attributed to several factors, such as EBM dosage.  The 
amount of EBM used in the CAM experiments was based on the EBM extraction results 
exhibiting higher amounts of certain growth factor compared to 6 mg/mL, as well as the 
in vitro studies demonstrating similar cellular responses between 3 and 6 mg/mL.  
However, in order to induce an angiogenic response, the EBM dosage may have needed 
to be increased since the response of a tissue, rather than isolated cells was being 
investigated.  Granted the angiogenic responses of CAMs to EBMs were subtle, the 
outcomes provided insight into a more complex model of angiogenesis compared to 
isolated cell responses.  Overall, while the EBM did not significantly affect angiogenesis 
with the ex ovo CAM assay, the in vitro studies demonstrated the retention of bioactive 
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factors within EBM that can effectively modulate specific cell behaviors essential to 
tissue remodeling.   
The total protein quantity extracted from EBM did not vary considerably between 
the two buffers, yet the differences in specific growth factor content were significant 
comparing non-HT with HT extractions.  Upon heat treatment, BMP-4 and FGF-2 were 
no longer detected by ELISA, in contrast to IGF-2 and VEGF-A which both showed 
increased levels compared to non-heat inactivated matrices, potentially indicating the 
effective denaturing of BMP-4 and FGF-2, but the increased extraction of IGF-2 and 
VEGF-A, by heat.  However, during the cooling of the extractions prior to further 
analysis, certain proteins that do not require other protein chaperones could have re-
folded alone.  During the re-folding process, epitopes that are recognized by the ELISAs 
may be less prominent or more prominent, thus resulting in either antibody decreased or 
increased detection levels, respectively.  Heating EBM at a high temperature for a short 
duration may catalyze the dissociation of matrix bound growth factors from the ECM 
without denaturation, thus resulting in an increased extraction of specific growth factors.  
However if the heat is increased and prolonged it could denature the bioactivity of the 
growth factors, as observed in the HT120 EBMs.  Additionally, heating the EBMs may 
have permitted the release of other angiogenic growth factors as well as activated certain 
ones.  Interestingly, members of the transforming growth factor-beta (TGF-β) family 
have roles in angiogenesis in a dose dependent manner and can also be thermally 
activated.  The gene expression of several Tgfb genes from the array results in Chapter 3 
(figure 3.5) demonstrated significantly increased expression at later time points, between 
days 7 and 10, as well as days 10 and 14.  At low concentrations, TGF-β has a 
 159 
stimulatory effect on ECs, yet at higher concentrations the effect becomes inhibitory 
[294, 295].  Furthermore, TGF-β is typically present in the ECM in its latent form and 
must be activated in order to bind to its receptors; one method to activate TGF-β is by 
thermal activation between 75° - 100°C for up to 5 minutes [296].   The heat treatment 
condition is in the temperature and time range to induce thermal activation TGF-β, which 
may explain the stimulation robust EC network formation seen when treated with HT95 
EBM compared to HT120 EBM, which would have inactive TGF-β due to the longer 
duration at a higher temperature.  Comparing the lack of networks formed in response to 
EBM extractions to the robust networks resulting from embedded EBM during EC 
network formation assay, these results suggest that EBM extractions potentially 
contained angiogenic inhibitors, which speculatively could be high levels of activated 
TGF-β, which are inhibitory; in contrast to, to the lower levels, stimulatory level, of 
activated TGF-β that could be slowly released from HT95 EBM when it was embedding 
in the GFRM.  Overall, heat-treating the EBM potentially inactivates certain growth 
factors while thermally activating others, either stimulatory and or inhibitory, which can 
further influence the bioactive response of various cell types.  
The amount of growth factors identified in the EBM extractions are considerably 
greater (~1000-fold) than previous reports of extracted growth factors from acellular 
matrices.  Growth factors, FGF-2 and TGFβ, were identified in extractions by Westerns 
from acellular SIS in conjunction with comparisons to bioactivity results of the purified 
growth factors to the extractions [158].  Chun et al. described effective extraction of nine 
growth factors from acellularized bladder submucosa using acetic acid [159]: PDGF-BB 
had the highest reported extracted amount (~286 pg/g) and epidermal growth factor 
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(EGF) had the smallest (0.99 pg/g).  These growth factor quantities are 1000-fold less 
than the quantities extracted from EBM on a mass basis.  Three growth factors previously 
reported in the literature to be extracted and quantified from acellular matrices coincided 
with the ones identified in the EBM – BMP-4, FGF-2, and VEGF-A.  In the non-HT 
EBM extractions, BMP-4 was present at ~50x103 pg/g while BSM extractions contained 
~4 pg/g; FGF-2 extracted from EBM was lowest, ~30 x103 pg/g and BSM yielded ~4 
pg/mg; and finally VEGF-A was present at ~3x103 pg/g in EBM extractions and at ~104 
pg/g in BSM extractions.  The considerable difference in growth factor quantities could 
potentially be due to the fact that acellularized BSM is mainly comprised of connective 
tissue, blood vessels, and nerves.  These structures generate the extracellular environment 
of the BSM, however, the homeostatic nature this somatic tissue, which generally does 
not undergo extensive morphogenesis, could explain the low levels of growth factor 
present compared to the differentiating EB environment.  However, these growth factor 
results were reported in the literature and were not conducted using the same means of 
extraction used for the EBM extractions.  Overall, these results from literature reports 
compared to the EBM results suggest that embryonic environments, which are notably 
undergoing remarkable morphogenesis, may potentially be enriched in growth factors 
and morphogens and can be captured following acellularization.  
The solutions used for extraction growth factors from EBMs compared TPER 
buffer, and serum-free media.  The extractions of BSM and SIS previously described 
used detergents and solutions that typically denature proteins, including TritonX-100, 
urea, and guanidine.  One recent study by Yang et al. provided evidence that VEGF and 
PDGF-BB were present in extracts from ABM using media [157].  The amount of growth 
 161 
factors quantified were similar to other acellular matrix extracts, ranging from ~158 – 
594 pg/g for PDGF-BB and ~108 – 477 pg/g for VEGF, depending on the 
acellularization techniques used, after 7 days of conditioning basal media with ABM.  In 
this EBM study, basal media was conditioned for only 24 hours and the amount of VEGF 
present was at least 50X greater than reported ABM extracts.   
Investigating the response of two different cell types to EBMs reflected the 
differences observed in comparing EB-CM, as described in Chapter 4.  Fibroblasts are 
omnipresent in the body and implicated in physiological processes such as tissue 
remodeling and wound healing due to their primary function – producing ECM.  
Stimulating endothelial cells is required to elicit an angiogenic response, one of the 
necessary processes that accompanies wound healing and tissue repair.  The factors 
contained in EBM extractions did not have a profound effect on stimulating cell 
proliferation, but did inhibit EC proliferation. The most noticeable effect was the 
difference in proliferation by day 7 non-HT and HT EBM extracts, which possibly 
demonstrates the presence of factors that inhibit proliferation in extractable EBM at day 
7, which may be destroyed during heat treatment but does not permit significant 
proliferation increases.  Interestingly, a study demonstrated the efficacy of soluble human 
ESC-secreted factors to inhibit growth of cancer cells, but not benign fibroblasts by 
delivering human ESC-conditioned media to cancer cell in vitro [297].  The factors (< 10 
kDa) contained in the hESC-CM blocked the growth of cancer cells and were not 
completely inactivated upon heating.   
Endothelial cells responded to the EBM in the opposite manner of fibroblasts.  
Fibroblasts increased in proliferation and migration in response to non-HT EB with a 
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decline in responses upon HT of EBM.  Extracted factors from non-HT EBM presented 
to the ECs typically inhibited proliferation, migration, and tube formation, as opposed to 
the pronounced effects observed upon treating the ECs with HT EBMs.  Kuzuya et al. 
reported that soluble heat-stable factors released from fibroblast CM did not have an 
effect on EC proliferation, but did increase motility and tube formation [298].  All 
together, these results suggest that the soluble molecules present in the extracted EBM 
are comprised of bioactive factors specifically inhibitory to ECs.  
On the other hand, when ECs were treated with matrix-associated factors in 
lyophilized EBM, not just the extracted soluble factors, the effect of heat treatment on 
EBM was prominent.  Network formation assay enabled analysis of extracted factors 
versus the entire matrix and clearly exhibited more profound network formation results 
when treated with the entire EBM compared to the extractions.  The absence of tubes in 
non-HT EBM + GFRM further demonstrated the presence of inhibitory factors, however, 
HT EBM + GFRM exhibited more robust network formation than GFRM alone and 
similar to VEGF-A + GFRM, suggesting that heating the EBM inactivated inhibitory 
factors as well as presented stimulatory factors.  Furthermore, CAM results, though they 
were not all as pronounced as EC network formation ones, indicated that day 10 HT 
EBM yielded the greatest angiogenic response in tissues compared to other EBM 
treatments.  There have been several studies examining heat-stabilization of growth 
factors by ECM factors such as heparin.  In 1986, Gospodarowicz et al. demonstrated the 
importance of heparin in stabilizing FGF-2 during heat treatment, which lead to increased 
FGF-2 bioactivity compared to no heat treatment [299].  Since there was no evidence of 
increased FGF-2 activity in the presence of other GAGs, including chondroitin sulfate 
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and HA, this result was specific to heparin.  The presence of heparin in EBM was not 
specifically examined, although there are several studies describing the necessity of 
heparin expression during development and ESC differentiation [225, 300].  
Additionally, increased levels of IGF2 and VEGF in EBM extractions were detected as a 
result of heating, potentially due to release from ECM and or binding proteins.  Even 
though VEGF-A levels increased in HT EBM extractions, VEGF-A bound to ECM 
would be undetected via ELISAs performed since the insoluble fraction was removed 
from the extracts prior to performing the assay, and the ELISA antibodies only detected 
splice variants 121 and 164 that are typically found in soluble fractions.  VEGF-A variant 
188 binds to ECM with greater affinity than 164 and has been reported to be effective in 
enhancing EC signaling in its ECM-bound state [301, 302].  Thus if this VEGF-A variant 
was present in the HT extracts it would not have been detected, but could still be 
bioactive and in turn stimulate EC network formation and CAM angiogenesis.  
Altogether, these results suggest that increased network formation and CAM 
angiogenesis resulting from HT EBM treatment are in part due to ECM-bound factors 
enhancing endothelial behavior. 
 
Conclusion 
Overall, the complex mixture of molecules harbored within EBMs enhanced 
certain cell behaviors implemented in tissue remodeling and angiogenesis.  The specific 
growth factors identified in EBM extractions exhibited retention of bioactivity that was 
further investigated via in vitro and ex ovo assays.  Not only did this study illustrate the 
modulation of paracrine factors secreted by differentiating ESCs, but also demonstrated 
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how the modulated EBM harnessed bioactive factors capable of impacting aspects of 
angiogenesis.  Furthermore, the differential angiogenic responses to factors presented as 
matrix-associated versus soluble EBM implied that the synergy of ECM and growth 





In this work, the reservoir of extracellular mediators secreted during ESC 
differentiation was investigated for their function in modulating embryonic 
morphogenesis.  Strategies to isolate and characterize this novel ESC-derived matrix 
were developed, and the harnessed bioactive factors demonstrated significant impact on 
exogenous cell and tissue morphogenesis.  Paracrine factors produced by stem cells have 
been touted as an essential means by which the cells exert therapeutic benefits; however, 
no reports have described capturing these factors in a naturally produced matrix for 
potential therapeutic applications. 
With the advent of stem cells came the notion that these cells could be 
transplanted to enhance tissue repair by differentiating and repopulating damaged tissue.  
Numerous studies have transplanted a variety of stem/progenitor cell populations in order 
to observe this enhanced healing, particularly using in vivo neovascularization models [6, 
7, 169, 171], yet the percent of cells that integrated into the target area were low [172, 
183, 185].  Thus, these outcomes led to studies examining the paracrine effects of these 
transplanted cells utilizing stem cell-CM [189, 190, 193, 243], which exhibited enhanced 
tissue function and angiogenesis as a result.  Efforts to detect regulation of the 
extracellular environment during stem cell growth and differentiation speak to the 
paradigm shift from stem cell engraftment and differentiation towards paracrine modes of 
action as a result of stem cell transplantation. By screening the exracellular environment 
using sensitive high throughput technology [303, 304] of different stem cells or 
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differentiated cells derived from stem cells, certain cell populations can be examined for 
their therapeutic capacity based on the factors they produce via the secretome [187, 188, 
240], glycome [305-308], and metabolome [309-311].  Factors of interest would depend 
on the specific tissue application, yet the induction of neovascularization and 
angiogenesis has emerged as a critical aspect for successful tissue regeneration.    
In parallel to the aforementioned published reports, this work has motivated 
further characterization of the extracellular factors secreted by differentiating EBs.  Gene 
expression arrays and ELISAs provided insight on the modulation of EB-generated 
extracellular molecules during differentiation, however, a more thorough profile of the 
secretome using high-throughput protein detection methods may elicit unique factors 
present in a dynamic ESC-derived EB environment undergoing morphogenesis compared 
to other studies examining the maintained pluripotent or multipotent state of stem cells 
[190, 297].  Furthermore, these unique factors may potentially be present in low 
abundance thus necessitating the use of recently developed methods [303, 304] 
employing sensitive detection limits to fully capture the extracellular environment of the 
EBM that would enable studies that could potentially discover novel low-abundance 
factors involved in ESC differentiation that have been not been investigated due to 
technology limitations. 
The simplest way to harness stem cell secreted factors in an acellular manner is by 
collecting stem cell-conditioned media.  The previously mentioned reports of stem cell-
derived paracrine factors enhancing tissue repair utilized stem cell-CM to deliver these 
factors via local injections.  The benefit to injecting stem cell-CM is the synergistic 
response typically elicited by a complex mixture of growth factors compared to isolated 
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growth factor delivery.  However, the in vivo half-life of soluble growth factors is short, 
on the order of hours, thus CM becomes less potent soon after injection; nevertheless, 
growth factors bound to ECM render them more effective due to longer half-lives.  
Currently, synthetic ECM analogs are being devised to capture naturally produced 
secreted factors from cell-conditioned media, including ESC-CM, as a vehicle to deliver 
factors in a cell-free manner in vivo.  The first report of capturing stem cell-secreted 
factors from CM was published in 2010 by Webber et al. describing the use of a self-
assembling nanofiber gel that presents biomimetic heparin to capture and deliver secreted 
stem cell factors in vivo to ischemic myocardium [234].  Soon after, another study 
presented in a series of two publications, examined similar CM capture again using self-
assembling nanofiber gel, but with an RGD peptide, and showed renoprotective effects 
[312, 313].  Similar studies could investigate the capture of EB-secreted molecules that 
are modulated during ESC differentiation and assess the effects in vitro and in vivo, 
expanding the EB-CM studies in Chapter 4. 
EB-CM studies demonstrated the presence of bioactive factors and established the 
foundation to further engineer means to exploit the EB-secreted factors.  Another means 
to deliver ESC-secreted factors in vivo is by the use of microparticles that can capture 
secreted factors and subsequently release them.  The composition of these microparticles 
could be tailored to capture specific fractions of molecules, just like affinity columns are 
used to fractionate complex mixtures.  Growth factors that bind heparin, such as FGFs 
and VEGFs [299, 301, 314], could bind selectively to heparin microparticles added to 
CM, and then tested for bioactive release using angiogenesis models.  Additionally, other 
extracellular components could be captured by tailored microparticles based on detection 
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technologies, such as lectin (a glycan-binding ligand) [315].  Lectin microparticles could 
bind naturally synthesized GAGs expressed by ESCs, or other cell types of interest, thus 
yielding a variety of GAG microparticles to deliver ESC-secreted GAGs, which could 
impact tissue repair in vivo [208, 316]. 
 The novel means to harness naturally produced ESC factors via acellularization 
and the initial characterization of molecules contained within the EBM, in this work and 
previous work [216, 270], could also inspire investigation of acellularizing EBs 
undergoing directed differentiation in order to obtain a more defined matrix for specific 
tissue regeneration applications.  For example, the propensity of EBs to spontaneously 
differentiate towards the mesoderm lineage using the rotary culture system [217] and the 
increased cardiovascular differentiation within the EB population at later days of 
differentiation could be further exploited to yield more homogenous cardiovascular EB 
differentiation.  Established protocols for endothelial differentiation via EB formation 
and purified growth factor delivery [198, 317, 318] combined with the rotary culture 
system may elicit enhanced EB cardiovascular differentiation.  Furthermore, these EBs 
could be followed by mechanical acellularization techniques to derive a more angiogenic-
inducing matrix compared to EBM from spontaneously differentiating EBs.   
Although EBM bioactivity was assayed in two forms, soluble extractions and 
lyophilized powder, delivering an exact amount of matrix was a challenge.  Extracting 
soluble factors is a simple means to deliver the factors, however, there is likely no 
optimal buffer to fully solubilize and retain bioactivity for all matrix-associated factors; 
hence, assessing the quantity and activity of the factors extracted with a certain buffer is 
necessary.  Preliminary studies discussed in Appendix A describe the derivation of 
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soluble EBM formulations using several solutions previously cited in the literature, 
including urea, acetic acid, and salt solutions (NaCl, MgCl2) [158, 159].  The factors 
extracted were assayed qualitatively via SDS-PAGE; however, continuing studies are 
being conducted using different extractions buffers in conjunction with more 
sophisticated techniques to analyze the extracted factors, such as fast protein liquid 
chromatography (FPLC), to further separate the extractions into fractions that can be 
examined for bioactivity.  Fractionation can be controlled by the specific column chosen 
to separate the solubilized matrix – size-exclusion, ion-exchange, affinity binding, or 
hydrophobicity.  Each of these column types would generate distinct fractions that could 
be tested for bioactivity via in vitro assays and further characterized for content using 
previously mentioned high-throughput protein detection methods.  By fractionating the 
solubilized EBM, mediating factors that elicit specific in vitro bioactivity outcomes may 
be more readily identified in a smaller subset of factors via inhibition assays or 
immunoprecipitation.   
Other acellular formulations of EBM, including detergent and enzymatic 
techniques yield a more viscous and consolidated matrix in comparison to the powdery 
lyophilized matrices in this work while retaining a number of matrix proteins – collagen, 
laminin, and fibronectin while [216, 270].  The benefit of a lyophilized, powder matrix is 
the “off-the-shelf” availability - typically the longevity of lyophilized proteins is greater 
than proteins in a hydrated state.  Consequently, methods to controllably deliver this 
lyophilized powdery EBM need to be considered before moving towards in vivo studies 
and are highly dependent on the animal model as well as the delivery site.  Studies in 
progress are able to load gelatin capsules with lyophilized EBM to deliver 
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intramuscularly into mice.  Previous studies cited in the literature report gels produced 
from naturally derived matrices that generally have high collagen content [319, 320], that 
are ideal for injectable delivery.  Due to low presence of collagen present in the EBM 
compared to other acellularized tissues [270], EBM could be combined with purified 
matrices capable of gelling, such as fibrin or collagen, or self-assembling nanofibers.  
Delivery of EBM to ischemic tissues, such as myocardium or hindlimb, would preferably 
be injection for ease of administration as is most commonly used, but rather than 
injecting solubilized matrix, it could potentially be beneficial to deliver EBM in 
combination with a matrix, preliminarily exhibited in network formations in Chapter 6, 
that can gel at body temperature to provide more prolonged release of the reservoir of 
ESC-derived factors.  By incorporating the lyophilized EBM within a gel, particularly 
one that solidifies at body temperature, the EBM can be stored as a lyophilized powder 
and only combined with liquid immediately prior to delivery as to maintain bioactivity.   
One unexpected result from the EBM bioactivity assays was the inhibition of EC 
proliferation, migration, and network formation in response to non-HT EBM, while HT 
EBM elicited increased responses in EC migration and network formation in comparison.  
Although several pro-angiogenic factors were assessed for content in the EBM, anti-
angiogenic factors were not.  The expression of a few anti-angiogenic molecules were 
examined via PCR array (Chapter 3), including thrombospondin 1 and 2, and did not 
exhibit increased in gene expression over the course of EB differentiation; however, there 
are a number of ECM components that inhibit angiogenesis and could be analyzed, such 
as endostatin and decorin [102].  Global analysis of the secretome could provide further 
insight into possible anti-angiogenic components of the EBM, which could help identify 
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mechanisms as to how EBM significantly inhibited EC processes critical to angiogenesis.  
Further studies could investigate the in vivo effects of EBM in inhibiting angiogenesis, 
which is critical for anti-angiogenic therapies for ocular neovascular diseases and cancer.  
From these global studies, knocking down certain anti-angiogenic molecules, using ESC 
knock-outs or siRNA delivery, could increase the angiogenic induction of EBM.  
However, due to the opposing forces at play within the embryonic environment, EBs 
generally do not spontaneously homogenously differentiate.  Thus, the observed increase 
in cardiovascular differentiation could most likely be met with an array of factors that are 
inhibiting this differentiation, which also could be knocked down to promote more 
cardiovascular differentiation.   
Due to the complex nature of EBM, in vitro and ex ovo studies were used as 
initial indicators of EB retention of bioactive factors while screening EBMs that may 
elicit a more angiogenic response in vivo, which is more complex than in vitro.  In vivo 
studies could be examined in non-injury models of angiogenesis, such as the corneal 
angiogenesis assay or the subcutaneous plug assay, where blood vessel infiltration and 
neovasculature development can be easily detected, however pathological angiogenesis is 
typically not present in these locations.  Injury models to look at the revascularization 
induction by EBM could be tested to assess angiogenic effects in the presence of 
ischemic tissues and inflammatory response, which are aspects that were not tested in 
vitro and can greatly influence the efficacy of the EBM in vivo.  By implanting the EBM 
in vivo, responses of local endogenous cell types can be monitored, such surrounding 
muscle and nerves fibers that also are damaged during tissue injury and are essential in 
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restoring normal function, as well as more systemic outcomes that can completely affect 
angiogenic response. 
In conclusion, this work has contributed to establishing the foundation that ESC-
derived matrices harbor potent morphogens that impact aspects of tissue remodeling.  
This EB matrix not only provided a novel means to investigate the paracrine factors 
produced by ESCs, but it delivered the therapeutic benefits of stem cells in an effective 
cell-free manner.  Future work will continue to elucidate the unique milieu of factors 
secreted by ESCs that will contribute to innovating advanced treatments that harness the 








Formulation of acellularized EB matrix was investigated in order to develop 
alternative means of delivering ESC-derived matrix factors.  Solubilization of 
acellularized EB matrices was performed using different solutions to following two 
different methods of acellularization.  Mechanically acellularized EBs (lyophilized EBM) 
were compared to chemically treated EBs (TritonX + DNase, T+D) using 4 different 
buffers – 4M guanidine hydrochloride (GuHCl), 2M magnesium chloride (MgCl2), 2M 
sodium chloride (NaCl), and 2M urea.    
Using one third of a 1x100mm plate of EBs per sample, acellular EB matrices 
were produced via previously established protocols [216, 270, 321].  All solutions were 
made in 50mM Tris-HCl (pH 7.4).  Each acellular EBM sample was solubilized in 1 mL 
of solution overnight at 4°C, and the supernatant was collected after centrifugation at 
12000xg for 30 minutes at 4°C.  To remove the solubilization buffers, each supernatant 
sample was dialyzed for 5 days against dI H2O at 4°C.  The dialyzed supernatants were 
then lyophilized to concentrate the proteins.  The protein extracts were analyzed for total 
protein content using BCA and separated via SDS-PAGE (Figure A.1), and exhibited the 





Figure A.1.  Acellular EBM protein extractions.  Protein extracts from two different acellularized matrices were characterized using 





EVALUATION OF THE ANGIOGENIC POTENCY OF 
ACELLULAR EMBRYOID BODY MATRICES IN VIVO USING A 
MURINE HINDLIMB ISCHEMIA MODEL 
 
  
Acellularized EBM captures the embryonic extracellular environment comprised 
of morphogens that induce proliferation, migration, and differentiation.  While the 
resulting matrix contains angiogenic proteins, their ability to stimulate angiogenesis has 
not been tested in vivo.  Since the acellular matrices examined will be derived from EBs 
with elevated expression of angiogenic factors, the activity of these factors was 
investigated.  Acellular matrices that harnessed higher concentrations of the angiogenic 
factors previously assessed were examined for their angiogenic potency in vivo using a 
hindlimb ischemia mouse model. 
Using a well-established HLI model, athymic male mice between weeks of age 
were anesthetized via intraperitoneal injection of xylazine (10 mg/kg) and ketamine (80 
mg/kg) and used for all in vivo experiments. To create unilateral hindlimb ischemia in 
mice, an incision will be made in the left hindlimb to ligate and excise the femoral artery 
and vein.  Animals were randomized into 3 groups – (1) lyophilized day 7 EBM, (2) L+D 
day 7 EBM, (3) untreated.  EBM powder was implanted around the area of the excised 
artery at the time of surgery, and the dermal incision was sutured.  
Laser Doppler perfusion imager (LDPI, Moor instrument) was used for serial 
noninvasive physiological evaluation of neovascularization.  Mice were anesthetized with 
an intraperitoneal injection of Ketamine (40-90mg/kg) and Xylazine (10mg/kg). Each 
mouse was followed by a serial recording of surface blood flow of the hindlimb 
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immediately after surgery and on days 3, 7, 14, 21 and 28.  After LDPI scanning, the 
stored digital color-coded images were analyzed to quantify blood flow of area and mean 
values of perfusion were calculated and expressed as the ratio of ischemic to non-
ischemic limb. 
For procedures requiring end point analysis (IHC and microCT), mice were 
euthanized, and the vasculature cleared using heparinized saline, perfusion fixed with 
10% neutral buffered formalin, and flushed with heparinized saline.  MicroCT required 
the vasculature to be perfused with silicone/lead chromate polymerizing contrast agent 
followed by removal of both hindlimbs that were treated in formic acid–based solution 
for 48 hours for bone decalcification.  High-resolution 3D images were acquired using a 
microCT imaging system (vivaCT 40, Scano Medical) that assessed vasculature volume 
within the limb.  For IHC evaluation, adductor muscles of the ischemic and control limbs 
were excised from perfusion-fixed mice, paraffin processed, and embedded for 
histological analysis.  Five µm histological sections were taken and stained with H&E to 
examine the progression of muscle repair at days 3, 7, 14, and 28. 
This pilot study was to determine the feasibility of delivering EBM to assess the 
angiogenic potency via a mouse HLI model.  The analytical methods to investigate the 
angiogenic response were well defined and able to yield results (Figures B.1 – B.3); 
however, a means to effectively deliver a defined amount of EBM into the ischemic 
region needs to be devised.  Additionally, the number of animals assessed (n=4 per 
treatment) was not sufficient to provide any concluding statements. While overall 
preliminary results showed differences in the EBM-treated hindlimbs compared to the 
untreated, future studies will need to incorporate efficient delivery vehicles as well as an 
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Figure B.1.  Preliminary effects of EBM in ischemic hindlimb model.  (A) Limb 
salvage observations of the ischemic hindlimb two weeks after surgery and EBM 








Figure B.2.  Histological analysis of HLI muscle.  Preliminary H&E staining of hindlimb muscles taken after 3 days (A) and 4 





Figure B.3.  Perfusion analysis of ischemic limbs.  (A) LDPI assessments of blood 
perfusion of ischemic limbs during the 4-week study.  (B) Quantitative analysis of 
perfusion based on the ratio of ischemic limb flux compared to control (non-ischemic) 
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